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Abstract
Strains of mice used in laboratory research differ markedly at a molecular, anatom­
ical and behavioural level. Genetic manipulation in mice has become a widely used 
tool for the selective study of single genes and has also produced a great diversity of 
phenotypes. However, the interaction between manipulated genes and background 
strain has been less well examined. Here, the effect of neurokinin-1 (NK1) receptor 
disruption is shown to depend heavily on the genetic background of the mouse that 
it is studied in. N K l- / ~ mice have previously been shown to display an anxiolytic 
and antidepressant-like phenotype, as well as having reduced sensitivity to the 
rewarding properties of the opiates. Here, after being transferred onto a C57BL/6 (B6) 
background, the anxiolytic effect of the mutation is lost, as is the differential response 
to morphine's locomotor stimulating properties. When the mutation is transferred 
onto a mixed C57BL/6 x 129/sv (B6:129) background the NKl_/_ mouse becomes 
more sensitive to morphine than wildtype counterparts, although no difference in 
anxiolysis is evident between the genotypes. Examination of the HPA axis in these 
animals revealed that B6:129 animals had higher levels of stress-induced corticosterone 
release than B6. Furthermore, NKl_/_ animals on the B6:129 background expressed 
higher levels of hippocampal glucocorticoid receptor and exhibited more neurogenesis 
in the hippocampus than wildtype. No differences in these parameters were observed 
for the genotypes in the B6 strain. Comparison of CRF and cFos mRNAs did not 
reveal any differences between genotypes in either strain. These results show that 
there are important epistatic interactions between genetic background and the NK1 
receptor. These findings may be relevant for the treatment of anxiety disorders and 
opiate addiction in the genetically heterogeneous patient population.
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Chapter 1
Introduction
The advent of genome engineering in the mouse has led to an explosion in biomedical 
research in rodents. These studies have been able to investigate specific molecules not 
just at a cellular or biochemical level but also their role in more complex behaviours. 
Research using the neurokinin-1 (NK1) receptor knockout mouse demonstrates this 
trend. The last decade has seen the NK1 receptor implicated in a number of conditions 
related to pain, motivation and affect, in part via work conducted in mice lacking a 
functional NK1 receptor. However, during this period NK1 antagonists introduced into 
clinical trials have failed to live up to their predicted potential as novel antidepressants. 
The validity of many studies using knockout mice has been questioned because of the 
failure of different laboratories to reproduce each other's results. Concurrently, our 
knowledge of molecular genetics has been expanding and the call for standardisation 
of practice between the laboratories that are using these sophisticated technologies has 
been increasing.
The majority of experimental work in this thesis is concerned with the effect of 
transferring the mutation in the NK1 receptor onto a different genetic background and 
detailing the effects this has on the mouse phenotype. This is an attempt to use these 
differences between genetic background to understand the role of the NK1 receptor in 
the behaviours examined.
This chapter briefly reviews the history of laboratory rodents and the approaches 
that have led to genome engineering in the mouse as well as the associated problems. 
This is followed by a history of research into substance P and the NK1 receptor
16
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including their known distribution and biological functions with particular reference 
to nociceptive, affective and addictive behaviours.
1.1 Labor a tory research using mice and ra ts
1.1.1 History
Rodents, particularly mice and rats, have been used in scientific laboratories for many 
years and have contributed enormously to our understanding of biological processes. 
Many different strains, both outbred and inbred, have been tested in a plethora of 
experimental paradigms and are very well characterised (Crawley et al., 1997). Recent 
advances in molecular genetics have made the use of transgenic and knockout animals 
commonplace in biomedical science. This has, however, introduced uncertainty into 
which particular strain of mouse is best suited for the intended work. Coupled with 
technical considerations involved in the creation of the mice this means that much 
research using these techniques has been irreproducible or in some cases has even led 
to contradictory results. In the next section, after an introduction to the differences 
between mouse strains commonly used, the techniques utilised to create a genetically 
modified mouse will be described followed by some of the common problems with this 
process.
1.1.2 Mouse strains
Laboratory mice have had a prominent role in biomedical research for over 100 years 
and their study has given rise to many insights concerning human disease states. 
Their mammalian lineage gives them far more relevance to our biology than other 
organisms such as zebrafish, Drosophila or yeast. Breeding is quick and easy to 
conduct and recently, with advances in genome engineering and the full sequencing 
of the mouse genome, powerful tools allowing the manipulation of this code have 
become available (Jockusch et al., 2004). Even preceding their use in science a great
17
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deal of genetic variation existed between mice from around the world. Some of this 
variation was naturally occurring, arising from migratory patterns, whilst some of it 
was introduced by human mouse 'fanciers' who both in the Far East and Victorian 
England kept and traded mice as pets (Wade and Daly, 2005). However, with the 
advent of laboratory facilities dedicated to breeding mice and the emergence of the 
field of genetics, different populations or sub-species of the mouse, Mus musculus, arose 
and have become properly characterised.
1.1.3 Inbred and outbred stocks
Laboratory mice can generally be divided into inbred or outbred stocks. The classically 
inbred mice were developed from small founder populations and include widely 
used strains such as C57BL/6 (B6), 129 lines and DBA/2J. These mice have lost the 
polymorphisms in their genome through inbreeding and are homozygous at the vast 
majority of alleles (Beck et al., 2000). These differ from strains referred to as outbred 
which retain polymorphisms in their genome (Chia et al., 2005). There are advantages 
and disadvantages to using inbred or outbred stocks that are important to consider 
when designing experiments.
1.1.3.1 Outbred mice
The official definition of an outbred mouse stock is one that is " a closed population 
(for at least four generations) of genetically variable animals that is bred to maintain 
maximum heterozygosity." (Festing, 1993). In order to maintain genetic variability it 
is essential that the colony is maintained at a relatively large size, at least 25 breeding 
pairs. In small colonies random genetic drift can occur as homozygosities occurring 
as a result of inbreeding become fixed in a population. This can become particularly 
problematic if two populations for comparison are maintained separately. This is 
of particular relevance to work using transgenic animals where, for example, the 
mutant and wildtype animals may be interbred separately. After several generations
18
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of breeding, the limited gene pool can lead to the genetic background of the two 
populations diverging as alleles become randomly segregated. This segregation can 
lead to phenotypic variation between the populations which is independent of the 
locus being studied (Chia et al., 2005). Although this is also a problem with inbred 
stocks, the potential for genetic drift is far less.
Outbred stocks are widely used though and do show advantages for some ex­
periments. Similarly to the human population, outbred stocks accumulate many 
breakpoints in their genome over time, fragmenting the chromosome into mosaic-like 
portions (Chia et al., 2005). These can be used with quantitative trait loci mapping to 
identify regions of the chromosome which statistically link to a phenotype of interest 
(Flint et al., 2005). As an example, breeding of the outbred MF1 mouse to inbred 
stock has been used to identify regulator of G-protein signaling 2 (RGS2) as a gene 
influencing anxiety (Yalcin et al., 2004).
Outbred mice are often used to develop mouse models of human conditions due 
to the high variability between strains and individuals. These features can be used to 
selectively breed for a phenotype of interest. Among mice generated in this way are 
those for high activity (Bronikowski et al., 2002), obesity (Horvat et al., 2000), prolificacy 
and weight (Kirkpatrick et al., 1998) and with different preferences to alcohol (Grahame 
et al., 1999). Once developed these mice are used to identify the physiological or genetic 
markers that underlie these conditions.
Another reason why outbred strains may be used is that the genetic variability also 
contributes to a better breeding performance than many inbred strains. This makes 
them attractive animals for the development and maintenance of transgenic animals. 
However, due to the reasons such as genetic drift mentioned above, this should be 
avoided if possible (Chia et al., 2005).
19
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1.1.3.2 Inbred mice
Inbred mice are more commonly used in laboratories than outbred mice. The lower 
genetic variability, in theory at least, gives rise to less experimental variability whether 
the trait under examination is behavioural, biochemical or molecular. This reduced 
variability will generally decrease the sample size required to see an effect in an 
experiment and so increase the experimental power (Chia et al., 2005). However, the 
likelihood of seeing an effect also has the potential to be masked or obscured depending 
on the inbred stock used and its particular modifying genes. As such, the inbred strain 
may be in some way resistant to a chemical being tested or compensations may render 
a particular gene redundant, a phenomenon known as epistasis (Crawley et al., 1997). 
Other problems associated with inbred strains are that the homozygosities that have 
been selected for may often be deleterious to the animal. As an example B6 mice 
are known to develop poor auditory responses as they age (Willott, 1986) and have 
severely depleted levels of melotonin due to a truncation in the enzyme responsible for 
synthesising it from serotonin (Roseboom et al., 1998). Their DNA is also resistant to 
modifications due to a high level of de novo DNA methylation at many loci (Schumacher 
et al., 2000). On the other hand they are one of the only inbred strains that perform well 
in the Morris water maze, a test commonly used for spatial memory (Crawley et al., 
1997). Furthermore, some inbred strains also display anatomical abnormalities that 
may affect behaviour. For example, 129 substrains of mice carry the pink-eyed dilution 
allele, which is associated with deficits in visual acuity (Brilliant et al., 1994; Crawley 
et al., 1997) and often show hypoplasia of the corpus callosum (Balogh et al., 1999).
1.1.3.3 Differences between mouse strains
Obviously the amount of genetic variation between different mouse strains means that 
they differ considerably at a molecular and cellular level. These differences in turn give 
rise to a specific behavioural phenotype for each strain. There have been many studies 
comparing the behavioural phenotypes of the different inbred and outbred strains.
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These include open field behaviour, learning paradigms, drug-induced behaviour, and 
reproductive and parental behaviours (Crawley et al., 1997). Table 1.1 summarises 
some of these findings for three different inbred strains. As mentioned in the previous 
section, the water maze tests spatial learning and B6 mice are the only inbred strain 
to show robust learning in it. However, in another learning-related phenomenon, 
contextual fear conditioning, many more strains show a good response implying less 
strain-dependence for this behaviour (Owen et al., 1997). Acoustic and tactile startle 
reflexes are another parameter that show variation between strains (Logue et al., 
1997; Paylor and Crawley, 1997). The startle reflex is highly conserved between all 
mammals and can be modulated by salient emotional and cognitive stimuli. It is 
believed to be involved in sensorimotor gating and the pathways mediating it may 
be affected in human disease states including schizophrenia. Prepulse inhibition, a 
related response involving the suppression of the startle reflex by a weaker prestimulus 
also shows variation between strains (Logue et al., 1997; Paylor and Crawley, 1997). 
The light/dark paradigm is a method of assessing anxiety-like behaviour and drugs 
that may affect it. It will be discussed in great detail elsewhere in this thesis. In the 
test an increased number of transitions between compartments after benzodiazepine 
administration indicates an anxiogenic effect of the drug. Analysis of several inbred 
strains in this paradigm showed that there were marked differences between many 
strains in their responses both at baseline and after diazepam (Crawley and Davis, 
1982; Mathis et al., 1994). Drugs of abuse also have a wide range of effects on the 
different strains. As such, drugs, including ethanol, nicotine, psychostimulants, opiates 
and the antipsychotics, affect different mice in different ways. For example, the opiates 
have been studied in detail in the different strains for their effects on different kinds of 
behaviours including analgesia, opiate withdrawal, morphine preference drinking and 
hyperlocomotion (Mogil et al., 1996).
With the preponderance of studies conducted in genetically engineered mice, a 
proper understanding how each strain performs on different tasks is essential to the 
designing of a good experiment and breeding strategy (Crawley et al., 1997), as will be
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Table 1.1: Comparison of different mouse strains. Performance of three inbred strains in 
behaviours relating to complex learning, startle responses, anxiety and drug-responsiveness. 
More information and references are given in the text. AU, arbitrary unit. Adapted from Crawley 
et al. (1997).
Behaviour C57BL/6 129/sv DBA/2J
Morris water maze Good Poor Poor
Fear conditioning Good Good Good
Startle reflex (tactile; Alls) 1306 ±140 425 ±  85 705 ±  138
Startle reflex (acoustic; Alls) 1317 ±  121 186 ± 3 3 440 ±  91
Pre-pulse inhibition (Alls) 31 ± 8 70 ± 5 48 ± 9
Light—dark transitions 49 ± 3 N/A 21 ± 2
...after diazepam 91 ±  11 N/A 27 ± 7
Morphine-induced locomotion High Low Low
discussed in more detail below.
1.2 Genome engineering in the mouse
1.2.1 Crea tion of a "knockou t"
There are various methods used to achieve different forms of genome engineering 
in the mouse. One of the most powerful techniques uses site-specific homologous 
recombination to produce mutations targeted to the gene of interest. A targeting vector 
is made comprising of a selection marker flanked by the DNA sequence surrounding 
the gene of interest. Information about the targeting vector used to create the NKl- / ~ 
mouse is given in Section 2.1.2 in the following chapter. This construct will then 
be transferred to embryonic stem (ES) cells via electroporation. Inclusion of the 
selection marker in the construct allows cells which have incorporated the vector to be 
selected for and disrupts transcription of the targeted gene preventing its expression.
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Blastocysts are injected with ES cells containing the targeted mutation to produce 
chimeric mice. Both the blastocysts and ES cells are usually derived from 129 inbred 
mouse lines as these are most commonly available as pluripotent cell lines. These 
chimeric mice are then mated with B6 mice. B6 mice are used here as a convenience 
(i) because they are good breeders and (ii) because the vast majority of laboratory 
work is conducted using them. If the mutation has been taken up by the germ cells 
in the chimeric mouse, this cross will produce mice that are heterozygous for the 
mutated allele. These mice can be detected via techniques such as Southern blotting 
or polymerase chain reaction (PCR). A further intragenerational cross should produce 
mice that are both homozygous for either the mutation or the wildtype allele, or 
heterozygotes (Jockusch et al., 2004; Glaser et al., 2005).
1.2.2 Flanking genes and breeding stra tegies
Several issues arise from this particular strategy, however. Firstly, the ES cells that 
traditionally have been used have been derived from 129 mouse lines. This is 
mainly because they possess particular germline properties which make such genome 
engineering possible (Jockusch et al., 2004). However, 129 substrains show a great 
deal of variation between each other and so can have a complex genetic background 
to begin with. Furthermore, some studies have shown certain ES cell lines to be 
polymorphic at several loci meaning they cannot have been derived from an inbred 
line (Simpson et al., 1997). Random segregation of these alleles can therefore lead 
to a badly defined genetic background. Another key problem is caused by flanking 
genes. B6 mice are used to breed with the chimeras to generate FI heterozygotes 
and subsequently F2 homozygotes. During homologous recombination the closer two 
alleles are to each other the higher the likelihood that they will be inherited together. 
This means that the area surrounding the mutated locus is more likely to be derived 
from the original 129 ES cells whereas in the wildtype allele this region is more likely to 
originate from the B6 breeders. Differences between the genotypes seen at this F2 stage
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have a high likelihood of deriving from a variation between these two background 
strains rather than from the chosen mutation (Gerlai, 1996). As the 129 and B6  strains, 
particularly, have been shown to differ on many behaviours as illustrated in table 1 .1 , it 
is especially necessary to eliminate these linkage problems. This is commonly achieved 
by either backcrossing the mutation onto an inbred strain, usually B6 , or the more rapid 
technique of using speed congenics (Jockusch et al., 2004). However, as neither of these 
can ever truly eliminate the differences in flanking regions other methods have been 
suggested. At the Banbury Conference in 1997 a group of scientists working in this 
field met to discuss a series of recommendations to deal with these problems (Silva 
et al., 1997). These included the establishment of two congenic lines using different 
genetic backgrounds. Their FI progeny can then be used as experimental animals.
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Figure 1.1: Chromosomal constitution of mice generated by gene targeting. Germ-line 
transmitting chimeric mice from 129-derived ES cells (grey) containing a mutation (red) in one 
allele are crossed with B6 mice (black) and give rise to an F1 population a proportion of which 
will be heterozygous for the mutation. Breeding these mice together, by Mendelian laws, creates 
homozygous wildtype, homozygous mutant and heterozygous mice. Crossover processes 
during gam etogenesis mean that the area surrounding the mutated locus (dashed lines) will 
be derived from the 129 parental strain whereas the area surrounding the wildtype locus will 
com e from the B6 strain. This linkage disequilibrium and its consequences is explained in more 
detail in the text. Adapted from Gerlai (1996).
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1.3 Substance P and the NK1 receptor
This thesis describes a set of experiments examining how genetic background influ­
ences the effect of NK1 knockout. The NK1 receptor is the preferred receptor for the 
neurotransmitter substance P (SP). The next section details the history, distribution 
and main biological functions of SP and the NK1 receptor with particular reference 
to previous work using NK1 receptor knockout (NKl_ /_ ) mice.
1.3.1 History of substance P and the NK1 receptor
Substance P (SP) was discovered somewhat fortuitously in 1930 from an intestinal 
extract that was found to contract the gut and lower blood pressure (Lembeck et al., 
2004). The extract was purified and concentrated and the active substance was referred 
to in the laboratory as preparation P, from which its current name derives. Only 
extracts from the gut and brain were found to contain the substance (Lembeck et al.,
2004). Although work continued with SP as the isolation process was improved and 
various similarities with other peptides were noted, it was not until 1971 that the amino 
acid sequence was published and it became possible to synthesize the peptide (Chang 
et al., 1971). Its full sequence is H-Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met- 
NH2 . The term tachykinin was coined to include SP and other similar peptides due to 
the speed of contractions they produced on smooth muscle preparations. Neurokinin 
A and neurokinin B were discovered as new members of this family as well as several 
non-mammalian tachykinins. In the 1980s the gene and precursor protein to SP 
were isolated, as well as the preferred receptors: NK1 for SP and NK2 and NK3 for 
neurokinin A and neurokinin B, respectively (Lembeck et al., 2004).
1.3.2 Biosynthesis of SP
The gene that synthesises the precursor to SP is named preprotachykinin A (ppt-a 
or TAC1) with its product similarly named preprotachykinin A (PPT-A). Differential
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transcription and /o r splicing mean that the same gene is also responsible for producing 
NKA, neuropeptide K and neuropeptide 7  (Cordon and Holzer, 2004). As well as 
its role in the biosynthesis of SP, recent work has shown PPT-A to contribute to the 
regulated trafficking of (5-opioid receptors into large dense core vesicles in the spinal 
cord (Guan et al., 2005). This may have implications for situations in which there is 
either a mismatch of agonist to receptor as mentioned below or explain differences 
between the PPT-A- and the N K l- /_  mice.
1.3.3 Distribu tion
Several studies have used immunocytochemistry to map the distribution of SP and the 
NK1 receptor. SP and the NK1 receptor are expressed at high levels both in the gut and 
in various regions of the central and peripheral nervous system (CNS; PNS). Here, the 
focus will be on the distribution in the CNS. Distribution patterns show a high degree of 
similarity between different species and in most cases the receptor expression matches 
with the agonist distribution, although not in all.
SP is mainly a subcortical peptide and only very low expression of the peptide 
and the NK1 receptor have been noted in the cortex or hippocampus (Gadd, 2003; 
Nakaya et al., 1994). The striatum, both the caudate putamen (CPu) and the nucleus 
accumbens (NAcc), show expression of SP and the NK1 receptor (Penny et al., 1986; 
Nakaya et al., 1994). SP is found in the dynorphin-positive, GABAergic medium spiny 
neurons which project to the substantia nigra, globus pallidus and ventral pallidum 
as well as back onto the cholinergic intemeurons within the striatum (Anderson and 
Reiner, 1990; Napier et al., 1995). The NK1 receptor is found densely expressed on the 
cell bodies and dendrites of these cholinergic cells and release of SP in the striatum 
causes an increase in their firing and release of acetyl choline and dopamine.
The medial and central nuclei of the amygdala show expression of SP and the NK1 
receptor is expressed strongly in the central, basomedial and medial nuclei as well as 
some of the amygdala's accessory regions (Emson et al., 1978; Nakaya et al., 1994).
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The hypothalamus contains both NK1 receptor and SP immunoreactivity throughout 
where they are believed to cause release of hormones from the pituitary (Aronin et al., 
1986).
The habenular nucleus possesses some of the strongest NK1 receptor expression in 
the brain, particularly its medial division. This region also sends SP-containing fibres 
to the ventral tegmental area (VTA) which may be related to the control of locomotor 
activity, learning and reward processes (Emson et al., 1977).
Paradoxically, the area of the brain with the highest amount of SP is the substantia 
nigra, a region that seems to have very little NK1 receptor expression (Davies and Dray, 
1976; Nakaya et al., 1994; Gadd, 2003).
The periaqueductal gray (PAG) contains some NK1 expression while the dorsal 
raphe nucleus (DRN), which gives rise to the major serotonergic projections shows 
well-defined cell bodies (Halliday et al., 1988; Nakaya et al., 1994; Santarelli et al., 2001). 
Similarly, the parabrachial nucleus (PbN) and the locus coeruleus (LC), which gives rise 
to the major noradrenergic projections, also show high NK1 expression (Guyenet and 
Aghajanian, 1977; Nakaya et al., 1994; Santarelli et al., 2001) and are innervated by SP 
containing fibres (Halliday et al., 1988).
Figure 1.2 shows examples of NK1 receptor staining in a number of these brain 
regions. The relevance of these expression patterns will be referred to as function is 
discussed later in this chapter.
1.3.4 Signalling via the NK1 receptor
The NK1 receptor is a member of the G-protein coupled receptor (GPCR) superfamily 
and as such contains 7 transmembrane domains with a ligand binding site at the 
extracellular N-terminus. The NK1 receptor signals via the G^/n, G«s and Gao 
proteins which activate phospholipase C/3 (PLC/3) and in turn stimulate the formation 
of inositol-3-phosphate (IP3) and diacyl glycerol (DAG) (Taylor et al., 1986; Sugiya 
et al., 1987; Nakajima et al., 1992; Takeda et al., 1992; Seabrook and Fong, 1993;
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Figure 1.2: NK1 receptor expression in the mouse brain. Panels show immunostaining in the striatum 
(a,b), amygdala (c), medial habenular nucleus (MHb) (d), periaqueductal grey (e), dorsal raphe nucleus 
(DRN) (f) and parabrachial nucleus (PbN) and locus coeruleus (LC) (g,h). The immunocytochemical 
methods used are described in chapter 2 and the appendix. Scale bars, a, h: 250 ^m; b, d, f: 100 ^m; c, 
e, g: 500 f/m. AC, anterior commissure; CeA, central nucleus of the amygdala; MeA, medial nucleus of 
the amygdala; BLA, basolateral nucleus of the amygdala.
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Figure 1.3: The NK1 receptor and its signaling pathway. 1, Substance P binds to the G-protein- 
coupled NK1 receptor; 2, Receptor-mediated GDP/GTP exchange; 3, Ga<?/13-GTP activation 
of PLC^; 4, IP3-gated intracellular Ca2+ mobilisation; 5, PKC activation; 6 Ca2+/CAM kinase 
activation. Adapted from Bremner et al. (2001)
Macdonald et al., 1996; Roush and Kwatra, 1998). The increase in IP3 induces 
the release of calcium from intracellular stores resulting in activation of kinases 
including calcium-calmodulin-dependent kinase (Merritt and Rink, 1987; Womack 
et al., 1988). The formation of DAG activates protein kinase C (PKC). Activation 
of the receptor also activates adenylyl cyclase leading to the accumulation of cyclic 
adenosine monophosphate (Mitsuhashi et al., 1992; Nakajima et al., 1992; Takeda et al., 
1992) and stimulates arachidonic acid production via phospholipase A2 (Garcia et al., 
1994). Together these processes lead to a slow excitatory potential by increasing 
sodium conductance and decreasing potassium conductance (Nicoll, 1978; Nowak and 
Macdonald, 1982; Stanfield et al., 1985; Shen and North, 1992) and can also lead to 
modulation of gene transcription. This signalling pathway is illustrated in figure 1.3.
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1.3.5 Antagonists at the NK1 receptor
A  number of receptor antagonists have been developed for the NK1 receptor partly 
due to their potential as therapeutic agents. The earliest of these were peptidergic 
and involved simple amino acid substitutions or rearrangements from the SP sequence 
(Engberg et al., 1981; Holmdahl et al., 1981; Folkers et al., 1984; Hagiwara et al., 
1994). Mostly they showed low potency and specificity, a degree of neurotoxicity, were 
broken down easily in vivo and had poor brain penetrance. More recently, highly 
selective, non-peptidergic antagonists have been developed (McLean et al., 1996). 
However, differences between rodents and other mammals in the primary structure of 
the receptor have limited their use in pre-clinical models using mice and rats (Appell 
et al., 1992; Jensen et al., 1994). This necessitates high doses in these animals which may 
compromise their specificity by binding to other tachykinin or neuropeptide receptors 
or interfering with calcium channel function (Schmidt et al., 1992; Guard et al., 1993). 
Often, gerbils or guinea pigs, which have a receptor structure far closer to humans, 
have had to be used instead. However, despite these limitations many of the studies 
have contributed useful data to the field and have been supported by later work using 
different approaches. These will be reviewed below where appropriate.
1.3.6 The N K 1 m o u s e
The use of genomic engineering to create mice lacking a functional NK1 receptor 
(NKl- /_  mice) has greatly aided study in this area. Three separate lines of N K l- / ~ 
mouse have been created using homologous recombination in different laboratories 
(Bozic et al., 1996; De Felipe et al., 1998; Santarelli et al., 2001). In general similar 
findings have been produced although where there are discrepancies these are likely 
due to differences in background strain or experimental procedure. The mice used 
in this thesis derive from those produced by C. De Felipe and A.H. Smith and are 
described in Section 2.1.2 in the following chapter (De Felipe et al., 1998).
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1.4 Functions of SP and the NK1 receptor
The next few sections will consider the functions of SP and the NK1 receptor with 
reference to a number of behaviours.
1.4.1 Nociception
The most widely studied physiological role of SP has been its involvement in process­
ing painful stimuli. The next section briefly describes the neuroanatomy of nociception, 
the animal models used to study it and the function of SP and the NK1 receptor within 
this system.
1.4.1.1 The neuroanatomy of pain
Pain is an experience consisting of both a sensory and an emotional component 
(International Association for the Society of Pain). Under non-pathological conditions 
it requires peripheral activation of non-myelinated afferents known as C-fibres and 
thinly myelinated AS fibres. Their cell bodies are located in dorsal root ganglia (DRGs) 
and their axons project to the periphery, where their terminals detect noxious stimuli, 
as well as centrally where they synapse on cells in the dorsal horn of the spinal cord 
(Todd and Koerber, 2006). The fibres are polymodal and will respond to thermal, 
chemical or mechanical stimuli. From the dorsal horn ascending projections relay 
the information to higher brain areas such as the somatosensory cortex, the anterior 
cingulate cortex and the amygdala, which are important for either the sensory or 
affective responses (Hunt and Mantyh, 2001). Projections to areas of the hind brain such 
as the rostroventral medulla (RVM) may also be important for mediating modulatory 
influences (Mantyh and Hunt, 2004). Under pathological conditions parts of this 
circuitry may become activated by either normally neutral stimuli or in the absence 
of peripheral stimulation. Neuropathic or inflammatory diseases can cause this and 
often arise from physical insults to the nervous system (Campbell and Meyer, 2006).
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1.4.1.2 Animal pain models
Most of the animal pain models use either chemical or surgical methods to mimic 
these long lasting pathologies allowing the underlying alterations to be studied. 
Surgically, ligation, constriction or axotomy of a nerve will produce central changes 
and a heightened sensitivity to pain. Chemically, peripheral administration of noxious 
substances such as capsaicin, formalin, or carrageenan will also result in persistent 
changes in pain sensation (Wang and Wang, 2003; Vierck, 2006).
1.4.1.3 The role of SP and the NK1 receptor in pain
The role of SP in processing nociceptive stimuli has been studied for many years. 
SP was originally hypothesised to be the primary neurotransmitter responsible for 
transmitting information about painful stimuli. This was prompted by the knowledge 
that SP was released in the spinal cord by painful manipulations (Randic and Miletic, 
1977). Additionally, SP is localised within a small subset of small diameter DRG cell 
bodies and terminal fields of the nociceptive primary afferents (Li and Zhao, 1998) and 
the NK1 receptor is found on the laminar I, III and V cells of the dorsal horn of the 
spinal cord that project to the brain (Nakaya et al., 1994). Furthermore, intrathecal 
administration of SP causes biting and scratching of the abdomen (Gamse and Saria, 
1986) and painful stimuli increase mRNA for both PPT-1A and the NK1 receptor in 
DRG cell bodies (Noguchi et al., 1988; McCarson, 1999). However, a role for SP or 
the NK1 receptor in the detection or modulation of acute painful stimuli has not been 
demonstrated. Although antagonists will reduce chronic inflammatory or neuropathic 
pain in many models they have no effect on acute pain. This is supported by work 
using the N K l_/_ mouse in which the second, but not the first, phase of the formalin 
test is attenuated (De Felipe et al., 1998). A reduction in secondary hyperalgesia 
produced by intraplantar capsaicin administration (Laird et al., 2000; Mansikka et al.,
2000) and Mycobacterium tuberculosus (Kidd et al., 2003) have also been found as well 
as a decrease in intensity coding of painful stimuli (Suzuki et al., 2002). Distribution of
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the ascending projections from the NKl-positive cells in laminar I have also hinted that 
SP may play a role in processing of the affective, rather than the sensory, components 
of pain (Suzuki et al., 2005). Current work also suggests that these cells form part of a 
spino-bulbo-spinal loop that produces descending modulation via connections to the 
PbN and the PAG and from the RVM (Millan, 2002; Suzuki et al., 2002). Together these 
results imply a role for SP in mediating long lasting pain states.
1.4.2 Drug abuse and addiction
SP and the NK1 receptor have been implicated in drug abuse and addiction, especially 
to the opiates. Here, the neurobiology and anatomy of drug addiction will be described 
as well as the various animal models used.
1.42.1 Anatomy and neural bases of drug addiction
The neural substrate common to almost all drugs of abuse is the dopaminergic 
projection that runs from the ventral tegmental area (VTA) of the hindbrain and 
terminates in the ventral striatum or nucleus accumbens (NAcc) (Wise, 1998; Nestler,
2001). This pathway is normally activated by natural rewards and reinforcers and 
is important for learning motivated behaviours (Berke and Hyman, 2000). Under 
pathological conditions of addiction, however, it can become strongly stimulated 
by drugs or drug-associated stimuli. Other areas such as the amygdala, prefrontal 
cortex and hippocampus also have a modulatory influence as do the monoaminergic 
projection areas, the LC and DRN, which supply noradrenaline (NA) and serotonin (5- 
HT), respectively, to the forebrain (Everitt et al., 1991; Carlezon and Wise, 1996; Nestler 
and Aghajanian, 1997; Nestler, 2001).
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1.4.2.2 Models of drug addiction
There are a number of models used to test various aspects of drug abuse: conditioned 
place preference (CPP), behavioural sensitisation, self administration, and tolerance 
and physical dependence. CPP refers to the pairing of a drug with a particular 
environmental context and is thought to test the rewarding properties of a drug (Bardo 
and Bevins, 2000). Behavioural sensitisation is the development of an augmented 
response, usually locomotor, after repeated administration of a drug and is believed 
to model the craving associated with drug abuse (Stewart and Badiani, 1993; Robinson 
and Berridge, 2003). Thirdly, in self-administration studies animals are required to 
perform an operant response, normally a lever press, to obtain an infusion of drug. This 
is thought to test the reinforcing properties of a drug (Self, 1998). Finally, tolerance to a 
drug, resulting from its repeated administration, and physical withdrawal, precipitated 
by the cessation of drug treatment, can also be produced in animals (Nestler and 
Aghajanian, 1997; Harrison et al., 1998).
1.4.2.3 SP and the NK1 receptor in drug addiction
A potential role for SP in drug addiction was first suggested by the finding that both 
systemic and local injection of SP into the nucleus basalis magnocellularis induced CPP 
in rats (Hasenohrl et al., 1998,2000). Injection of SP intracerebroventricularly (i.c.v.) or 
local injection into different areas of the midbrain and striatum have also been shown 
to mimic some features of drug administration such as stimulated locomotor activity 
and rats will also self-administer SP into the striatum (Elliott et al., 1992; Krappmann 
et al., 1994).
The N K l_/_ mouse fails to develop CPP or behavioural sensitisation to opiates and 
will not self-administer morphine or heroin (Murtra et al., 2000; Ripley et al., 2002). 
Antagonism of the NK1 receptor also reduces opiate-induced locomotion (Piacenza 
et al., 2006). In contrast, all these drug-associated behaviours develop with cocaine 
and, additionally, CPP to natural rewards such as food is still present (Murtra et al.,
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2000). Furthermore, although opiate withdrawal is attenuated in the NK1 1 mouse 
the analgesic properties of morphine are unaffected (De Felipe et al., 1998).
1.4.3 Affective disorders
Affective disorder is a broad term encompassing major depression and anxiety as well 
as a range of other psychiatric complaints such as posttraumatic stress disorder (PTSD), 
obsessive compulsive disorder (OCD) and attention deficit hyperactivity disorder 
(ADHD). These are growing problems around the world and represent a massive 
financial burden (Murray and Lopez, 1996). A number of medicines do exist which, 
when used in conjunction with counselling or cognitive therapy, can produce dramatic 
results. However, in many patients the current treatments have little effect or succeed 
only in preventing some of the more severe symptoms e.g. suicidal tendencies, without 
providing a cure (Ebmeier et al., 2006). The NK1 receptor has been implicated in 
the pathopsychology of some of these disorders, most notably depression and anxiety 
(Rupniak et al., 2000, 2001; Santarelli et al., 2001, 2002; Gadd, 2003). The next section 
reviews the neural bases believed to underlie these conditions before considering how 
SP and the NK1 receptor may be involved in mediating them.
1.4.3.1 The neurological basis of affective disorders
Most of what is known about the pathophysiology of depression and anxiety is due 
to the medicines we have to treat them. In depression these are the antidepressants, 
classically the monoamine oxidase inhibitors (MAOs) and the tricyclic antidepressants 
(TCAs), and in anxiety the benzodiazepines (BZs) (Ebmeier et al., 2006).
The classic antidepressants were discovered by serendipitious clinical findings in 
the 1950s. Research into depression since then has mainly focused on investigating 
these drugs' targets rather than examining the underlying pathopsychology (Berton 
and Nestler, 2006). These drugs, as well as the more modem classes of antidepres­
sant, all work by increasing monoaminergic tone in the brain. Accordingly, distur­
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bances of the monoaminergic system comprising of noradrenaline (NA), serotonin 
(5-hydroxytryptamine, 5-HT) and dopamine (DA) seem to be an important factor in 
depression (Nestler et al., 2002). MAOs inhibit the breakdown of these compounds and 
selective serotonin reuptake inhibitors (SSRIs) and noradrenaline reuptake inhibitors 
(NRIs) prevent the reuptake of 5-HT and NA into the synaptic terminals, respectively. 
TCAs are also believed to inhibit monoamine uptake although their exact mechanism 
of action is less well understood (Manji et al., 2001; Nestler et al., 2002).
However, although monoamine levels are increased by antidepressants almost 
immediately, a behavioural improvement in the patient is often not seen for a number 
of weeks. Furthermore, once it has occurred this alleviation of symptoms may persist 
long after cessation of treatment (Nestler et al., 2002). These points argue against a 
simplistic explanation and imply that a secondary event must take place before the 
depression is alleviated.
A popular view is that increased monoaminergic tone may be the first step in a 
complicated cascade of molecular changes that lead to gene regulation. One candidate 
molecule is the 5-HT^ autoreceptor. Activation of the receptor in the dorsal raphe 
nucleus (DRN) inhibits firing and so decreases serotonergic tone in the forebrain. 
Prolonged antidepressant treatment has been shown to functionally desensitise the 
receptor, thereby increasing serotonin levels in the brain (Le Poul et al., 2000).
Another view is that hippocampal neurogenesis may be crucial for the alleviation 
of depression. Several observations have linked disturbances in neurogenesis to 
the pathophysiology of depression. Cognitive deficits in depressive states have 
implicated impaired hippocampal function (Austin et al., 2001). Additionally, patients 
with depression have smaller hippocampal volumes when using structural magnetic 
resonance imaging (MRI) (Sheline et al., 1996; Bremner et al., 2000). In animals, 
chronic treatment with most of the major antidepressants or with electroconvulsive 
shock therapy (ECT) increases neurogenesis (Madsen et al., 2000; Malberg et al., 2000; 
Santarelli et al., 2003). The neurogenesis caused by antidepressants is required for 
their behavioural effects (Malberg et al., 2000; Santarelli et al., 2003). Antidepressant
37
Chapter 1
treatment also upregulates hippocampal brain-derived neurotrophic factor (BDNF) 
(Coppell et al., 2003). BDNF and other neurotrophins have been implicated in 
the pathophysiology or depression and the actions of antidepressants (Duman and 
Monteggia, 2006). Stress, which is also known to be a major precipitating factor in 
depression in humans and animals, decreases neurogenesis as well as reducing BDNF 
expression (Duman and Monteggia, 2006; Tsankova et al., 2006). High corticosterone 
levels have also been shown to decrease neurogenesis in vitro and in vivo, in rodents 
and primates (Gould and Tanapat, 1999; Wong and Herbert, 2004). Early life stress 
also decreases neurogenesis in adulthood (Karten et al., 2005). Furthermore, subjecting 
animals to an inescapable stressor decreases neurogenesis and increases behavioural 
depressive symptoms, which are reversed by antidepressant treatment (Malberg and 
Duman, 2003). Finally, the time taken for neurons to be produced and reach maturity 
closely matches that observed in the clinic for depressive symptoms to alleviate after 
the start of antidepressant treatment (Sapolsky, 2004). However, there is still work to 
be done to prove the necessity for neurogenesis in human treatment and to elucidate 
whether it is a causative factor or an epiphenomenon.
Another possible explanation for the lag between treatment and effect has sug­
gested that antidepressants might exert their effects through changes in chromatin 
structure. Using an animal model Tsankova et al. (2006) showed increased DNA 
methylation at BDNF promoter regions after chronic psychosocial stress in mice. This 
methylation seems to be a permanent modification and results in a reduction in 
hippocampal BDNF. Chronic, but not acute, treatment with antidepressants resulted 
in acetylation of histone proteins associated with BDNF promoter regions. Although 
the methylation of these regions was not reversed, an increase in BDNF expression was 
observed and alleviation of the depressive-like symptoms was seen in their behavioural 
model.
Clearly, all of these different processes are likely to be important in the treatment 
of depression and will contribute to the efficacy of antidepressants. It is of importance 
now to elucidate which are the most crucial in determining the speed of treatment
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effect and the length of remission as well as which ones contribute to the pathogenesis 
of depression. Patients presenting for depression have often been suffering for weeks, 
months or even years before seeking help. Consequently, clinical findings such as 
anatomical changes in brain regions may be an effect rather than a cause of the 
depression (Ebmeier et al., 2006). After treatment this problem becomes greater as 
the effect of the particular treatment regimen also needs to be taken into account 
as well. With studies using post mortem tissue these problems are greatest as the 
sufferer is likely to have experienced many bouts of depression and accordingly many 
different treatment regimes over a period of years (Rajkowska, 2000). The cause of 
death often may be related to the depression, suicide or drug overdose being very 
common (Purselle and Nemeroff, 2003; Ebmeier et al., 2006). Disentangling all these 
factors therefore becomes very difficult.
1.4.3.2 Genetics and affective disorders
Over recent years many studies have attempted to find genetic links to depression. Sev­
eral candidate genes have been identified as particular vulnerability alleles. Of these, a 
polymorphism in the serotonin transporter has generated the most interest (Anguelova 
et al., 2003; Lasky-Su et al., 2005). Other key components such as BDNF, catecholamine 
methyl transferase (COMT) and D-amino acid oxidase activator (DAOA) have also 
been shown to vary in people who suffer from depression (Craddock and Forty, 2006; 
Ebmeier et al., 2006).
1.4.3.3 Stress, the HPA axis and affective disorders
Another common feature of affective disorders that may contribute to their patho­
genesis is hyperactivity of the hypothalamic-pituitary-adrenal axis (HPA axis; see 
section 5.1.1 in Chapter 5). Many depressed patients have an elevated and flattened 
circadian rhythm of corticosterone production (Holsboer, 2000; Gillespie and Nemeroff,
2005). In animals in which this rhythm has been induced experimentally, negative
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feedback that acts to terminate response to a stressor via the glucocorticoid receptor 
is impaired. Similarly, patients with depression subjected to the dexamethasone 
repression test also show this impairment (Modell et al., 1997). Depressed patients 
also show a blunting of the ACTH response to CRF challenge and increased CRF levels 
in the CSF (O'Keane et al., 2005). Behavioural responses to chronic stress in animal 
studies show similar features to depression seen in humans, for example, anhedonia 
(Willner, 1997; de Kloet et al., 2005).
1.4.3.4 Animal models of affective disorders
Preclinical animal models pose a particular problem to those working in the field of 
affective disorders. Clearly, modelling of a complex psychological disease such as 
depression in a rodent is a challenge. As well as difficulties in assessing when a rodent 
is 'depressed' it could even be argued that differences in the complexity of human 
and animal brains would question the existence of any disease akin to depression 
in lower mammals (Cryan and Mombereau, 2004). However, as drugs exist, such as 
the classical antidepressants, which alleviate disease symptoms in human patients and 
have observable effects in animals, we are able to use these to help validate the models. 
Although this approach may help to identify new drugs it is likely that these will work 
via the same mechanisms as established treatments. As such, the optimal treatment 
solution, that will come only with a full understanding of the disease processes, may 
remain obscured (Berton and Nestler, 2006).
Despite these caveats there is much preclinical work using animal models of 
affective disorders and progress is being made in their development and refinement 
(Lucki, 2001). In depression research the two most widely used models are the forced 
swim test and the tail suspension test (Porsolt et al., 1977; Cryan and Mombereau, 
2004). After being placed in an inescapable situation rodents will eventually appear 
to give up and become immobile. This cessation of struggling behaviour is known
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as learned helplessness or behavioural despair. Many antidepressants administered 
acutely will decrease this immobility time.
A group of models using chronic stressors have gained popularity more recently. 
Depending on the precise protocol the stressor may be either physical or psychosocial 
in nature and the outcome measure may have a physiological readout or a behavioural 
one, such as decreased social interaction (Willner, 1997). Again, antidepressants 
have been used to validate these models but, as opposed to the forced swim or tail 
suspension test, in general, chronic administration is needed for an effect of treatment 
(Tsankova et al., 2006). Taken together with the fact that stress is supposed to be an 
important factor in leading to depression, these models appear to have more construct 
validity and be more ethologically sound than the previous standards.
A related group of models use early life manipulations to induce a depression­
like syndrome. Postnatal animals subjected either to an emotional stressor such as 
prolonged maternal separation or an immunological challenge will develop a number 
of lifelong behavioural and physiological alterations including anhedonia, decreased 
social interaction and hyperresponsivity of the HPA axis (Plotsky and Meaney, 1993; 
Millstein and Holmes, 2006).
As with depression research, difficulties in interpreting animal behaviour in terms 
of a complex human disease necessitate the use of preclinical models of anxiety that 
have been validated by the use of drugs known to have an anxiolytic or anxiogenic 
effect in humans. Generally, benzodiazepines are used for this purpose (Belzung and 
Griebel, 2001). The most commonly used model is the elevated plus maze (EPM). 
When given benzodiazepines, rodents will make more entries into the maze's open 
arms. Any other manipulation — pharmacological, genetic or otherwise — that 
mimics this effect could be said to be anxiolytic (Lister, 1987). Another commonly 
used model is the open field test in which increased time spent in the centre of 
the arena is believed to reflect anxiolytic behaviour. Both of these tests suffer from 
large differences in sensitivity between strains, testing centres and individual animals. 
Effects of a particular manipulation on locomotor behaviour may also confound the
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results. Additionally, although traditional anxiolytics such as benzodiazepines give 
consistent results other compounds recently tested such as 5-HT 1,4 receptor agonists 
(e.g. 8 -OH-DPAT, busiprone) have yielded discrepancies (Lee and Rodgers, 1991; 
Micheau and Van Marrewijk, 1999)
As with the depression models with many of these tests it is highly likely that a 
single simplistic aspect of anxiety-like behaviour is being examined rather than the 
complex, multi-factorial disease we know anxiety to be in the human. Equally, most 
of the traditional tests are unable to differentiate between the anxiolysis induced by 
different anxiolytic compounds. Clinical findings suggest that these different agents 
have distinct effects depending on the anxiety disorder being treated. It has been 
suggested that the spatiotemporal measures normally used are supplemented, if not 
replaced, with more ethological behaviours such as head-dipping, time spent in flat- 
back approach or other such risk-assessment behaviours (Rodgers, 1997). Studies using 
these measures in a modified form of the test have found that they are normally more 
sensitive to drug effects than the avoidance behaviours. The light/dark exploration box 
(LDEB), which is described in more detail later in this thesis, is another model in which 
the spatiotemporal parameters can be complemented by a number of other ethological 
measures (Bourin and Hascoet, 2003). Similarly, the mouse defense test battery can 
also be used to provide a comprehensive behavioural profile (Blanchard et al., 1997). 
As such, models which are capable of providing a more complete profile of a drug's 
actions spread over a number of different ethological parameters may be of more use 
in designing new drugs and interpreting their effects.
Models for the other affective disorders also exist which may overlap to a certain 
extent with those for depression and anxiety. For PTSD the models focus more on the 
encoding of a single traumatic event by combining measures of an affective behaviour 
such as anxiolysis with a conditioning paradigm (Siegmund and Wotjak, 2006). In 
ADHD research, impulsivity and the response to amphetamines are thought to be 
important features of most models (Granon and Changeux, 2006).
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1.4.3.5 The NK1 receptor and affective disorders
The NK1 receptor has been implicated in both depression and anxiety. Promising 
preclinical work has led to NK1 receptor antagonists' introduction in clinical trials as 
a putative new class of antidepressant (Kramer et al., 2004). Although these have met 
with varying degrees of success, the preclinical and clinical work leading up to this will 
now be discussed.
Established antidepressants such as fluoxetine are known to inhibit neonatal 
vocalisations induced by maternal separation in guinea pigs. Comparable effects have 
been found using several NK1 receptor antagonists, MK869, L-760735 and L-733060 
(Kramer et al., 1998; Rupniak et al., 2000). Additionally, blocking SP release in the 
amygdala following aversive stimulation prevents vocalisations associated with these 
stimuli (Ebner et al., 2004). NK1 antagonists also reduce anxiety in the rat and the 
gerbil in the social interaction test. This work led to the first clinical trials in which 
MK869 was shown to reduce major depressive disorder with moderately high anxiety 
(Kramer et al., 2004). However, further work was hampered by differences in NK1 
receptor pharmacology between species.
The N K l- / ~ mouse also shows a very similar profile to that produced by the 
antagonists and exhibits alterations similar to those observed after chronic antide­
pressant treatment. Knockout mice show a decrease in neonatal separation-induced 
vocalisations compared to wildtype and an increase in struggle behaviour in the 
forced swim test and tail suspension test, effects that are mimicked in the wildtype by 
administration of an antidepressant such as fluoxetine (Rupniak et al., 2000; Santarelli 
et al., 2001). Similar findings have been produced after knockout of the PPT-A gene 
(Bilkei-Gorzo et al., 2002). The N K l- / ~ mouse is also reported to have reduced 
aggression in the resident intruder test (De Felipe et al., 1998).
In tests for anxiety-like behaviour there is less consensus of opinion. Some groups 
have found increased exploratory behaviour in open field, increased open-arm entry 
in the elevated plus maze (EPM) and a reduction in novelty-suppressed feeding, in
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the N K l_/_ mouse suggesting an anxiolytic phenotype (Santarelli et al., 2001, 2002). 
These differences were not reported in the NK1 mouse developed by De Felipe et al.
(1998); Rupniak et al. (2001). However, reductions in risk-assessment behaviours in the 
light/dark exploration box imply an anxiolytic profile in this mouse as well (Herpfer 
et al., 2005; Fisher, 2005). The most parsimonious explanation for these discrepancies 
is the difference in background strain of the two mice.
As mentioned in the previous section increased hippocampal neurogenesis is 
thought to be related to antidepressant activity. NKl~/_ mice have been shown to have 
increased neurogenesis in the hippocampus. This increase is at approximately the same 
level as is caused by antidepressant treatment and is correlated with an upregulation of 
BDNF. Furthermore, administration of the antidepressants desipramine and paroxetine 
increased neurogenesis in wildtype but not N K l_/_ mice (Morcuende et al., 2003).
Another pathway in which the NK1 receptor may be impacting on affective 
behaviours is by modulating monoaminergic tone in the nervous system. As already 
mentioned the NK1 receptor and SP are highly expressed within the LC and the DRN 
(Froger et al., 2001; Santarelli et al., 2001; Lacoste et al., 2006), the major projections for 
NA and 5-HT, respectively. Many studies have shown that disruption or antagonism 
of the NK1 receptor can lead to profound changes in regulation of the monoaminergic 
systems.
The LC is the main noradrenergic input area to the forebrain. Within the LC almost 
every neuron expresses the NK1 receptor at a high level and the region is heavily 
innervated by SP-containing fibres (Halliday et al., 1988; Nakaya et al., 1994; Chen 
et al., 2000; Santarelli et al., 2001). Application of SP to the LC either in vivo in an 
anaesthetised rat or in vitro in a slice preparation increases the firing rate of the majority 
of cells (Guyenet and Aghajanian, 1977; Cheeseman et al., 1983). Paradoxically, 
NK1 antagonists have also been shown to increase activity within the LC. L-760735 
induces burst-firing of LC neurons (Maubach et al., 2002) whilst L-760735 increases 
the firing rate of LC cells in the anaesthetised rat (Millan et al., 2001). Furthermore, 
using microdialysis the NK1 antagonist GR205171 has also been shown to increase
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cortical NA efflux in freely-moving rats (Millan et al., 2001) and anaesthetised N K l_/_ 
mice show elevated cortical NA compared to wildtype counterparts (Fisher, 2005). 
Whilst the NK1 antagonists WIN51,708 and CP-96,345 have no affect on spontaneous 
firing-rates in the LC, they do attenuate the actions of clonidine, an a2 -adrenoceptor 
antagonist, supporting a role for this autoregulatory receptor in the interaction between 
NA and the NK1 receptor. Recently it has also been shown that this receptor, which acts 
to inhibit NA release, is functionally desensitised in the N K l_/_ mouse (Fisher, 2005).
The serotonergic system is also modulated by the NK1 receptor. NK1 receptor 
antagonists and knockout of the NK1 receptor both cause a downregulation and 
functional desensitisation of inhibitory presynaptic 5-HTi^ receptors in the DRN 
(Froger et al., 2001; Santarelli et al., 2001). This downregulation also occurs following 
chronic antidepressant treatment. Normally, administration of an SSRI such as 
fluoxetine results in an initial increase in 5-HT release which is subsequently reduced 
via its effects at the 5-HTi/i receptor (Le Poul et al., 2000). The downregulation/de­
sensitisation of the receptor, caused by blockade or disruption of the NK1 receptor, 
therefore leads to an enhancement of 5-HT efflux after SSRI challenge with, for 
example, paroxetine (Froger et al., 2001; Santarelli et al., 2001). As the time course for 
downregulation/desensitisation of the 5-HT 1,4 receptor seems to follow that required 
for behavioural effects of antidepressants, this feature is believed to be crucial for their 
actions (Nestler et al., 2002).
1.4.3.6 The NK1 receptor and stress
SP and the NK1 receptor are also critically involved in many stress-associated be­
haviours. As such agonists at the NK1 receptor injected centrally cause the appearance 
of species-specific defensive behavioural changes (Elliott et al., 1992; Bristow and 
Young, 1994; Rupniak and Williams, 1994; Piot et al., 1995; Rupniak et al., 2000) 
and cardiovascular responses (Culman and Unger, 1995; Tschope et al., 1995). NK1 
receptor antagonists reduce the stress-induced increase in the noradrenergic pathways
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that originates in the LC (Hahn and Bannon, 1999). The NK1 receptor seems 
therefore to have an important role in orchestrating the response, both behavioural and 
physiological, to external stressors. This is backed up by the finding that N K l- / ~ mice 
have reduced stress-induced analgesia and reduced aggression in the resident intruder 
test (De Felipe et al., 1998).
1.5 Summary and aims
The NK1 receptor and SP are expressed widely throughout the nervous system 
and contribute to many behaviours including nociception, addiction and affective 
disorders. Knockout of the receptor has been shown to affect many of these and ma­
nipulation of the receptor or neurotransmitter may prove to be an effective therapeutic 
treatment. Despite the preponderance of studies using genetically modified models, 
there are few that examine the role of background strain in modulating the effect of a 
genetic manipulation.
In this thesis I will summarise a series of experiments which examine the influence 
of genetic background on knockout of the NK1 receptor. I will concentrate on 
behaviours related to addiction and affective disorders. The results in the different 
strains will be linked to possible disturbances in the HPA axis and certain components 
of it will be examined.
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Materials & M ethods
2.1 Subjects
2.1.1 Housing
All experiments described in this thesis used mice of between 6  and 16 weeks old. They 
were housed in the Biological Services Unit, UCL, London 2-6 per cage and maintained 
on a 12 h light/dark cycle (lights on at 8  a.m.), at a temperature of 21 ±1 °C and 50 % 
humidity. Singly-housed mice were never used due to the adverse effects on their 
behaviour and stress responses. Food (Harlan Teklad TRM Rat/Mouse Diet; Harlan, 
Bicester, UK) and tap water were available ad libitum. All animal procedures were 
carried out under the UK Animals (Scientific Procedures) Act 1986.
2.1.2 Creation of the NK1 -/- mouse
A number of different strains of N K l_/_ mice were used in this thesis. In this section 
the creation of the original knockout mouse will be described first. The crosses used 
to create the different strains will then be discussed as well as the nomenclature to be 
used throughout the thesis.
Three different strains of NK1 receptor knockout (NKl~/_ ) mice were used in this 
thesis. All three strains were derived from those described by De Felipe et al. (1998). 
Targeted disruption of the gene encoding the NK1 receptor, as illustrated, was used 
to create the knockout line. A cassette consisting of an internal ribosome entry site
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(IRES), the lacZ coding sequence and a neomycin resistance gene was inserted at a 
unique Stul site causing disruption of exon 1. These constructs are shown in figure 2.1. 
Homologous recombination in embryonic stem cells and subsequent mating generated 
a 129/sv x C57BL/6 mouse line. From this mouse three different strains have been 
created and used in this thesis. These are illustrated in figure 2.2.
2.12.1 MF1 mice
The MF1 mice referred to in this thesis were produced by crossing the homozygous 
mutant 129/sv x C57BL/6 created by De Felipe et al. (1998) once onto the MF1 
background (Harlan). This procedure allowed rapid dilution of the 129/sv component 
of the mice which has been shown to perform poorly on a number of behavioural tests 
and diminished the influence of flanking genes.
2.1.2.2 B6 mice
The B6 mice referred to in this thesis were produced by crossing the homozygous 
mutant 129/sv x C57BL/6 onto the C57BL/6 background over 10 generations. This 
breeding procedure further diluted out the 129/sv background and removed the 
confounding effect of flanking genes. Additionally, as C57BL/6 mice perform well in 
cognitive tests it improved the suitability of the knockout mouse for this area of study.
2.1.22 B6:129 mice
The B6:129 mice referred to in this thesis were produced by crossing the homozygous 
B6 mutant described above once onto the 129/sv background (Harlan). The reintro­
duction of the 129/sv component was undertaken for reasons given elsewhere in this 
thesis.
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Figure 2.1: The NK1“ /_  construct used by De Felipe et al. (1998). Using homologous 
recombination, the NK1 gene was disrupted by insertion of the targeting (replacement) vector 
into the region of the wildtype NK1 locus containing exon 1. The 5 ’ probe fragment used  
for Southern blot confirmation and the sizes of predicted restriction fragments following Xbal 
digestion are also shown. B Gal, lacZ coding region; IRES, internal ribosome entry site; MC1 
MC1 promoter; Neo, neomycin resistance gene; TK, Herpes simplex virus thymidine kinase 
gene. Small arrows indicate restriction sites. Adapted from Gadd (2003).
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a, original 129/sv x C57BL/6 (129:B6)
x C57BL/6 
(ten generations)
x MF1 
(one generation)
b, MF1 x 129/sv x C57BL/6 (MF1) c> backcrossed C57BI-/6 (B6)
x 129/sv 
(one generation)
Y
d, 129/sv x C57BL/6 (B6:129)
Figure 2.2: The different strains of NK1- / ~ mouse. The original 129/sv x C57BL/6 (129:B6; 
a) mouse made by De Felipe et al. (1998) was used in experiments by Murtra et al. (2000) 
and others. This was bred with outbred MF1 mice to create the MF1 x 129/sv x C57BL/6 
(MF1; b) mouse that was used by Ripley et al. (2002), Gadd et al. (2003), Gadd (2003) 
and Morcuende et al. (2003) as well as in this thesis. The original 129:B6 mouse was also 
backcrossed over 10 generations onto the C57BL/6 background to produce the B6 (c) mouse 
used in this thesis. Additionally, this mouse was then crossed back onto the 129/sv background 
over one generation to produce the C57BL76 x 129/sv mouse (B6:129; d) which has also been 
used in this thesis.
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2.1.3 Breeding
Mice were bred from homozygous breeding pairs. Homozygous mice from the FI 
generation of heterozygous breeding pairs were frequently introduced into the colony 
to minimize the effects of genetic drift. Mice were weaned at approximately three 
weeks of age.
2.1.4 Verifica tion of genotype
The genotype of all mice used was verified by PCR of tail-tip DNA. Three PCR primers 
were used: NK1-F, NK1-R and Neo-F. NK1-F and NK1-R amplify a 350-base section 
of exon 1 of the gene encoding the NK1 receptor gene. Neo-F and NK1-R amplify 
a 260-base section of the NK1 receptor gene including part of the inserted cassette. 
Resolution of these PCR products gives a single band of either 350 or 260 bases for 
homozygous NK1+/+ or NKl_/_ mice, respectively, whilst both bands are seen with 
the heterozygous NK1+//" mouse. Full genotyping method is given in section A.2 in 
Appendix A. Figure 2.3 shows an example gel on which bands corresponding to the 
different genotypes appear.
Figure 2.3: NK1 PCR for genotyping purposes. 600
Two bands representing the PCR products of 
350 and 260 bases can be seen  alongside 400
the molecular ladder. The band of 350 bases  
represents NK1+/ + , the band of 260 bases the
onn
NK1 and both bands the heterozygote.
+ /+  + /-  - /-
51
Chapter 2
2.1.5 Culling
Mice were killed either by decapitation, CO2 asphyxiation or via perfusion. Mice 
killed by asphyxiation were placed in a chamber and the concentration of CO2 was 
slowly raised. When the animals had stopped breathing, death was verified by physical 
breaking of the neck, exsanguination or removal of the brain.
2.1.6 Perfusions
Perfused mice were terminally anaesthetised by intraperitoneal (i.p.) injection of 0.2 ml 
pentobarbitone sodium (200 mg/ml; Euthatal; Rhone Merieux, Harlow, UK) before 
being perfused intracardially with 10 ml of heparinised PBS, followed by 100 ml ice- 
cold 4 % paraformaldehyde (PFA; BDH) solution in 0.1 M PB.
2.1.7 Drugs
Morphine sulphate was purchased from Sigma (Poole, UK). It was dissolved in sterile 
0.9 % saline and administered i.p.. All injections were given in a volume of 6.67 ml/kg. 
Doses were calculated as the free-base.
2.2 Molecular techniques
2.2.1 Immunocytochemistry
Immunohistochemistry (IHC) was the main technique used for identification and 
quantification, in a region-specific manner, of tissue constituents in this thesis. In IHC, 
specific constituents can be identified by using a visible marker to label specific antigen- 
antibody binding. Specific antibodies to proteins are raised by injecting an animal 
such as a goat, a sheep or a rabbit with a short peptide corresponding to part of the 
sequence of the protein under investigation conjugated to a large carrier protein such 
as bovine serum albumin (BSA). Plasma is collected from the animal and antibodies
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present are purified. Unlabelled primary antibodies are applied to tissue sections 
where they will bind the appropriate antigen. Often a second amplification step is 
added using the avidin/biotin system. This extra step amplifies the signal by exploiting 
the high affinity of the egg white glycoprotein avidin for the small molecular weight 
vitamin, biotin. Both avidin and biotin can be easily conjugated to other molecules 
and each avidin molecule is able to bind four biotin molecules. Biotinylated secondary 
antibodies, raised to antibodies from the primary antibody's host, can be used to link 
avidin-bound visible markers to the antigen of interest. These visible markers can 
either be chromogenic, radiographic or fluorescent, as described below. Additional 
amplification steps, such as tyramide signal amplification (TSA), may also be used to 
improve the signal-to-noise ratio.
2.2.1.1 Chromogenic staining (DAB)
3,3'-diaminobenzidine tetrahydrochloride (DAB) has been used as a label for most of 
the IHC in this thesis. It is a chromogenic electron donor in the presence of the enzyme 
horseradish peroxidase (HRP) which catalyses its oxidation to create an insoluble 
brown polymer. By using an HRP-avidin complex this reaction product can be used 
to visualise complexes surrounding the primary antibody. Nickel ions can be added to 
the reaction mixture to produce a more intense grey-black precipitate. DAB is highly 
carcinogenic so great care must be taken using and disposing of it.
22.1.2 Fluorescent staining
Fluorescent dyes bound to avidin are often used to visualise labelled antigens. As 
different dyes can be excited by different wavelength light they may also be used to 
label separate antigens in the same tissue. Photomicrographs can then be merged to 
inspect the degree of colocalisation of the antigens.
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Table 2.1: Primary antibodies
Antigen
NK1 receptor
Source
Eurogentec
Host animal Detection method Optimal dilution
Rabbit DAB, FITC 
Alexa488
1:5000
Glucocorticoid receptor Abeam 
Bromodeoxyuridine Beckton Dickinson
Rabbit 1:1000
Rat DAB 1:5000
2.2.1.3 Tissue preparation
Animals were perfused as described in Section 2.1.6. Perfused tissue was dissected 
and post-fixed for between 2 h and 24 h in 4 % PFA. Brains were cryoprotected in 30 % 
sucrose in 0.1 M PB containing 0.02 % NaN3, and stored at 4 °C for at least 12 h until 
being sectioned.
Brains were mounted onto a pre-cooled sledge microtome (SM 2000R; Leica 
Microsystems, Milton Keynes, UK) and frozen with dry ice. Sections were cut coronally 
at 40 pm, collected in 5 % sucrose in 0.1 M PB containing 0.02 % NaN3, and stored at 
4 °C.
Before use in immunocytochemistry, all primary antibodies were tested at a range 
of dilutions, using different conditions and detection methods to optimise their use.
A detailed method for all IHC experiments is given in Appendix A.
2.2.1A Specificity of the glucocorticoid antibody
As the antibody for the glucocorticoid receptor had not been used in our laboratory 
before, an immunoblot was conducted to ensure binding to an antigen of appropriate 
size and distribution was observed. A detailed protocol for the immunoblotting 
procedure is given in section A.4 in Appendix A.
Figure 2.4 shows an immunoblot conducted on various brain regions with a band 
corresponding to a protein of the same size as GR (97 kDa) and with appropriate 
distribution throughout the central nervous system (De Kloet and Reul, 1987).
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Figure 2.4: Immunoblot to test speci­
ficity of the GR antibody. A band 
is seen  representing the 97 kDa 
protein in all brain areas examined, 
stri, striatum; cb, cerebellum; hip, 
hippocampus; mid, midbrain; hyp, 
hypothalamus.
2.2.2 In situ hybridisation
105—►
7 5 —►
stri cb hip mid hyp
Autoradiographic in situ hybridisation was the main technique used for identification 
and quantification of RNA in this thesis. Radioisotope-labelled antisense oligonu­
cleotides corresponding to a section of the gene sequence of interest are hybridised 
to tissue sections. Exposure to photographic film results in a regionally-specific and 
semi-quantifiable image being produced on the film.
22.2.1 Tissue preparation
Brains were removed after decapitation and frozen in isopentane maintained at —45 
±5 °C. Tissue was mounted onto the chuck of a cryostat (CM1900, Leica Microsystems) 
and allowed to warm to the temperature of the chamber (—22 °C). 15 pm  coronal 
sections were cut and thaw-mounted onto poly-L-lysine coated slides (BDH). Sections 
were allowed to air-dry at ambient temperature for at least 1 h before being fixed in 
sterile 4 % PFA in 0.1 M PBS for 5 min, washed in sterile 0.1 M PBS for 1 min, and 
dehydrated in sterile 70 % ethanol for 5 min. Slides were transferred to sterile 95 % 
ethanol and stored at 4 °C until in situ hybridisation was performed.
2.2.22 Probe labelling
Antisense probes (table 2.2) were labelled using 35SdATP (Perkin Elmer, Beaconsfield, 
UK) and terminal deoxytransferase (rTdT; Promega, Southampton, UK). Oligonu-
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Table 2.2: Antisense probes
Molecule Sequence
CRF TCGGGAAATGAAATGTTGCGCTTGGCCAAAACGATTCTGCATTTA
cFos GCAGCGGGAGGATGACGCCTCGTAGTCGGCGTTGAAACCCGAGAA
cleotide was added to isotope and rTdT and placed in a waterbath at 37 °C for 
30 — 60 min before the reaction was quenched with 40 }i\ TE. The resulting solution 
was spun through a column (Micro Bio-Spin P-30 Tris, Bio-Rad, Hemel Hempstead, 
UK) to remove unbound isotope and the amount of labelling was quantified using a 
scintillation counter (LS60001C, Beckman Coulter, High Wycombe, UK). Probes had 
1 pi\ dithiothreitol (DTT; Sigma) added to them and were stored at -20 °C until use.
Probe sequences were compared to other genomic sequences to ensure that they 
were unique. Pilot studies with the CRF probe showed that its expression was highly 
localised to the PVN. Pilot studies using the cFos probe showed that its expression was 
upregulated in the striatum 2  h after cocaine treatment compared with saline treated 
animals (data not shown). Additionally, no expression of cFos mRNA was seen in the 
PVN of unstressed animals.
Non-specific binding controls were also performed and showed no labelling of 
sections for either probe.
2.22.3 Hybridisation
Sections were removed from storage under ethanol and allowed to airdry for 1 — 2 h. 
A hybridisation mixture was prepared by adding the labelled probe and DTT to 
a hybridisation buffer. Non-specific binding (NSB) controls were also prepared by 
adding an excess of unlabelled oligonucleotide to the solution. In these slides the 
unlabelled oligonucleotide should outcompete the radiolabelled oligonucleotide. The 
appropriate mixture was applied to the slides which were then coverslipped and left in
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a hybridisation oven at 42 °C overnight. The following day slides had their coverslips 
removed and were washed twice for 30 min in 1 x SSC buffer (National Diagnostics, 
Hull, UK) at 55 °C, once in 0.1 x SSC at room temperature, and dehydrated in 70 % 
ethanol and 95 % ethanol. Slides were then left to air-dry before being secured in a 
cassette. A piece of photographic film (Kodak BioMax MR; Sigma) was placed in the 
cassette for 1 - 2  weeks exposure.
22.2.4 Emulsion-dipping
To enable higher resolution of probe labelling including specific cellular distribution, 
sections were exposed to photographic emulsion and developed. This allowed sections 
to be examined under a microscope. In the dark, slides were dipped in pre-warmed 
emulsion (K5; Ilford, Mobberley, UK) and allowed to dry. Slides were kept in light­
tight boxes at 4 °C for 5 times the length of time that they were exposed to film. 
Subsequently, slides were developed with Kodak D19 developer (Sigma) and counter­
stained with thionin.
A detailed method for probe labelling, hybridisation and emulsion-dipping is given 
in section A.5 in Appendix A. Analysis of autoradiographic films is detailed in section 
2.2.3.
2.2.3 Microscopy and Photography
Antibody-labelled sections were visualised using a Leica DMR microscope (Leica 
Microsystems) or a Nikon Eclipse E800 microscope (Nikon, Kingston-upon-Thames, 
UK). For chromogenically-labelled antigens bright-field conditions were used, whereas 
fluorescent dyes were visualised under the appropriate excitation from a 50 W mercury 
lamp (HB050; Osram, Munich, Germany). Bright-field photography was carried out 
using a Photometries Coolsnap CF camera attached to a Dell PC running Microcom­
puter Imaging Device Basic 7.0 (MCID Basic 7.0; Imaging Research, Amersham, UK). 
Images on photographic film were analysed using a Northern Light B90 light box
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(Imaging Research) and a MicroNikkor 55 mm CCD video camera (Nikon). Analysis 
of optical density was carried out using MCID Basic 7.0 (Imaging Research). Areas of 
interest were quantified using densitometric analysis.
To measure luminosity of cells a confocal microscope was used (Bio-Rad 600, Bio- 
Rad). Cells were visualised at x 60. Background measurements were subtracted from 
the mean cell luminosity on each separate section.
2.3 Corticosterone measurements
For all experiments examining the HPA axis detailed in Chapter 5, animals were 
handled for 5 d prior to blood sampling or tissue collection to minimize handling- 
evoked stress responses. Handling consisted of removal from the home cage and 
transport to and from the procedure room before being returned to the home cage. 
This was performed by the same experimenter on all days.
On day 6  control animals were removed from the home cage, taken to the procedure 
room and rapidly killed by cervical dislocation. Animals undergoing restraint were 
taken to a different room and restrained in a 50 ml Falcon tube with an airhole for 
30 min prior to being killed by cervical dislocation or being removed and placed back 
in a cage for 30 -  60 min.
Blood was taken via cardiac puncture, collected into EDTA-coated microvette tubes 
(Sarstedt, Numbrecht, Germany) and placed on ice until all samples were collected. 
Tubes were then spun at 13,000 g for 15 min to separate plasma. The plasma was stored 
at -20 °C prior to analysis for corticosterone levels.
Corticosterone was measured via radioimmunoassay. Plasma was added to an 
acidic citrate buffer. The acidity of the buffer causes all bound corticosterone in the 
whole blood samples to dissociate from capillary blood glucose (CBG). These samples 
were then loaded in triplicate with the radioactive tracer (125I-corticosterone) and 
specific antibody (courtesy of Dr Gabor Makara, Institute of Experimental Medicine, 
Budapest Hungary). Samples were covered and incubated at 4 °C overnight. A
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standard curve was also prepared. The following day activated charcoal solution was 
added to all tubes. Charcoal-filled samples were then vortexed and centrifuged at 
4,000 rpm for 15 min at 4 °C. The supernatant containing all antibody-bound corti­
costerone was removed and discarded via aspiration leaving all "free" corticosterone 
bound to the charcoal pellet. The level of radioactivity in each sample was then 
measured using a gamma counter.
An 11 sample standard curve was set up using serially diluted corticosterone 
standards (Sigma), ranging from 10 ng/m l to 0.0970 ng/m l. These were set up in 
parallel to the samples except that they were assayed in triplicate. Also counted were 
three tubes containing pure tracer and three tubes containing tracer and buffer. Quality 
control samples (from CORT stock; Sigma) were also counted.
2.4 Behavioural Techniques
Behavioural experiments using animals are useful for studying how underlying 
cellular processes affect the whole organism and interact at the systems level. However, 
the complexity of animal behaviour means that there are many confounding factors 
that need to be taken into account when conducting behavioural work. Of these the 
animal's relation to its environment is probably the most important. This includes the 
nature of the environment as well as how the individual animal reacts to it. As such 
stress and anxiety about features in the environment can drastically affect an animal's 
behaviour in an unpredictable way. Because of this it is important to keep these features 
well-controlled so that they do not become confounds. A few examples are given here.
2.4.0.1 Habituation
Habituation to the experimental room and/or equipment is vital (Leussis and Bolivar, 
2006). Animals find novel environments very stressful and unless the object is to 
study an animals' behaviour under these conditions a habituation period is generally 
necessary. Habituation to handling and experimental procedures such as injections
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may also be required to prevent confusing effects of stress and anxiety with results of 
a treatment.
2.4.0.2 Timings
The time of day and day of the week are both very important for animal experiments. 
Circadian changes in steroid levels affect behaviour over the course of the day and 
routine patterns of activity in the housing facilities such as cleaning out or feeding will 
also disturb animals.
2.4.0.3 Sensory cues
Species differ in how they use and relate to their senses. For example, compared to 
humans, rodents have a highly developed sense of smell. Olfaction forms a large 
component of their sensory experience and they are highly sensitive to odours in 
their environment. Changes that are undetectable to the experimenter may provide 
the animal with a different set of cues that may impact on the experiment. Keeping 
disturbances to other sensory modalities to a minimum will also minimize animals' 
anxiety levels, for example, keeping noise levels constant.
All behavioural experiments were carried out in the same room under fluorescent strip 
lighting at an intensity of 40 lx except where indicated
2.4.1 EthoVision
To monitor animals' behaviour a computerised tracking system was used for many 
experiments (EthoVision 2.3; Noldus Information Technology, Waginen, The Nether­
lands). A black and white CCD camera (High Resolution B/W CCD Camera Model 
VCB-3372P; Sanyo Electric Company, Osaka, Japan) attached to a computer was used 
to track the animal's position by detecting differences from a standardised background
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image. The camera converted the signal from analogue to digital and sampling 
was conducted at a frequency of 5 Hz. The digitised image was subtracted from a 
previously collected reference image to determine the position of the animal within 
the arena. The construction of the arenas and camera set-up allowed the simultaneous 
recording of up to 8  animals. For some experiments an infrared lightbox was used 
to illuminate the arenas from below. By attaching an infrared filter to the camera 
a Shadow' of the animals against the background was produced. This prevented 
problems due to reflections from the lighting in the room and difficulties in detecting 
animals with a coat colour that matched the background. It also enabled filming of 
animals under lower light intensities. A variety of parameters could be subsequently 
analysed such as average speed, distance to a point or time spent in a particular zone. 
Figure 2.5 shows an example screen shot from an experiment using EthoVision.
2.4.2 Drug-induced locomotion
Most drugs of abuse at certain doses will produce hyperlocomotion when administered 
to animals. This is often due to the sustained release of dopamine in the striatum and 
so may be related to the same neural substrates that mediate the rewarding or addictive 
properties of a drug. The extent of this locomotor activation can therefore be used to 
elucidate certain properties of the drug or effects of a particular manipulation on these 
properties. See section 3.1.1 in the following chapter for more details.
Locomotor responses elicited by morphine were assessed in black Perspex boxes 
(internal dimensions: 9 cm [w] x 20 cm [1] x 11  cm [h]). After at least 1 h habituation to 
the experimental room, animals were placed in the arenas and activity was monitored 
for 1 h using EthoVision. After this, animals were removed, injected with drug and 
placed back in the same arena. Recording via EthoVision resumed immediately for a 
further 2 h. A video camera attached to a computer running EthoVision 2.3 (Noldus 
Information Technology) was used to monitor the position of the mice and locomotor 
activity was assessed by calculating the mouse's mean speed in m m /s over the 15 min
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Figure 2.5: A typical screenshot of EthoVision recording a LDEB experiment. Animals were 
detected via subtraction from the background image and are seen  here highlighted in red. 
Various parameters could subsequently be analysed, for example, distance moved, time in 
zones or velocity.
recording session. All the activity tests were carried out between 10.30 a.m. and 13.30 
p.m.
2.4.3 Light/dark exploration box
The light/dark exploration box (LDEB) is a simple piece of equipment consisting of 
two differently-lit compartments with a shuttle door joining them. Under a certain set 
of parameters, depending on the experiment, animals will be encouraged to explore 
the two chambers for a set period of time. The test exploits a conflict between 
the rodent's innate aversion to bright lights and their innate tendency to explore a
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novel environment (Bourin and Hascoet, 2003). It has mostly been used as a screen 
for compounds with anxiogenic or anxiolytic effects. However, due to the many 
behaviours that can be scored it is also possible to use it for other purposes. More 
detail is given in section 3.1.2 in the following chapter.
The light/dark exploration box (LDEB) was made of Perspex and divided into two 
compartments with a removable door separating them (see figure 2.6). The light side 
was 200 mm x 300 mm and illuminated at 20 lx. The dark compartment was 150 mm 
x 200 mm and illuminated at 5 lx. The floor of each box was transparent and the boxes 
were placed on an infrared light box. Animals were allowed to habituate to the dark 
zone for 1 h and were then placed in the centre of the light compartment facing away 
from the opening. Animals were recorded for 30 min both with EthoVision software 
for automated scoring of certain behaviours and with a video camera for behaviours 
requiring manual scoring.
Dark compartment Light compartment
Position of guillotine door
o
E
E
150 mm 300 mm
Figure 2.6: The light/dark exploration box
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2.5 Statistical analysis
A number of different statistical tests were used to analyse the data presented in this 
thesis. In this section the general principles underlying these tests are described and 
some general rules that were used throughout. Specific tests are described in more 
detail in their relevant chapters.
2.5.1 Students t-test
The t-test is a method of comparing the means of two data sets. If the data sets arise 
from the same population then their means are unlikely to differ greatly, except by 
chance. The standard error is used to gauge the natural variability within the sample 
set so that the extent of variability expected in the means can be calculated. T-tests 
can be either paired or unpaired depending on whether the two samples are related 
or independent. The t-test is a parametric test meaning that it is assumed that the 
population is normally distributed. If this assumption is not met then a non-parametric 
test must be used.
2.5.2 Analysis of Variance (ANOVA)
The ANOVA test is a parametric method for examining how a number of different 
independent variables interact and how this affects the dependent variable. The 
amount of variance within a data set can be divided into systematic or non-systematic 
variance and this ratio provides a measure of the experimental effect. More than two 
groups and more than two independent variables can be analysed making it more 
powerful than the t-test, although post-hoc tests are needed to discover the specific 
relationships between different groups. Repeated measures ANOVA tests can be used 
to analyse how the same subjects respond under a number of different conditions, for 
example, in a time course study. Analysis of covariance (ANCOVA) tests can be used 
to remove the effect of a particular experimental variable from the overall effect on the
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dependent variable. Multivariate ANOVA (MANOVA) tests can be used to prevent 
false positives resulting from the analysis of several dependent variables within the 
same data set.
All statistical analysis in this thesis was carried out using SPSS 12.0.1 for Windows 
(SPSS Inc., Chicago, US). The data were checked for violation of the assumptions of the 
test procedures such as homogeneity of variance and Normality of the error. Where 
these assumptions were not upheld, the data were transformed using square root, 
logarithmic, or inverse transformations as appropriate or an alternative statistical test 
was used. P<0.05 was the criterion for statistical significance.
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Results I: Behavioural differences in 
MF1 and B6 mice
3.1 Introduction
This chapter describes a set of experiments comparing the behavioural phenotype 
of the N K l- / ~ mouse on two different genetic backgrounds. The original mouse 
created by De Felipe et al (1998) was on a mixed 129:B6 background. To partially 
eliminate the influence of flanking genes on the phenotype, this mouse was crossed 
with the outbred MF1 strain to give a mixed MF1:129:B6 (MF1) mouse. Work using 
the resulting mouse corresponded closely with previous studies (De Felipe et al., 1998; 
Murtra et al., 2000; Ripley et al., 2002; Gadd et al., 2003; Gadd, 2003). However, this 
was a suboptimal solution to the problem caused by flanking genes. Additionally, it 
performed poorly on cognitive tests such as the Morris water maze. C57BL/6 mice are 
known to outperform other inbred strains on these tasks. Therefore, to reach genetic 
homogeneity of background and to enable investigation into the cognitive effects of 
NK1 receptor knockout a backcrossing strategy was adopted in parallel. This involved 
backcrossing over 10 generations onto the C57BL/6 background (B6 ).
The experiments described below compare the effect of NK1 receptor knockout in 
the mixed MF1 hybrid and the B6  strain. Morphine-induced hyperlocomotion and 
behaviour in the light/dark exploration box (LDEB), a test commonly used to screen 
for anxiety-like behaviours, are examined.
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3.1.1 Morphine-induced hyperlocomotion
As with many drugs of abuse, administration of morphine at certain doses produces 
a hyperlocomotor response in animals. This is thought to be related to the rewarding 
properties of the drug due to similarities in the underlying neural substrates (Robinson 
and Berridge, 2003). The hyperlocomotion is thought to result from increased activa­
tion of the mesolimbic dopaminergic system which projects ventrally from the ventral 
tegmental area (VTA) to the nucleus accumbens (NAcc), the caudate putamen, and the 
prefrontal cortex (Wise, 1998). Morphine activates this system by inhibiting GABAergic 
intemeurons in the VTA by binding to //-opioid receptors. This results in a disinhibition 
of the dopaminergic projection cells and elevated dopamine (DA) release in the NAcc 
(Johnson and North, 1992). It is this system that is believed to become sensitised in drug 
addiction when the resulting homeostatic plasticity manifests as pathology (Berke and 
Hyman, 2000). However, other factors that are specific to the species and strain of the 
animal, or to the testing conditions and protocol will be involved in the expression of 
this hyperlocomotion. As such, morphine also acts at numerous other sites within the 
brain and may modulate other aspects of an animal's behaviour such as anxiety (Costall 
et al., 1989; Dockstader and van der Kooy, 2001). Furthermore, a study by Murphy 
et al. (2 0 0 1 ) that tested three inbred strains showed that although morphine increased 
striatal dopamine in all of them, there was no correlation with the locomotor response. 
This implies that locomotion is subserved by a number of different systems and is 
likely to be modulated in a complex manner. Additionally, other sites of action may 
important in mediating the rewarding properties of morphine. Although lesions of the 
NAcc profoundly disrupt conditioning to psychostimulant drugs, morphine-induced 
place preference has been shown to be unaffected, or at most attenuated (Olmstead and 
Franklin, 1996).
As discussed in the previous chapter the N K l_/_ mouse has been shown to have 
a reduction in the rewarding, reinforcing and locomotor responses to opiates (Murtra 
et al., 2000; Ripley et al., 2002; Gadd, 2003). Additionally, rats given NK1 receptor
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antagonists have an attenuated morphine-induced locomotor response and an increase 
in self-administration of heroin (Piacenza et al., 2006). We therefore decided to compare 
morphine-induced hyperlocomotion between the genotypes in the MF1 and B6  strains.
3.1.2 The light/dark exploration box (LDEB)
The LDEB is a test that has most commonly been used to screen for compounds with 
anxiolytic or anxiogenic properties. Rodents have an innate aversion to brightly-lit 
open spaces as well as a tendency to explore novel environments in response to mild 
stressors (Crawley and Goodwin, 1980). A conflict between the tendency to explore and 
the tendency to avoid the unfamiliar (neophobia) is set up and the resulting exploratory 
activity reflects the combination of these two tendencies (Bourin and Hascoet, 2003). 
The standard test consists of a brightly lit chamber connected to a smaller darkened 
one by a door. Behaviours in each chamber can be measured. Modifications to the 
apparatus can include changes in the sizes and illumination of the compartments 
(Costall et al., 1989; Young and Johnson, 1991) and the presence of a tunnel joining 
them (Belzung et al., 1987). Traditionally, the number of transitions between the 
two compartments, independent of increases in locomotion, was used as an index 
of increased exploratory behaviour. Increases in exploratory behaviour have been 
linked to an anxiolytic profile in many tests (Crawley and Goodwin, 1980). Other 
researchers have used different spatiotemporal parameters as indices for anxiolysis- 
induced exploration including, time spent in each compartment and latencies to leave 
or return to each compartment (Costall et al., 1989; Bourin and Hascoet, 2003). Ideally, 
many more active and passive behaviours can be scored in parallel and provide a more 
sophisticated profile for the animal (Rodgers, 1997).
Many drugs have been tested using the LDEB. Anxiolytic drugs, especially the 
benzodiazepines, cause the most reliable changes in behaviour and will generally 
increase exploratory behaviours (Bourin and Hascoet, 2003). Drugs working at most of 
the different 5-HT receptors have also been extensively studied using this paradigm.
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Agonists at the 5-HTm and 5-HTib receptors have the most consistent anxiolytic 
profiles (Costall et al., 1989; Metzenauer et al., 1992; Hascoet and Bourin, 1998) whilst 
antagonists at the 5 -HT3 receptor have also been demonstrated to have anxiolytic 
effects (Costall et al., 1989; Bill et al., 1992).
Other factors related to the strain and age of the mice being used are also known to 
impact on results in the LDEB (Crawley et al., 1997; Hascoet and Bourin, 1998; Hascoet 
et al., 1999; Bourin and Hascoet, 2003). These may often interact with each other or 
other manipulations such as a targeted genetic mutation or anatomical lesion. Large 
differences have also been noted between laboratories and experimenters (Wahlsten 
et al., 2003). Taken together all these features mean that comparison between different 
studies is often difficult, if not impossible. Assertions that any one behaviour, such as 
transitions, can be taken as a strict representation of anxiety are dangerous. To prove 
an anxiolytic effect therefore the best that can be done is to use a proven anxiolytic 
such as diazepam as a positive control. Even this situation is suspect as it relies on the 
telelogical assumption that because diazepam is known to reduce anxiety in humans 
it will reduce anxiety in mice. Using these assumptions only drugs with the same 
mechanism of action as ones currently available may be picked up and so give false 
negatives in some cases (Belzung and Griebel, 2001).
Another important consideration when using the LDEB is that locomotor behaviour 
can often be a confounding factor (Bourin and Hascoet, 2003). Drugs or manipulations 
that alter spontaneous locomotion will cause changes in other behaviours that may be 
associated with other affective states. It is important to remove the effect of locomotion 
either by using it as a covariate when analysing or by prior screening for locomotor 
effects.
The LDEB has been used in our laboratory as an ethological behavioural screen 
that does not require prior training of the animals. Previously, differences in behaviour 
between N K l- /_  and wildtype mice have been found in the LDEB. In one study, 
the NKl~/_ mouse on the MF1 background was found to have a reduction in risk 
assessment behaviours and an increase in locomotor activity. Removal of locomotor
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activity as a covariate revealed that transitions and rearing also differed between the 
genotypes and were previously masked by the increases in locomotion (Herpfer et al., 
2005). More recently, similar results were found for risk-assessment behaviours and 
locomotor activity although no difference was found in rearing once locomotor activity 
had been removed. Additionally, N K l_/_ mice were found to spend less time in the 
light zone (Fisher, 2005). Both studies implicated differences in noradrenergic function 
in the knockout mouse through the use of desipramine (Herpfer et al., 2005) and the 
o l- 2  adrenoceptor antagonist RX821002 (Fisher, 2005).
3.2 Materials & Methods
3.2.1 Subjects
Mixed 129:B6 hybrid N K l_ /~ mice crossed onto the MF1 background for 1 generation 
(MF1) or onto the C57BL/6 background for 10 generations (B6) were compared here. 
More detail is given in section 2.1.2.
3.2.2 Morphine-induced locomotion
EthoVision was used to monitor animals behaviour. Animals were allowed to habituate 
to the activity boxes for 1 h before being injected with saline or morphine and 
recorded for 2 h. Figure 3.1 shows this protocol. Locomotor activity was recorded 
continuously and binned into 15 min periods for plotting and analysis. Each strain 
was analysed separately using 3-way repeated measures ANOVA with genotype and 
dose as the between subjects factors and time as the within subject repeated measure. 
Significant main effects or interactions were then investigated further using 1-way 
ANOVA on individual time points with group as the between subjects factor and post 
hoc Tukey tests. Dose response data for B6 mice were analysed using 2-way ANOVA 
with genotype and dose as the between subjects factors and post hoc Dunnett's tests. 
Additionally, data from the habituation period was collapsed over all dose groups and
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Figure 3.1: Protocol of morphine-induced locomotion experiments. Animals were taken to the 
testing room 1 h before the start of the experiment (grey box). Animals were weighed, placed 
in arenas and activity was monitored for 1 h (yellow box). Animals were removed from boxes 
and injected with saline or morphine (green box). Animals were placed back into the sam e 
arena and activity was recorded for a further 2 h (red box). Timings in minutes are shown at 
the bottom of the diagram. The cyan bar underneath represents the time during which animals 
were recorded.
1-way ANOVA with genotype as the between subjects factor was used to investigate 
changes in baseline locomotion in each strain.
3.2.3 The LDEB
Animals were allowed to habituate to the dark compartment with the door closed for 
1 h before being placed in the centre of the light zone and having their behaviour 
recorded for 10 min. Locomotor activity and time spent in each compartment was 
measured automatically using EthoVision while all other behaviours were scored by 
a experimenter blinded to treatment. A MANOVA test was initially used to analyse 
all behaviours and reduce Type I errors. Significant behaviours were subsequently 
analysed using 2-way ANOVAs with genotype and strain as between subject factors 
and using 2-way ANCOVA with locomotor activity as a covariate. 1-way ANOVA 
with group as the between subjects factor and Post hoc Tukey tests were used to look
Test period
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for specific differences between groups.
3.3 Results
3.3.1 Baseline locomotion
Figure 3.2 shows the baseline locomotion in each strain from analysis of the habituation 
period and after saline injection. In the B6 strain, 1-way ANOVA on the habituation 
period revealed no main effect of genotype (Fi/6o=3.746, p=0.058). In contrast, in 
the MF1 strain, 1-way ANOVA revealed that N K l- / ~ mice had a higher baseline 
locomotion than wildtype counterparts during the habituation period (Fi,22=1 2 .0 0 0 , 
p=0.002). Analysis of the test period of animals administered saline also showed 
the same pattern. 1-way ANOVA revealed an effect of genotype in the MF1 mice 
(Fi,io=8.300, p=0.016) but not in the B6 strain (Fi/i6=2.340, p=0.146). Under these test 
conditions N K l“ /_  mice in the MF1 strain displayed higher locomotor behaviour than 
wildtype MF1 mice.
a b - +/+
20
15
10
B6 MF1
n  -/-
10
B6 MF1
Figure 3.2: Baseline locomotion. Mean ±  SEM speed travelled by NK1- / ~ and wildtype 
mice on B6 and MF1 backgrounds during the habituation period (a) and after administration 
of saline (b) *P<0.05 vs. +/+; n=6-25.
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3.3.2 Morphine-induced locomotion
Figure 3.3 shows the results of the morphine-induced hyperlocomotion experiment in 
the NKl~/_ and wildtype mice on the MF1 and B6 backgrounds.
3.3.2.1 B6 mice
Three-way repeated measures ANOVA with genotype (G) and dose (D; 0 vs. 20 
m g/kg) as between subjects factors and time (T) as the within subjects factor revealed 
significant main effects of time and dose and a significant T x D interaction. These data 
are summarised in table 3.1.
Subsequent 1-way ANOVA tests on each time point with group (wildtype mor­
phine vs. wildtype saline vs. N Kl- / ~ morphine vs. N K l_ /“ saline) as the between 
subjects factor were performed and revealed that dose had a significant effect at all time 
points except for 15 min. Post hoc Tukey tests revealed that morphine-treated animals 
moved faster than saline-treated regardless of genotype.
Table 3.1: Results of 3-way ANOVA of morphine-induced locomotor data in B6 mice
Factor d.f. Error d.f. F P
Genotype (G) 1.000 26.000 1.090 0.306
Dose (D) 1.000 26.000 81.159 <0.001
Time point (T) 3.054 79.396 7.128 <0.001
G x D 1.000 26.000 0.004 0.949
G x T 3.054 79.396 0.545 0.656
D x T 3.054 79.396 83.614 <0.001
G x D x T 3.054 79.396 0.501 0.686
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Figure 3.3: Morphine-induced locomotion. Mean ±  SEM speed traveled by NK1- / “ and 
wildtype mice on B6 (a) and MF1 (b) genetic backgrounds after administration of morphine 
(20 mg/kg) or saline. Arrows indicate time of injection. *P<0.05 vs. NK1 ###P<0.001 vs. 
saline; n=6-8.
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3.3.22 MFlmice
Three-way repeated measures ANOVA with genotype (G), dose (D; 0 vs. 20 mg/kg) 
as between subjects factors and time (T) as the within subjects factor on all time points 
revealed significant main effects of dose and time and significant T x G, T x D and G x 
D interactions. These data are summarised in table 3.2.
Subsequent one-way ANOVAs on individual time points with group (wildtype 
morphine vs. wildtype saline vs. NK l_/_ morphine vs. N K l- / ~ saline) as 
the between subjects factor were performed. Post hoc Tukey comparisons revealed 
significant differences between speeds moved by morphine-treated N K l_/_ and 
wildtype mice at all time points after 105 min as shown in figure 3.3b. Significant 
differences between morphine-treated wildtype mice and both saline groups were also 
found in all time points other than the first one. Differences between morphine and 
saline-treated N K l~/_ mice were not found at any time points and no differences 
between saline-treated NK l_/_ and wildtype mice were found.
These data indicate that the hyperlocomotion produced by morphine administra­
tion in wildtype mice is attenuated in NKl~/_ mice on the MF1 background.
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Table 3.2: Results of 3-way ANOVA on morphine-induced locomotor data in MF1 mice
Factor d.f. Error d.f. F P
Genotype (G) 1.000 20.000 1.121 0.302
Dose (D) 1.000 20.000 23.131 <0.001
Time point (T) 2.877 57.550 19.409 <0.001
G x D 1.000 20.000 8.232 0.009
G x T 2.877 57.550 6.788 0.001
D x T 2.877 57.550 14.792 <0.001
G x D x T 2.877 57.550 2.685 0.057
3.3.3 Dose response to morphine in B6 mice
No difference between the genotypes was seen in the hyperlocomotion induced by 20 
m g/kg of morphine in the B6 strain. To test the hypothesis that this was a ceiling effect 
a number of different doses of morphine were tested.
2-way ANOVA with genotype (G) and dose (D) as between subjects factors revealed 
a main effect of dose but not genotype and no G x T interaction. These results are 
summarised in table 3.3. Post hoc Dunnett's tests showed that morphine increased 
locomotor activity at all doses compared with saline controls (5 m g/kg, p=0.003; 10 
m g/kg, p<0.001; 20 mg/kg, p<0.001; 30 mg/kg, p<0.001). These data show that in 
the B6 strain morphine increases activity in wildtype and N K l- / ~ mice to the same 
extent.
Table 3.3: Results of 2-way ANOVA on morphine dose response in B6 mice
Factor d.f. Error d.f. F P
Genotype (G) 1 66 0.941 0.336
Dose (D) 4 66 57.485 <0.001
G x D 4 66 0.392 0.814
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Figure 3.4: Dose response data for B6 mice after morphine administration. Mean ±  SEM 
speed travelled in 2 h test period following injection. **, p<0.01; ***, p<0.001 vs. saline using 
Dunnett’s post hoc test. N=5-9.
3.3.4 The LDEB
The LDEB was used to screen a number of behaviours to look for differences between 
the strains and genotypes. Table 3.4 gives the mean ±  SEM data for all behaviours 
scored. These were first analysed with MANOVA to prevent generating false positives 
due to multiple comparisons. Significant behaviours were subsequently tested using 
two-way ANOVA with strain (S) and genotype (G) as the between subjects factors. 
These data are shown in table 3.5.
All the behaviours analysed subsequent to the MANOVA showed a main effect of 
strain (total activity, activity in the dark, number of transitions, stretch-attend postures 
(SAPs), total rears, rears in the dark, rears in the light, grooming bouts). Three 
behaviours showed a main effect of genotype (SAPs, rears in the dark and grooming
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bouts). Four behaviours showed a G x S interaction (transitions, SAPs, total rears and 
rears in the light).
Because locomotor activity showed a significant effect of strain, further ANCOVA 
tests using locomotor activity as a covariate were performed. These data are given in 
table 3.6. After this procedure a main effect of genotype was revealed on total number 
of rears and the main effect of genotype on grooming bouts was lost. All the other 
behaviours remained as before. These results show that, with the exception of two 
behaviours, strain and genotype both have striking effects on a number of behaviours 
in the LDEB that are independent of the strain difference in locomotor activity.
Post hoc Tukey tests were conducted to investigate specific differences between the 
groups. The resulting data are summarised in table 3.5 and the significant results are 
shown graphically in figure 3.5 and described below.
Post hoc tests on the total activity revealed that, despite there being a main effect of 
strain, there were no significant differences between any of the groups.
Post hoc tests on the number of transitions, which showed a main effect of strain 
and a G x S interaction, revealed that there was no difference between genotypes on 
the MF1 strain but that NKl_ /“ mice on the B6 background performed significantly 
more transitions than their wildtype counterparts (p=0.002). Wildtype B6 mice also 
performed more than both MF1 genotypes (+/+, p<0.001; - / - ,  p<0.001) and N K l_/_ 
B6 mice also performed more than wildtype MF1 mice (p=0.011).
The number of stretch-attend postures (SAPs), a form of risk assessment behaviour, 
showed a main effect of genotype, a main effect of strain and a G x S interaction. Post 
hoc tests revealed that wildtype MF1 mice performed significantly more SAPs than 
knockout MF1 mice (p<0.001) or either genotype on the B6 background (+/+, p<0.001; 
- / - ,  p<0.001). There was no difference between the B6 genotypes.
Post hoc tests on the total number of rears, which showed a main effect of strain 
and a G x S interaction, revealed that NKl~/_ mice on the MF1 background performed 
significantly more rears than their wildtype counterparts (p=0.020) but that there was 
no difference between the genotypes on the B6 background. Both genotypes on the
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Table 3.4: LDEB results in the MF1 and B6 strains. Means ±  SEM are shown for each 
behaviour. Symbols indicate behaviours that showed a main effect of genotype (*), strain (+) or 
a  significant interaction (t) after analysis by ANOVA. The results of these analyses are shown 
in tables 3.5 and 3.6.
Behaviour MF1 +/+ MF1 -/- B6+/+ B6 -/-
Latency (s) 53.0 (20.5) 48.3 (13.1) 10.2 (1-8) 32.7 (15.1)
Return to light 16.2 (5.0) 12.7 (3.7) 9.4 (4.5) 11.6 (3.7)
Activity (cm/s) + 4.8 (0.5) 4.8 (0.2) 6.1 (0.2) 5.5 (0.2)
Activity (Dark) (cm/s) t 4.1 (0.6) 4.0 (0.3) 5.6 (0.2) 5.1 (0.2)
Activity (Light) (cm/s) 5.3 (0.6) 5.4 (0.2) 6.5 (0.3) 5.7 (0.2)
Time (Dark) (s) 181.6 (26.6) 177.9 (22.7) 191.7 (15.8) 170.3 (8.3)
Time (Light) (s) 404.1 (28.5) 410.7 (23.7) 387.8 (12.7) 423.8 (9.4)
Transitions t  £ 22.0 (1.8) 31.8 (2.2) 58.3 (5.5) 38.5 (3.1)
SAPs * +t 52.8 (7.6) 16.1 (2.6) 5.5 (1.5) 7.4 (2.4)
Rears (Total) 29.5 (4.5) 46.5 (2.7) 62.4 (4.9) 59.9 (2.6)
Rears (Dark) * t 5.5 (0.8) 10.4 (1.7) 12.6 (1.6) 17.3 (2.0)
Rears (Light) 24.0 (4.4) 36.1 (2.5) 49.8 (4.7) 42.6 (2.0)
Grooming (Bouts) * t 0.4 (0.2) 1.5 (0.8) 1.1 (0.4) 3.4 (1.0)
Grooming (s) 3.1 (2.3) 21.0 (12.8) 16.8 (8.3) 36.5 (13.3)
B6 background performed more rears than wildtype MF1 mice (+/+, p<0.001; - / -  
, p<0.001) and wildtype B6 mice performed more than N K l_/_ mice on the MF1 
background (p=0.032).
Post hoc tests on the number of rears in the dark, which showed a main effect of 
strain and of genotype, revealed no differences between the genotypes of each strain. 
N K l- /_  mice on the B6 background performed more rears in the dark than either 
genotype on the MF1 background (+/+, p<0.001; - / - ,  p=0.023) and wildtype B6 mice 
performed more than wildtype MF1 mice (p=0.018).
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Table 3.5: 2-way ANOVA on behaviours in the LDEB 
Behaviour Genotype Strain Interaction
Total activity Fi,28-0.663 P=0.422 Fi,28=7.938 P=0.009 Fi,28=0.992 P=0.328
Activity (Dark) Fi,28=0-868 P=0.359 Fi,28=9.477 P=0.005 Fi/28=0.421 P=0.522
Transitions Fi,28=2.106 P=0.158 Fi,28=38.941 P<0.001 Fi,28=18.328 P<0.001
SAPs Fi/28=12.741 P=0.001 Fi,28=58.324 P<0.001 Fi/28=17.964 P<0.001
Rears (Total) Fi,28=3.574 P=0.069 Fi,28=36.357 P<0.001 Fi,28=6.463 P=0.017
Rears (Dark) Fi,28=9.005 P=0.006 Fi,28=19.556 PcO.001 Fi ,28=0.006 P=0.938
Rears (Light) Fi ,28=0486 P=0.492 Fi,28=20.208 P<0.001 Fi,28=7*200 P=0.012
Grooming (Bouts) Fi,28=4.867 P=0.036 Fi,28=6.050 P=0.020 Fi,28=0.303 P=0.587
Table 3.6: 2-way ANCOVA using locomotor activity as a covariate on behaviour in the LDEB
Behaviour Genotype Strain Interaction
Transitions F1/27=1.428 P=0.242 F1;27=23.425 P<0.001 Fi,27=16.639 P<0.001
SAPs Fi/27=14.248 P=0.001 FU7=38.559 P<0.001 F1/27=15.808 P<0.001
Total rears F1/27=5.136 P=0.032 FU7=21.732 P<0.001 F1/27=5.104 P=0.032
Rears (dark) FU7=9.174 P=0.005 Fi/27=12.720 P<0.001 Fi/27=0.002 P=0.969
Rears (light) F1/27=0.983 P=0.330 FU7=10.728 P=0.003 F1/27=5.795 P=0.023
Grooming (bouts) Fi/27=3.980 P=0.056 Fi/27=9.153 P=0.005 Fi/28=0.062 P=0.806
Post hoc tests on the number of rears in the light, which showed a main effect of 
strain and a G x S interaction, did not show differences between the genotypes of each 
strain. Wildtype MF1 mice performed less than either genotype on the B6  background 
(+/+, p<0.001; - / - ,  p=0.005).
Post hoc tests on the number of grooming bouts, which showed a main effect of 
strain, revealed that wildtype MF1 mice performed less grooming bouts than NKl_/_ 
mice on the B6  background (p=0.013).
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B6 MF1
Figure 3.5: Behaviours in the light/dark exploration box. Mean ±  SEM of (a) total activity, (b) 
total rears, (c) stretch-attend postures and (d) transitions in the LDEB. *, p<0.05 vs. +/+; n=8.
3.4 Discussion
The aim of the experiments in this chapter was to investigate differences between the 
NK1 ~ /-  phenotype produced on two different genetic backgrounds: a mixed MF1 x 
129/sv x C57BL/6 hybrid (MF1) and the C57BL/6 backcross (B6 ). Two behaviours 
shown previously to be altered by disruption of the NK1 receptor were chosen: 
morphine-induced hyperlocomotion and behaviour in the light/dark exploration box 
(LDEB).
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3.4.1 Morphine hyperlocomotion
Hyperlocomotion in response to many drugs of abuse results from increased dopamin­
ergic input to the striatum and is therefore believed to reflect the motivational 
processes that underlie aspects of drug addiction (Wise, 1998). The N K l- / ~ mouse has 
previously been shown to decrease its locomotor response to morphine at doses which 
cause an increase in the wildtype (Murtra et al., 2000; Gadd, 2003). Additionally, the 
rewarding, reinforcing and sensitising properties of the opiates as measured via CPP, 
self-administration or locomotor sensitisation, respectively, are also attenuated in the 
N K l- /_  mouse (Murtra et al., 2000; Ripley et al., 2002). In this chapter NKl~/_ mice 
on the MF1 background are shown to have an attenuated, but not abolished, locomotor 
response to morphine. In contrast, there was no difference between the two genotypes 
when the mutation was transferred onto the congenic B6  background. A further set of 
experiments confirmed that this was not an effect of dose by showing that in B6  mice 
there was no difference between genotypes at a series of other doses. Furthermore, 
analysis of the habituation period showed heightened locomotor activity in NK l- / ~ 
mice compared to wildtype in the MF1 but not in the B6  strain.
3.4.2 Discrepancies with previous work
Each strain then presents discrepancies with the previous work by Murtra et al. (2000), 
Ripley et al. (2002) and Gadd (2003), which may be explained by differences in genetic 
background, experimental conditions and protocol, or a combination of both. Firstly, in 
the MF1 mice, disruption of the NK1 receptor did not produce a complete abolition of 
the locomotor response to morphine. Previously, a reduction in speed after morphine 
compared to saline was found in the N K l_/_ mouse by both Murtra et al. (2000) and 
Gadd (2003). Gadd (2003) observed that the MF1 mice used in that study (and in 
this thesis) displayed a lower sensitivity to the effects of morphine than those used by 
Murtra et al. (2000) in both a locomotor stimulating paradigm and CPP experiments. 
This indicates that some differences are conferred by the change in genetic background.
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However, for comparison of the studies other than Murtra et al. (2000), experimental 
conditions are likely to be important as well. Of these conditions, two key differences 
to highlight are the amount of habituation, if any, and the doses of morphine examined.
3.4.2.1 Effect of habituation
In the experiments in this thesis the animals were habituated to the test arenas for one 
hour before morphine administration. During this hour the animals were observed to 
habituate to the boxes by decreasing their activity. As a result the speeds in response 
to saline injection were very low in all groups and continued to decrease throughout 
the further two hours recording. This produced a low baseline locomotion over 
which drug-induced increases were easy to detect. In contrast, in the experiments by 
Murtra et al. (2000) and Gadd (2003), there was no habituation to the test environment 
before drug administration. Novel testing environments represent stressful stimuli 
to rodents even if care is taken to minimize the overtly stressful features such as 
bright lighting or loud noises (Leussis and Bolivar, 2006). The effects of stress on 
animals can be unpredictable and depend on many factors. These include the animal's 
genetic background as well as the effects of drugs. Interactions with the physiological 
reactions to stress will affect the outcome of any behavioural measures. Stress can have 
either a hyperlocomotor or a hypolocomotor effect in different situations depending 
on the nature of the stressor, the species and strain, and the testing conditions 
used. Stress is also known to affect responses to many drugs among them the 
psychostimulants (Marinelli and Piazza, 2002), morphine (Stohr et al., 1999; del Rosario 
et al., 2002), nicotine (Kita et al., 1999) and ethanol (Blakley and Pohorecky, 2006). In 
behavioural sensitisation paradigms stress can lead to a cross-sensitisation with drugs 
of abuse (Deroche et al., 1992). Many of these effects are believed to be mediated 
by corticotrophin releasing factor (Samyai et al., 2001). The effect of stress during 
behavioural experiments will be revisited in other sections of this thesis in more detail.
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3.4.2.2 Effect of dose
Both Murtra et al. (2000) and Gadd (2003) examined morphine-induced locomotion 
and CPP at a range of doses. Gadd (2003) used 15 m g/kg as the highest dose tested 
and although a separation of genotypes was observed with N K l_/_ mice decreasing 
their speed, this dose did not cause an increase in locomotion in wildtype mice. This 
is in agreement with pilot studies conducted in wildtype mice before the experiments 
presented here. These showed only a small increase at 15 m g/kg and resulted in the 
decision to use 20 m g/kg in the later experiments (data not shown). The results of 
Murtra et al. (2000) are difficult to interpret because the original mixed 129:B6 strain 
was used, although it has been suggested that the MF1 mice show a reduced sensitivity 
to morphine compared to the original 129:B6 mice (Gadd, 2003).
N K l_/_ mice on both the MF1 and the 129:B6 backgrounds have been shown 
to develop CPP to morphine at high doses (Murtra et al., 2000; Gadd, 2003). This 
observation fits with the data presented here showing that the response to morphine 
is blunted but not abolished completely. Together these data suggest that there may 
be a shift in the dose response curve to morphine in the NKl~/_ mouse in the 
MF1 strain and there are also differences between wildtype mice on each of these 
backgrounds (Gadd, 2003). Deletion of the NK1 receptor then does not bring about 
a complete insensitivity to morphine, an observation supported by the finding that 
hot-plate analgesia to morphine is intact in the knockout mouse (De Felipe et al., 1998). 
Furthermore, no differences between morphine metabolism, ^/-opioid receptor number, 
binding or function, receptor mRNA expression and modulation of adenylate cyclase 
activity by morphine have been found between the genotypes (Murtra et al., 2000; 
Gadd, 2003). This implies that the shift in morphine sensitivity in the knockout mouse 
is downstream of the receptor or involves a more complex change in behaviour at a 
systems level.
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3.4.3 Strain-genotype interactions
In B6  mice no difference in morphine-induced locomotion was observed between 
genotypes at any dose tested. A stimulatory effect of morphine was detected after 
administration of 5 m g/kg indicating a substantial shift in the dose response curve 
of the drug. This suggests that there is an interaction between some feature of the 
particular genetic background, the response to opiates and the NK1 receptor. Different 
genetic backgrounds can result in highly variable sensitivity to pharmaceutical agents 
due to a number of reasons. Differences in ligand receptor function or number, drug 
metabolism, and access to target structure as well as complicated epistatic interactions 
with other genes and regulatory elements can all result in shifted sensitivity to a 
particular compound (Horowitz and Dudek, 1983). On the other hand, differences in 
the dose response curve between genetic backgrounds may exist because morphine's 
effects are mediated by different pathways in each strain. Locomotion is not a simple 
behavioural output but is a polygenic trait that relies on the integration of a number 
of different neural substrates (Mink and Thach, 1993; Flint et al., 1995). Although the 
psychostimulants such as cocaine are known to increase locomotion primarily through 
increasing striatal dopamine (Wise, 1998), there is evidence that morphine acts on 
different pathways and can have a variety of effects on both motivational and affective 
systems (Dockstader and van der Kooy, 2001).
Hence, as well as the mesolimbic projection that mediates motivation, morphine 
acts at a number of other sites as well. Morphine has important effects on ]i opioid 
receptors within areas involved with the control of the HPA axis and affect, such as 
the LC and the amygdala. Morphine has been shown to produce anxiolytic effects in 
the light/dark box paradigm (Costall et al., 1989) and in place preference experiments 
(Dockstader and van der Kooy, 2001). These and other studies have differentiated 
between the motivational effects of morphine, which require disinhibition of the 
dopaminergic cells in the VTA, and its anxiolytic effects mediated by limbic structures 
via the HPA axis (Costall et al., 1989; Dockstader and van der Kooy, 2001). Both of
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these effects are known to produce changes in spontaneous locomotion as tested here, 
despite being subserved by different neural substrates. Importantly, lesion studies have 
also indicated that the rewarding effects of morphine are in part mediated by systems 
other than the motivational pathways (Olmstead and Franklin, 1996).
There is evidence to suggest that the NK1 receptor may be involved in mediating 
the anxiolytic actions of morphine. Experiments have used the selective neurotoxin 
saporin-substance P to specifically ablate cells expressing the NK1 receptor in different 
brain regions. These studies have implicated cells in the amygdala, but not the 
nucleus accumbens, as being essential for the development and expression of morphine 
reward (Gadd et al., 2003). Whilst the amygdala is part of the limbic system and 
is known to modulate anxiety, the nucleus accumbens is a critical site for motivated 
behaviours. Destruction of the NK1 receptor-expressing cells in the amygdala also 
influenced anxiety-related behaviour and reduced the hyperlocomotor response to 
morphine (Gadd et al., 2003). These results suggest that NK1 receptors located in the 
amygdala are involved in the expression of morphine-mediated behavioural effects via 
their role in anxiolysis.
In the MF1 and 129 strains which are known to be highly reactive to stressors 
morphine may preferentially increase their locomotion via its anxiolytic effects that 
increase exploration of novel environments. However, in strains of mice in which the 
anxiolytic effect of morphine is less important than the motivational component, the 
NK1 receptor may not be an important factor in influencing responses to morphine. As 
such in B6  mice, which display low levels of anxiety in novel environments, morphine 
may produce its effects primarily via stimulation of the mesolimbic dopaminergic 
pathway. In B6  mice, morphine is known to cause roughly a two-fold increase 
in extracellular striatal dopamine as compared to 129 mice (Murphy et al., 2001). 
Furthermore, in this thesis B6  mice were observed to increase their locomotion at far 
lower doses of morphine than the other strains tested. As such, B6  mice may be very 
sensitive to the locomotor stimulating effects of morphine mediated via motivational 
systems.
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More support for the hypothesis that the NK1 receptor is involved in the affective, 
and not the motivational, properties of morphine comes from work using other drugs. 
Responses of N K l_/_ mice or wildtype mice administered NK1 receptor antagonists 
have been shown to be unaffected to cocaine (Murtra et al., 2000; Ripley et al., 
2002; Piacenza et al., 2006). Cocaine is believed to increase locomotion primarily 
via stimulation of the mesolimbic motivational pathway and also lacks an anxiolytic 
component (Dockstader and van der Kooy, 2001).
Taken together these results imply that morphine increases locomotion through at 
least two separate pathways and that the NK1 receptor is critically involved in one of 
these. Morphine activates these pathways to a differing extent in each strain which 
may account for the observed differences in the effect of NK1 receptor disruption in 
each strain.
3.4.4 Differences in basal locomotion
Another significant feature of the results in this chapter was revealed by analysis of the 
habituation periods of mice. As described above, the studies previously conducted 
on morphine-induced locomotion in N K l_/_ mice differed as they did not use an 
habituation period (Murtra et al., 2000; Gadd, 2003). In this study, analysis of the 
habituation period revealed that NKl_/_ mice on the MF1 background moved faster 
than wildtype. The knockout mice also displayed higher locomotion than wildtype 
following saline injection. In contrast, on the B6  background no difference was found 
between the genotypes during habituation although if anything there was a trend for 
wildtype mice to move faster than N K l_/_ mice (p=0.058). Similarly in the B6  strain 
after saline injection there was no difference between genotypes. This result implies 
that in MF1 mice the novel environment has a strain-dependent stimulating effect on 
locomotion that is greater in N K l_//_ mice than wildtype. This result supports the idea 
that anxiety-related behaviours dependent on the NK1 receptor are of more importance 
in the MF1 strain than the B6  strain.
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3.4.5 Behaviour in the LDEB
As well as morphine-induced hyperlocomotion, behaviour in the LDEB was also ex­
amined in this chapter. NKl_/_ mice on the MF1 background differed from wildtype 
counterparts on a number of behaviours. Most of these behaviours corresponded with 
a more exploratory, anxiolytic phenotype. As such, N K l- / ~ mice performed less 
risk assessment behaviours and more rears than wildtype mice. On the other hand, 
N K l_/_ mice on the B6  background differed from their wildtype counterparts on only 
one behaviour, the number of transitions between compartments, in which wildtype 
mice made significantly more than knockout animals. Increased transitions have been 
associated by many authors as indicating anxiolytic properties (Bourin and Hascoet, 
2003).
The biggest overall effect in the experiment was that of strain. Of the fourteen 
behaviours measured, eight showed a main effect of strain and four of these behaviours 
also showed an interaction between strain and genotype.
It has previously been reported that changes in locomotor behaviour can confound 
the measurement and interpretation of results in the LDEB. As locomotor activity was 
identified as being dependent on strain, it was factored into the statistical design and 
removed as a covariate. Following this procedure, all eight behaviours still showed 
a main effect of strain and the main effect of genotype was gained on total rears but 
lost on grooming bouts. This demonstrates that differences in locomotion between the 
strains cannot account for the differences in behaviour measured. The interactions in 
a number of behaviours between strain and genotype show that knockout of the NK1 
receptor can have strain-dependent effects on behaviour in the LDEB.
With a number of the behaviours it is possible that there were no differences 
between genotypes in the B6  mice because of a floor or ceiling effect. For example, 
the wildtype B6  mice perform so few SAPs that it is unlikely that the N K l_/_ mouse 
could perform less. Similarly, wildtype B6  mice perform far more rears than MF1 mice 
and this high rate of responding may obscure any increase due to the mutation. It
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could be argued that the B6  mouse was outside the "working range" for many of the 
behaviours measured in the LDEB suggesting that they would be a poor mouse to 
use in this test. However, according to many reports B6  mice are one of "the strains 
of choice for anti-anxiety testing in the light/dark test" due to the robust effect of 
diazepam on increasing exploratory behaviours (Crawley and Davis, 1982; Bourin and 
Hascoet, 2003). On the other hand, other studies have failed to show B6  mice displaying 
anxiolytic behaviour in the light/dark box at any dose (Hascoet and Bourin, 1998; 
Griebel et al., 2000). Clearly, many differences exist in the parameters and laboratory 
conditions between different experimenters and these need to be considered carefully, 
especially for experiments to investigate anxiety and affective disorders.
3.4.6 Different mouse strains in the LDEB
Although many of the commonly used mouse strains have been tested in the LDEB, 
this is the first study to directly compare these two strains, a hybrid MF1:129:B6 
and the B6 . Likewise, few studies investigating strain differences have examined as 
many parameters in the test as were looked at here. The most comprehensive study 
examining a variety of strains in the light/dark test was conducted by Griebel et al. 
(2000). They studied nine different strains including B6 . Their apparatus included a 
tunnel between compartments and two parameters were measured, time spent in the 
light side and number of transitions. B6  mice, which were included in this study, were 
classified as displaying an intermediate level of anxiety and were not sensitive to the 
anxiolytic effects of diazepam in this test (Griebel et al., 2000). B6  mice have also been 
tested in this paradigm by a number of different authors with the general conclusion 
that they exhibit low anxiety (Crawley and Davis, 1982; Crawley et al., 1997; Hascoet 
and Bourin, 1998; Lepicard et al., 2000; Rodgers et al., 2002; Carola et al., 2004). One of 
these studies also examined the behaviour of 129 substrains in the LDEB (Rodgers et al., 
2 0 0 2 ), due to their importance in the creation of genetically modified animals (reviewed 
in section 1.2). Although differences in 129 substrains have been noted (Simpson et al.,
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1997; Cook et al., 2002), the majority of work supports the notion that in exploration- 
based anxiety models they exhibit a hypolocomotor response which may compromise 
some behavioural parameters (Crabbe et al., 1999; Homanics et al., 1999; Contet et al., 
2001; Bolivar et al., 2000).
In contrast to B6  and 129 backgrounds, the MF1 strain has been little studied with 
respect to anxiety-related behaviours. As an outbred strain there is a higher degree of 
variability in its behaviour than inbred strains. This variability has been used pinpoint 
RGS2 as a modulator of anxiety using quantitative trait analysis (Yalcin et al., 2004). 
However, a thorough understanding of how addition of the MFl-derived alleles may 
contribute to anxiety-related behaviours is lacking from the literature.
In this study, wildtype B6  mice exhibited higher locomotion, exploration (as 
assayed by rears and transitions) and performed fewer risk-assessment behaviours 
(SAPs) than the mixed MF1 background, as would be suggested by work comparing 
the B6  and 129 strains (Rodgers et al., 2002). Even after accounting for hypolocomotion 
in the MF1 strain by removing it as a covariate many of the behavioural parameters 
still displayed highly significant strain effects. This indicates an extremely high level of 
strain dependency for behaviours in this anxiety model, and by inference, for many 
of the other tests used to assay anxiety-related behaviour in mice. These findings 
accentuate the need to consider background strain carefully when creating genetically 
modified mice.
3.4.7 Mutant mice and the LDEB
The LDEB has also been used extensively to study anxiety-related behaviours in 
genetically modified mice (Bolivar et al., 2000; Belzung and Griebel, 2001). Here, 
we have shown strain-dependent effects on the anxiety-related behaviour of N K l- / ~ 
mice. N K l_/_ mice on the MF1 background displayed anxiolytic behaviour whereas 
knockout mice on the B6  background did not. In concordance with these results, 
other studies using N K l- /_  mice on the MF1 background have detected an anxiolytic
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effect of the mutation in the LDEB (Fisher, 2005; Herpfer et al., 2005). Both of these 
studies implicated the noradrenergic system in these changes. In other animal models 
of anxiety, an anxiolytic effect has been found in NK l_/_ mice and wildtype mice after 
administration of NK1 receptor antagonists (Rupniak et al., 2001; Santarelli et al., 2001; 
Bilkei-Gorzo et al., 2002; Santarelli et al., 2002).
The lack of anxiolytic profile in NKl~/_ mice on the B6  background could be 
attributed to their low anxiety profile as highlighted in previous paragraphs. The 
lack of effect of diazepam in a number of these studies has been attributed to this 
explanation. Another interpretation of the data is that in the B6  strain the NK1 receptor 
is not involved in anxiety-related behaviours, at least as measured in the LDEB. Future 
experiments using more aversive stimuli and tests examining other components of 
anxiety-related behaviour are required to determine which of these hypotheses is 
correct.
3.4.8 NK2 and NK3 effects
There is also a body of evidence that implicates the other tachykinin receptors, NK2 
and NK3, in behaviours linked to affective disorders. The NK2 receptor antagonists, 
GR159897 and SR489698, have shown efficacy in a number of animal models of anxiety 
(Stratton et al., 1993; Walsh et al., 1995; Teixeira et al., 1996; Griebel et al., 2001; Salome 
et al., 2006). Additionally, SR489698 has also displayed antidepressant-like effects in 
the forced-swim test in rats (Steinberg et al., 2001; Dableh et al., 2005). Although NK3 
antagonists have been less extensively studied, senktide has been observed to decrease 
anxiety in the EPM (Ribeiro et al., 1999) and SR142801 has produced anxiolytic effects in 
the social interaction test in gerbils (Salome et al., 2006) and antidepressant-like effects 
in the forced-swim test in rats (Dableh et al., 2005). Additionally, NK3 receptors in 
the LC have been shown to be essential for the activation of neurons in this area by 
NK1 receptor agonists (Bert et al., 2002). The involvement of the other tachykinins 
and tachykinin receptors in modulating anxiety-related behaviours is another area that
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warrants further study.
3.4.9 Summary
The experiments in this chapter have shown that knockout of the NK1 receptor affects 
both addiction- and anxiety-related behaviours in a profoundly strain-dependent 
manner. Morphine-induced hyperlocomotion was severely attenuated in NKl~/_ 
mice on the MF1 background. In contrast, when the mutation was backcrossed onto the 
B6  background the knockout animal was indistinguishable from the wildtype. In the 
LDEB the N K l~/_ mouse on the MF1 background exhibited several behaviours that 
were indicative of an anxiolytic phenotype. After crossing onto the B6  background 
the anxiolytic profile was lost but the genotypes were separable by a different trait 
— decreased number of transitions — normally associated with anxiogenic drugs. In 
conclusion, these experiments show that complex interactions exist between genetic 
background and targeted genetic mutations made for experimental purposes. The next 
chapters explore this finding in more detail.
92
Chapter 4
Results II: Reintroduction of the 129/sv 
strain_______________________________
4.1 Introduction
In the previous chapter, a set of experiments demonstrating the strain dependency 
of the N K l- /_  phenotype were described. Many of the key behavioural differences 
between the genotypes in the MF1 strain were lost on the B6  background making 
the study of NK1 receptor function difficult, if not impossible, in this mouse. It was 
therefore decided to reintroduce the 129/sv strain, one known to have higher basal 
anxiety-like behaviour. By backcrossing over several generations the mutation could 
be transferred onto this background thereby allowing the production of hybrid FI mice 
as recommended by the Banbury Conference (Silva et al., 1997) (see figure 1.1). While 
this breeding program was in progress the behavioural and molecular phenotype of 
the intermediate generations of mice was studied to see how the gradual dilution of 
the B6  background affected their responses. This and the next chapter describe these 
experiments.
4.2 Materials & Methods
The mice used in this and the next chapter were produced by crossing female B6  
N Kl~/_ mice with wildtype male 129/sv mice purchased from Harlan (Bicester, UK).
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The resulting heterozygotes on a mixed B6:129 hybrid background were crossed to 
produce homozygotes and heterozygotes. Either mice from this original cross or the 
FI generation of crosses between these homozygotes were used. These mice will be 
referred to as B6:129 mice to differentiate them from the original 129:B6 mixed strain 
used by De Felipe et al. (1998) and Murtra et al. (2000). See figure 2.2 for more 
information.
The morphine-induced locomotor hyperactivity and LDEB experiments were per­
formed as described in the previous chapter. For the morphine hyperlocomotion 
experiment, after 1 h of habituation mice were administered morphine and had their 
locomotor activity recorded for the subsequent 2 h. Mice were administered either 0, 
10,20 or 30 m g/kg morphine. For the LDEB experiments after 1 h habituation, animals 
were placed in the light compartment and behaviour was observed and scored for 1 0  
min.
4.3 Results
4.3.1 Baseline locomotion
Baseline locomotion was assessed as in the previous chapter by analysing the activity 
of all animals during the habituation period as well as animals that received saline 
injections during the testing period. Figure 4.1 summarises these results. 1-way 
ANOVA conducted on speed moved during habituation with genotype as the between 
subjects factor revealed a main effect of genotype (Fi/85=14.956, p<0.001) showing that 
N K l_/_ mice moved faster than their wildtype counterparts during this period. In 
contrast, 1-way ANOVA on speed moved after saline injection revealed no difference 
between the genotypes (Fi/i4=1.041, p=0.325). This result implies that N K l_/_ mice 
may react to a novel environment differently than wildtype mice when the mutation is 
in the B6:129 strain. This result partly recapitulates what was found in MF1 mice in the 
previous chapter.
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Figure 4.1: Baseline locomotion. Mean ±  SEM speed traveled by NK1~/_  and wildtype mice 
on the B6:129 background during the habituation period or after administration of saline. ***, 
p<0.001 vs wildtype; n=7-17.
4.3.2 Morphine-induced locomotion in B6:129 mice
Figure 4.2 shows the locomotor activity induced by different doses of morphine in 
NKl~/~ and wildtype mice on the mixed B6:129 genetic background. 3-way repeated 
measures ANOVA with genotype (G) and dose (D) as the between subjects effects and 
time point (T) as the within subjects effect revealed main effects of genotype, dose and 
time as well as significant G x D, T x D and T x G x D interactions. These results are 
summarised in table 4.1.
Subsequent 2-way ANOVA on the average speed travelled in the 2 h period 
following injection with genotype (G) and dose (D) as between subjects factors revealed 
main effects of genotype and dose and a significant G x D  interaction. 1-way ANOVAs 
for each dose to examine the effect of genotype revealed a main effect of genotype at 2 0  
m g/kg but not at any other dose (figure 4.3).
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Figure 4.2: Morphine-induced locomotion. Mean ±  SEM speed traveled by NK1_ / _  and 
wildtype mice on the B6:129 background after administration of saline (a) or morphine (10 
mg/kg, b; 20 mg/kg, c; 30 mg/kg, d). Arrows indicate time of injection. n=7-17.
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Table 4.1: Results of 3-way ANOVA on morphine-induced locomotor data in B6:129 mice
Factor d.f. Error d.f. F P
Genotype (G) 1 .0 0 0 79.000 10.736 0 .0 0 2
Dose (D) 3.000 79.000 10.788 < 0 .0 0 1
Time point (T) 2.465 194.738 76.856 < 0 .0 0 1
G x D 3.000 79.000 9.150 < 0 .0 0 1
G x T 2.465 194.738 1.123 0.335
D x T 7.395 194.738 9.328 < 0 .0 0 1
G x D x T 7.395 194.738 5.802 < 0 .0 0 1
20 i
IE
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Figure 4.3: Morphine dose response. Mean ±  SEM speed traveled by NK1~/_  and wildtype 
mice on the B6:129 background after administration of saline or morphine. ***, p<0.001 vs 
wildtype; n=7-17.
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4.3.3 LDEB in B6:129 mice
N K l- /_  and wildtype mice on the mixed B6:129 background were tested in the LDEB 
as outlined for the MF1 and B6  strains in the previous chapter. All behaviours were 
scored and values are given in table 4.2 below. A MANOVA test with genotype as the 
main factor was conducted to control for multiple comparisons. As genotype failed to 
reach significance (Fi3/3=1 .3 4 5 , p=0.455) further probing of the dataset was precluded 
although two behaviours, latency to leave the light compartment and number of 
SAPs, appeared to show a trend that differed between the genotypes. In general, the 
values obtained for behaviours fell in between those found in the two other strains. 
These results suggest that crossing B6  mice with 129 mice resulted in a strain with 
intermediate phenotype. This may have masked the effect of the mutation previously 
observed in different strains.
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Table 4.2: LDEB results in B6:129 mice. Values are mean with SEM in parentheses; n=8-9.
Behaviour B6:129 + /+ B6:129 - /-
Latency (s) 23.2 (5.0) 1 2 .0 (2 .0 )
Return to light 27.3 (14.3) 29.7 (19.8)
Activity (mm/s) 32.5 (2.9) 35.3 (4.4)
Activity :Dark (mm/s) 23.4 (2 .1 ) 28.2 (3.6)
Activity:Light (mm/s) 44.4 (1.5) 45.6 (3.0)
Time:Dark (s) 315.1 (37.2) 272.1 (48.6)
Hme:Light (s) 283.7 (37.2) 327.1 (48.5)
Transitions 35.0 (3.9) 38.3 (6 .0 )
SAPs 15.3 (3.2) 8 .2 (2 .8 )
Rears (Total) 38.5 (6.5) 47.3 (9.6)
Rears (Dark) 1 0 .6 (1 .6 ) 1 1 .6 (2 .8 )
Rears (Light) 27.9 (5.5) 35.8 (7.2)
Grooming (bouts) 1.3 (0.3) 2 .0 (0.3)
Grooming (s) 16.0 (3.1) 20.4 (4.8)
4.4 Discussion
In this chapter the behaviour of a newly created hybrid strain of N K l_/_ and wildtype 
mice was tested. Two protocols, morphine-induced hyperlocomotion and behaviour 
in the LDEB were examined. In the previous chapter the effect of disruption of 
the NK1 receptor on these two behaviours was shown to be strain-dependent. As 
such, the attenuation of morphine-induced hyperlocomotion in N K l_/_ mice on the 
MF1 background was not present when tested on the B6  congenic background. The 
NK1- / " mouse on the MF1 background also displayed an anxiolytic profile in the 
LDEB. These behaviours similarly disappeared after crossing onto the B6  background. 
By crossing back onto the 129/sv  background in this chapter it was hoped that the
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behaviours associated with the MF1 mouse (and the original 129:B6 mouse) would be 
recapitulated.
4.4.1 Morphine-induced locomotion
Morphine-induced hyperlocomotion was assessed at a number of different doses in the 
newly created B6:129 strain. At 10 m g/kg no increase in locomotion compared to saline 
was observed in either genotype. This result replicates what was found in the MF1 
strain. 20 m g/kg produced a significant locomotor activation in the NK l- /_  mouse 
that was not seen in their wildtype counterparts. This result is intriguing as it contrasts 
with what has previously been found in the MF1 strain and in the original 129:B6 strain. 
30 m g/kg of morphine produced an increase in locomotion to the same extent in both 
genotypes. These results suggest that there is an interaction between the NK1 receptor, 
an aspect of the opioid system and genetic background that is capable of producing 
complex effects on the behavioural output. The NK1 receptor appears to be uninvolved 
in the locomotor response to the opiates in the B6  strain as disruption of the receptor 
has no effect on this behaviour. In contrast, in the MF1 strain the NK1 receptor appears 
to be responsible in part for mediating the increase in locomotion caused by morphine 
as disruption of the receptor causes a major attenuation of this behaviour. Additionally, 
in the MF1 strain the rewarding, reinforcing and sensitising properties of morphine are 
attenuated in the NKl_/_ mouse and the physical responses to opiate withdrawal are 
reduced (Murtra et al., 2000; Ripley et al., 2002). Surprisingly, here we find that on a 
mixed B6:129 background the locomotor response to morphine is increased. It appears 
that on this background knockout of the NK1 receptor potentiates or sensitises the 
opioid system to morphine challenge. Although variation in experimental procedure 
can not be completely discounted, the reasons for this difference most likely stem from 
differences in the genetic background of the mice.
Differences have been noted, as described in the previous chapter, between the 
sensitivity to morphine in each of the strains tested. Gadd (2003) observed MF1 mice to
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be slightly less sensitive to the rewarding and stimulating properties of morphine than 
the original 129:B6 mice used by Murtra et al. (2000). Additionally, work in this thesis 
has shown B6  mice to be far more sensitive than either of these strains, at least to the 
effects of morphine on locomotion. The B6:129 mouse tested in this chapter displays 
a relatively low level of locomotion both before and after administration of morphine 
that is more akin to that observed in the MF1 and the original 129:B6 mice used by 
Murtra et al. (2000) and Gadd (2003). This is in agreement with studies describing 129 
strains as showing hypolocomotion in a number of behavioural tasks (Crabbe et al., 
1999; Homanics et al., 1999; Bolivar et al., 2000; Contet et al., 2001).
4.4.2 Strain differences in morphine-induced behaviours
The finding that NKl~/_ mice on the B6:129 background appear more sensitive to 
the locomotor stimulating effects of morphine is surprising and warrants further 
consideration. Substantial variability exists between the propensity for different 
individuals to develop addiction to drugs, including the opiates. It should therefore 
not come as a surprise that variability exists between different mouse strains in this 
regard. Although there is a large body of work examining many of the mouse 
strains, there is a paucity of data specifically comparing opiate-mediated behaviours 
in 129/sv and C57BL/6 mice. This is likely due to 129 substrains performing poorly 
on the behavioural tests used to assay reward (Miner, 1997). Some studies have 
been conducted, however, and these may be instructive in helping to explain the 
results presented in this chapter. One such study has directly compared B6  mice and 
129:B6 hybrid mice with regard to heroin-induced conditioned reward and locomotor 
sensitisation (Szumlinski et al., 2005). Here, B6  mice were found to develop a strong 
place preference to heroin that was reversed to a place aversion in B6:129 mice. As 
the hybrid mouse was backcrossed onto the B6  background this aversion was in 
turn reversed back to a preference in a strain dose-dependent manner. Furthermore, 
locomotor sensitisation was only observed in B6  mice whilst B6:129 hybrids and
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intermediate generations with varying amounts of B6 strain displayed a reduction in 
locomotion after repeated administration of heroin. Although only one dose of heroin 
was tested in these studies, the result is of interest with regard to the differences in 
morphine-induced locomotion reported in this chapter.
In the study by Ripley et al. (2002), NKl~/_ mice were shown to have reduced 
responding to morphine in self-administration studies. In contrast, other groups have 
shown that NK1 receptor antagonists will increase self-administration of heroin in rats 
(Piacenza et al., 2006).
These differences, as well as the ones reported in this chapter, likely arise due to 
differential sensitivities to morphine in the different strains or genotypes. The reward­
ing and reinforcing properties to morphine may rely on changes in the specific neural 
circuitry underlying these behaviours or may instead reflect different distributions, 
expression patterns or functional activities of the opioid receptors.
There is evidence from a number of sources that differences at a cellular level may 
account for the variability in responses observed here. Genetically, there is a divergence 
between 129 and B6 mice in the intronic sequences surrounding exons 2 and 3 of 
Orpm, the gene encoding the //-opioid receptor. These regions may regulate transcript 
stability and C-terminal splicing (Zhou et al., 2001). Quantitative trait loci mapping has 
identified regions of Chromosome 10, near Orpm, as being important for oral morphine 
preference (Berrettini et al., 1994). The same QTL has also been identified as being 
important for other opiate-related traits such as morphine analgesia and [3H]naloxone 
binding (Belknap et al., 1995). There is also considerable evidence that differences exist 
in p. opioid receptor expression levels between mouse strains. It is thus possible that 
interstrain variability in the genomic sequence comprising of or surrounding Orpm 
gives rise to differences in receptor expression, distribution and /o r function and that 
in turn this could lead to unique patterns of opiate-mediated behaviour in each strain. 
Interestingly, a polymorphism in the gene encoding the human ]i opioid receptor may 
also be linked with opiate-dependence in the human population (Bond et al., 1998).
In the 129/SvEv substrain morphine tolerance does not develop either to implanted
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pellets or repeated injections, an effect that may be mediated by an NMDA receptor 
defect (Kolesnikov et al., 1998). As well as opiate reward-mediated behaviours, there 
are well-characterised pain-related phenotypic differences observed for the B6 and 
129 backgrounds as well as many other mouse strains (Mogil, 1999). Interestingly 
however, strains of mice that show high sensitivity to opiates in one particular test do 
not necessarily show high sensitivity on other tests. This is the case for B6 mice which 
have a low sensitivity to morphine analgesia but are highly sensitive to other opioid- 
mediated phenomena, including locomotor activation, learning and memory, and 
muscular rigidity (Mogil et al., 1996). This suggests a high degree of interaction with 
other components of the nervous system and implies that differences may well exist 
in patterns of receptor expression as well as absolute levels. This may be important 
for explaining the genotype-dependent results observed in this thesis as interactions 
between the NK1 receptor and the \i opioid receptor may occur in several brain regions 
and this may vary between strains.
4.4.3 Interactions between NK1 and opiate receptors
The NK1 receptor and the opiate receptors are both expressed in the regions of the 
limbic system such as the amygdala, hypothalamus and the LC as well as in the dorsal 
horn of the spinal cord (Gadd, 2003; Mansour et al., 1987; Moyse et al., 1997; Chen et al., 
2000). In vitro experiments have shown heterodimerisation of the NK1 and \i opioid 
receptor which may lead to alterations in internalisation (Pfeiffer et al., 2003) and PPT- 
A, the precursor protein to substance P has been shown to regulate trafficking of the S 
opioid receptor in the spinal cord (Guan et al., 2005). Additionally, in mice lacking 
]i opioid receptors, substance P mRNA expression is reduced in the ventromedial 
hypothalamus (Yoo et al., 2005) and morphine also upregulates NK1 receptor mRNA 
and protein in cultured cortical neurons (Wan et al., 2006).
Furthermore, it is also unknown at present whether there is interstrain variability 
in NK1 receptor expression levels or distribution. Although immunocytochemical
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techniques suggest that there are no gross differences between the strains studied 
here, this question has not been addressed in a systematic and quantitative manner. 
Interestingly, another QTL discovered to influence oral morphine drinking was located 
on Chromosome 6, in the region of the gene encoding the NK1 receptor. As with the 
work investigating Orpm, it may be that differences in this region between the strains 
account for the behavioural variability in response to morphine and after disruption 
of the receptor (Berrettini et al., 1994). Behaviourally, animals heterozygous for the 
functional NK1 receptor are indistinguishable from wildtypes indicating that the gene 
is haplosufficient (Santarelli et al., 2001). This would argue against an explanation 
involving expression levels of the receptor. However, it may be that there are changes 
in the functional activity or subcellular distribution of the receptor between different 
strains that are important.
As well as interstrain differences in or around the sequences of the genes that 
may be directly involved in the changes seen in these mice there is also evidence for 
differences in regulatory elements that may be distal to these genes (Padjen et al., 2005). 
Such elements can include enzymes and transcription factors which act to modify, 
either specifically or otherwise, the expression of genes of interest. Such changes may 
affect the methylation state of important genes. Methylation of regions of DNA is one 
method of repressing their expression by changing the chromatin structure (Tsankova 
et al., 2006). The genes responsible for this methylation can often be passed down via 
epigenetic mechanisms (Weaver et al., 2004; Mager and Bartolomei, 2005). Work has 
shown that B6 mice may differ from other strains in the methylation patterns of their 
DNA making it more resistant to modifications (Schumacher et al., 2000; Padjen et al., 
2005).
Other studies using different drugs of abuse have found strain-genotype inter­
actions when examining transgenic mice. Notably, an effect of genetic background 
was reported for mice over-expressing the 5 -HT3 receptor. The mouse was originally 
characterised on a B6SJL/F2 background. A phenotype that included reduced alco­
hol drinking preference, attenuated cocaine place preference and increased cocaine-
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induced locomotor stimulation, was found in the transgenic mouse (Engel and Allan, 
1999; Allan et al., 2001). However, to investigate the influence of the parental strains, 
the transgene was bred onto two backgrounds known to differ on a number of these 
behaviours, the B6 and DBA/2J (D2) strains. Mutant mice on the B6 strain recapitulated 
the phenotype originally seen. In contrast, the effect of the transgene was only 
observed in one test when using the D2 mice (Metz et al., 2006). Another study 
investigating the role of the dopamine D2 receptor in ethanol-induced stimulation also 
showed an epistatic interaction between deletion of the gene and background strain, 
this time between B6 and 129 mice (Palmer et al., 2003). Furthermore, differences in the 
percentage of B6-derived genes have been shown to confer differing susceptibility to 
cocaine in a study using a self-administration paradigm (Ruiz-Durantez et al., 2006).
Together these results suggest that genetic background can have a substantial effect 
on the sensitivity of an animal to specific properties of a drug, which may reflect 
changes at a molecular, cellular or systems level. Additionally, there are likely to 
be important interactions between the NK1 receptor and opiate receptors which also 
contribute to an animars sensitivity to morphine as well as the particular behavioural 
consequences this has.
4.4.4 Behaviour in the LDEB
Previously, in this study and others, NK l_/_ mice on the MF1 background have been 
shown to have an anxiolytic profile in the LDEB (Fisher, 2005; Herpfer et al., 2005). This 
anxiolytic profile was absent in NKl~/_ mice on the B6 background, however, either 
due to being masked by the strain's low baseline anxiety or due to an uninvolvement 
of the NK1 receptor in anxiety-related behaviours on this background. In this chapter, 
crossing back onto a 129/sv background to produce a mixed B6:129 mouse failed to 
uncover any major differences between the genotypes. Two behaviours associated with 
anxiolysis displayed a trend towards increasing in the knockout but neither reached 
significance. Overall, however, the phenotype of this mouse appeared intermediate
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with respect to the MF1 and B6 strains. The original studies using the N K l_/_ mouse 
on a mixed 129:B6 background by De Felipe et al. (1998) also failed to show an anxiety- 
related phenotype using the EPM indicating that this particular mix of strains may 
not be ideal for studying these phenomena. In work using an N K l- /_  mouse on 
a congenic 129 background by Santarelli et al. (2001) an anxiolytic effect in the EPM 
was observed. 129 strains, as discussed, show a high baseline anxiety and are thought 
to be highly "emotional". Taken together these results imply that the effect of NK1 
receptor disruption on anxiety-related behaviour is more likely to be observed in highly 
"emotional" strains than others.
It would be predicted from this work that continuing the backcrossing strategy onto 
a congenic 129 background would eventually, after a number of generations, result in 
a return of the anxiolytic profile in the NK l- / ~ mouse. Similarly, as suggested in the 
previous chapter, the use of more aversive stimuli or different testing procedures may 
allow the effect of the receptor knockout to be observed.
4.4.5 Summary and conclusions
In summary, the results in this chapter show that crossing the mutation in the NK1 
receptor back onto the 129/sv background over one generation leads to the unmasking 
of an interesting phenotype. Disruption of the receptor caused the knockout mouse to 
become more sensitive to the locomotor stimulating properties of morphine but had no 
effect on behaviour in the LDEB. These results again underscore the need to consider 
the complications introduced by strain selection on experiments using genetically 
manipulated mice. The next chapter explores differences between these two strains 
at a molecular level with particular emphasis on the hypothalamic-pituitary-adrenal 
(HPA) axis.
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Results III: The HPA axis in the NK1-/- 
m ouse
5.1 Introduction
The previous two chapters detail a set of experiments comparing the behavioural 
responses of NKl~/_ mice on three different genetic backgrounds. Much of the 
phenotype caused by the NK1 receptor mutation on the MF1 background was lost 
after crossing onto a congenic B6 background. After crossing back onto the 129/sv 
background for one generation a complex phenotype emerged. The differences in 
baseline locomotion found in the MF1 strain were recapitulated. However, although a 
genotype-dependent difference in morphine-induced hyperlocomotion was uncovered 
it opposed the previous findings in the MF1 (and original mixed 129:B6) strain. 
Behaviours measured in the LDEB seemed for the most part to take on an intermediate 
phenotype between the wildtype B6 and MF1 strains and although two behaviours 
associated with anxiolysis showed a trend towards increasing in the knockout they did 
not differ significantly. This intriguing set of results is the effect of the complex set of 
interacting genetic factors present in each strain. The consequences of manipulating 
a single gene are subject to a different set of modifying factors within each genome 
resulting in unpredictable phenotypic variation. This is not unprecedented and has 
been found in other studies using transgenic mice. Many of these studies identified 
changes in the HPA axis between different mouse strains as contributing to observed
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variability (Peinado et al., 2005; Carter, 2006). We therefore hypothesised that differing 
responsivity of the HPA axis may account for some of the inter-strain variation in the 
NK1 receptor mutant. This chapter examines a number of features of this HPA axis in 
the N K l_/_ mouse on the B6  and the 129 background.
5.1.1 The hypothalamic-pituitary-adrenal (HPA) axis
The HPA axis is responsible for orchestrating the stress-responsive endocrine system 
via a complex series of connections and feedback loops. Anatomically, as suggested by 
it's name, it consists of the hypothalamus, the pituitary gland and the adrenal glands. 
Its main function is to control levels of circulating glucocorticoids which fluctuate in 
response to external environmental stressors as well as due to sleep/wake patterns 
(Herbert et al., 2006). Corticotrophin releasing factor (CRF) and arginine vasopressin 
(AVP) are synthesised in the paraventricular nucleus of the hypothalamus (PVN) and 
released by nerve terminals into the median eminence. They are transported through 
the portal blood vessel system of the hypophyseal stalk to the anterior lobe of the 
pituitary where they stimulate release of adrenocorticotropic hormone (ACTH). ACTH 
is transported in the blood to the adrenal cortex of the adrenal gland where it stimulates 
biosynthesis of glucocorticoids from cholesterol (Pariante, 2006). For a summary see 
figure 5.1. These glucocorticoids, corticosterone in rodents and cortisol in man, have 
many effects throughout the body, including within the brain. There are two main 
receptor types: mineralocorticoid or Type I receptors (MR) and glucocorticoid or Type 
II receptors (GR). They differ in their affinity for corticosterone such that MR have 
high affinity and so are fully occupied at low hormone levels while GR have far lower 
affinities and so only become activated upon greater release of corticosterone (Korte, 
2001).
GRs can have direct effects on intracellular molecules or can act as transcription 
factors controlling gene regulation. They also form part of a negative feedback loop in 
the brain whereby their activation acts to terminate further corticosterone release. This
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action is important for coupling the physiological response to a stressor to hormonal 
release (Korte, 2001). Although release of corticosterone is essential for many processes 
including the ability to respond to environmental threat, prolonged periods of high 
release can be harmful (Korte et al., 2005; Herbert et al., 2006). Depression has been 
linked to disturbances in control of the HPA axis as described in section 1.4.3 of 
Chapter 1.
5.1.2 Interactions between the HPA axis and behaviour
Differences in corticosterone levels and HPA axis activity may account in part for some 
of the behavioural differences observed in this thesis. The HPA axis is known to impact 
upon the locomotor response to morphine (Marinelli et al., 1994; Deroche et al., 1995; 
Stohr et al., 1999) and behaviour in the LDEB (Bourin and Hascoet, 2003), which have 
been examined in the two previous chapters.
5.1.2.1 The opiate system and the HPA axis
The opiate system and the HPA axis interact at a number of different sites. ]i opioid 
receptors are expressed in several areas, such as the LC, the hypothalamus, the 
hippocampus and the amygdala, which are all known to modulate HPA activity. 
Opiates affect the HPA axis indirectly via actions on the noradrenergic system (Samyai 
et al., 2001). These effects can be complex, probably due to the wide distribution of 
opiate receptors, and as such systemic morphine has been shown to both stimulate and 
inhibit corticosterone release in unstressed and stressed rats, respectively (Suemaru 
et al., 1989). In vitro experiments have shown that direct stimulation of hypothalamic 
opioid receptors inhibits CRF release (Buckingham, 1982). In turn, glucocorticoids 
also have a variety of effects on opiate-mediated behaviours such as morphine- 
conditioned place preference (Ferguson et al., 2004), hyperlocomotor effects (Deroche 
et al., 1992) and analgesia (Mousa et al., 1981). Long term opiate exposure also inhibits 
neurogenesis (Eisch et al., 2000).
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5.1.2.2 Anxiety-related behaviours and the HPA axis
Behaviour in the LDEB assays the effects of a novel environment on animal behaviour. 
Novel environments represent mild stressors to rodents and so behaviour in this test 
is also critically linked to activation of the HPA axis (Costall et al., 1989; Bourin and 
Hascoet, 2003). More work is required in this area to understand why different strains 
react to testing conditions in different ways and how activation of the HPA axis is 
involved.
5.1.3 Neurogenesis
For many years it was believed that neurogenesis, the formation of new neurons, 
occurred only during foetal development. However, it is now known to persist 
throughout adulthood in at least two discrete regions of the brain: the hippocampus, 
where neurons are bom in the subgranular zone of the dentate gyms, and the olfactory 
bulbs, which neurons migrate to from the subventricular zone. It has also been 
observed in the neocortex and striatum, albeit controversially (Gould and Tanapat, 
1999). In the olfactory bulb it is believed that new neurons are simply replacing old 
ones. In the hippocampus, however, the functional role of neurogenesis is less well 
understood. The addition and assimilation of new neurons into existing circuits would 
be postulated to enhance hippocampal function. Indeed, suppression of neurogenesis 
produces memory impairments in hippocampus-dependent trace conditioning (Shors 
et al., 2001). Similarly, training in a hippocampus-dependent task results in a increase 
in the number of newly-generated adult granule cells (Gould et al., 1999) and long­
term memory of water maze learning shows a requirement for neurogenesis (Snyder 
et al., 2005). Furthermore, genetic differences in neurogenesis between mouse strains 
also correlate with acquisition of water maze learning (Kempermann and Gage, 2002). 
Evidence is therefore accumulating that neurogenesis may contribute to learning and 
memory processes. Recent work highlights ways in which newly bom neurons may 
contribute to information storage via their NMDA receptors (Tashiro et al., 2006) and
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may be involved in episodic memory storage (Aimone et al., 2006).
The role of hippocampal neurogenesis in depression is less well known. As detailed 
in section 1.4.3 support for the hypothesis linking the two together has come mostly 
from the investigation of antidepressant effects. The actions of the HPA axis on 
neurogenesis also provide another causative link. Elevated HPA axis activity, which 
is associated with depression, has a inhibitory effect on neurogenesis (Cameron and 
Gould, 1994). The effect of increased circulating glucocorticoids in inhibiting cell 
proliferation is likely mediated via NMDA receptors (Gould et al., 1994; Cameron 
et al., 1995). Acute or chronic exposure to stressors in many species also decreases 
neurogenesis (Gould et al., 1997).
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Figure 5.1: The HPA axis. Stress causes the release of noradrenaline (NA) and other peptides 
which stimulate the release of corticotrophin releasing factor (CRF) and arginine vasopressin 
(AVP) from the hypothalamus. These act synergistically in the anterior pituitary to produce 
adrenocorticotropic hormone (ACTH) which is transported via the blood stream to the adrenal 
glands where it stimulates production of corticosteroids from cholesterol. These corticosteroids 
have a number of peripheral and central effects and also act as a negative feedback to terminate 
the stress response via actions in the hippocampus and hypothalamus.
112
Chapter 5
5.2 Materials & Methods
Corticosterone was measured at four different time points in B6  and 129:B6 strains as 
described in Chapter 2. Brains were taken from all animals and processed using in situ 
hybridisation to examine mRNA levels of CRH and cFos in the PVN.
Neurogenesis was measured using the 5-bromo-2/-deoxyuridine (BrdU) labelling 
technique. BrdU is a synthetic thymidine analogue which is incorporated into newly 
divided cells. Animals were administered with four injections of BrdU (50 mg/kg; 
i.p.) 2 h apart. 24 h after the last injection animals were perfused as detailed in 
Section 2.1.6 in Chapter 2 and IHC was carried out using anti-BrdU antibody and 
the DAB technique. Sections were taken through the dorsal hippocampus every 120 
pm  (approx. 1 0  sections) and stained cells in the dentate gyrus were counted by an 
experimenter blinded to genotype.
Glucocorticoid receptor (GR) expression was labeled using IHC and quantified 
using a confocal microscope as detailed in Chapter 2. Cells in hippocampal CA1 region 
were measured as they were the best defined. The luminosity of 10 cells per section was 
measured and a background score measured from outside the cell layer was subtracted 
from these. 5-6 sections per animal in the dorsal hippocampus were measured.
5.3 Results
5.3.1 Plasma corticosterone
To investigate differences in HPA axis regulation between the strains and genotypes, 
the corticosterone response to a stressor was measured. 30 min of restraint in a Falcon 
tube was used as the stressor. 4 treatment groups were examined: no stress; 30 min 
restraint; 30 min after termination of restraint; and 60 min after termination of restraint. 
Figure 5.2 summarises this data. 3-way ANOVA with genotype (G), strain (S) and 
treatment (T) as between subjects factors revealed a main effect of strain and treatment 
and a significant S x T interaction. The results of this ANOVA appear in table 5.2.
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Table 5.1: Plasma corticosterone levels. Mean value in ng/^l with SEM in parentheses. 30 min, 
immediately after 30 min restraint stress; 60 min and 90 min, 30 min and 60 min, respectively, 
after termination of 30 min restraint stress. N=8.
Treatment group B6  + /+ B6 - /- B6:129'+ /+ B6:129 -/-
Basal 16.1 (3.4) 15.0 (4.3) 13.7 (2.4) 20.9 (4.1)
30 min 257.0 (18.9) 274.7 (15.1) 354.4 (26.1) 347.9 (31.3)
60 min 158.4 (15.0) 185.8 (14.2) 323.1 (52.8) 242.4 (17.4)
90 min 79.5 (23.9) 8 8 .8 (11.3) 152.9 (13.6) 196.8 (32.4)
Subsequent 2-way ANOVAs were conducted on each treatment group with genotype 
and strain as between subjects factors and are shown in table 5.3. Treatment groups 
with significant main effects or interactions were further analysed with 1-way ANOVA 
using group as a between subjects factor and post hoc Tukey tests to identify specific 
differences.
The basal levels of corticosterone showed no effects of either genotype or strain or 
a significant interaction implying that resting corticosterone levels are not modulated 
by NK1 receptor knockout or differences between the strains.
2-way ANOVAs on CORT levels in other treatment groups (30 min restraint; 30 
min after restraint; 60 min after restraint) revealed a main effect of strain but no effect 
of genotype and no significant interactions. Data were collapsed across genotypes and 
1-way ANOVAs with strain as the main factor revealed a main effect of strain after 30 
min restraint (p=0.001) and 30 min (p=0.001) and 60 min after termination of restraint 
(p<0.001). In other words, after being subjected to a stressor, mice on the B6:129
ft
background released higher levels of corticosterone compared to B6  mice. Although 
both strains exhibited elevated levels above basal for the following hour the 129:B6 
levels were significantly higher than B6 . These effects were independent of genotype.
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Figure 5.2: Corticosterone levels in B6 and B6:129 mice. Mean ±  SEM plasma corticosterone 
levels basally, after 30 min restraint stress and 30 min and 60 min after termination of restraint 
stress in B6 and B6:129 strains. N=8. ***, p<0.001 B6 vs 129.
Table 5.2: Results of 3-way ANOVA on corticosterone data
Factor d.f. Error d.f. F P
Genotype (G) 1 112 1.354 0.247
Strain (S) 1 112 28.631 <0.001
Treatment (T) 3 112 270.997 <0.001
G x S 1 112 0.015 0.902
G x T 3 112 0.574 0.634
S x T 3 112 3.721 0.014
G x D x T 3 112 1.425 0.239
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Interaction
F1/28=1.298 P=0.264 
Fi/28=0.260 P=0.614 
Fi/28=2.585 P=0.119 
Fi,28=0.132 P=0.719
Table 5.3: 2-way ANOVAs on corticosterone levels
Treatment group Genotype Strain
Basal F1/28=0.693 P=0.412 Fi/28=0.232 P=0.634
30 min Fj,28=0.055 P=0.816 Fi/28=12.942 P=0.001
60 min FU8=0.018 P=0.894 Fi/28=15.371 P=0.001
90 min F1/28=1.542 P=0.225 F1/28=17.085 P<0.001
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5.3.2 Neurogenesis
Neurogenesis was measured using the BrdU-labelling technique. The photomicro­
graphs in figure 5.3 show neurogenesis occurring in the dentate gyrus. At higher 
magnification it is possible to see clusters of dividing cells. All counting was performed 
at this higher magnification. The data are summarised in table 5.4. Because the 
different strains were processed at different times no comparisons of strain effects have 
been made. Unpaired student's t-tests have been used to compare genotypes for both 
strains and data have been normalised to the wildtype mean for plotting in figure 5.3. 
Statistical analysis revealed that there was no difference in neurogenesis between the 
genotypes in the B6  strain (p=0.903). In contrast, in the B6:129 strain NKl_/_ mice 
exhibited significantly more neurogenesis than wildtype mice (p=0.015).
5.3.3 Glucocorticoid receptor
GR expression in the hippocampus was measured using IHC as described. The 
specificity of the antibody was determined using immunoblot analysis as shown in 
section 2.2. Strong expression of GR was seen in many subfields of the hippocampus 
with the most clearly labelled cells in CA1 region. Photomicrographs of GR expression 
are shown in figure 5.4. Unpaired Student's t-tests were used to compare the genotypes 
in both strains. No difference was found in GR expression between wildtype and 
N K f-/-  mice in the B6  strain (p=0.899). In contrast, in the B6:129 strain GR expression 
was significantly increased by approximately 40 % in the NKl~/_ mouse compared to
Table 5.4: Neurogenesis data. Mean number of cells per section with SEMs in parentheses. 
N=6-8.
Strain NK1+ /+ NK1“ / -
B6  22.8 (1.9) 22.5 (1.6)
B6:129 15.9 (1.6) 23.8 (2.4)
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Figure 5.3: Neurogenesis in B6 and B6:129 mice. Photomicrographs show representative 
examples of BrdU-labelled cells in wildtype and NK1 mice on the B6 (a,c) and the B6:129 
(b,d) backgrounds. Clusters of cells can be seen  dividing at higher power (e). Data are plotted 
as mean ±  SEM (f). *, p <0.05  vs. +/+; N=6-8.
wildtype (p=0.008).
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Figure 5.4: Glucocorticoid receptor expression in B6 and B6:129 mice. Photomicrographs 
show representative examples of GR-labelled cells in wildtype and NK1- / _  mice on the B6 
(a,c) and the B6:129 (b,d) backgrounds. The whole hippocampus is shown at low power with 
the equivalent region of CA1 marked by white box (e). Data are plotted as mean ±  SEM (f). *, 
p<0.05  vs +/+; N=6-8.
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5.3.4 CRF
CRF mRNA levels were measured in the PVN of animals using in situ hybridisation. 
Strong labelling of the PVN was seen that was specific to this region. Figure 5.5 shows 
example images and a summary of the data. Unpaired student's t-tests were used to 
compare the genotypes in both strains. No significant differences were found in either 
B6  (P=0.651) or B6:129 (P=0.538) strains.
5.3.5 cFos
cFos mRNA was measured via in situ hybridisation in the PVN of animals that had 
undergone 30 min restraint stress. A discrete activation of cFos was observed in 
the PVN compared to control animals which had not undergone stress (figure 5.6). 
Unpaired Student's t-tests were used to compare the genotypes in both strains. No 
differences were found in either B6  (P=0.977) or B6:129 (P=0.733) strains.
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Figure 5.5: Basal CRF mRNA in the PVN (indicated by arrow in a) in B6 and B6:129 mice. 
Photographs show representative examples of brain sections labelled with 35S-CRF in wildtype 
and NK1- / _  mice on the B6 (a,c) and the B6:129 (b,d) backgrounds. Specific expression is 
seen  in the PVN as shown by this example of darkfield emulsion-dipped section (e). Data are 
plotted as mean ±  SEM (f). N=4.
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Figure 5.6: Restraint-induced cFos mRNA in the PVN (indicated by arrow in a) in B6 and B6:129 
mice. Photographs show representative examples of brain sections labelled with 35S-cFos in 
wildtype and N K 1 m i c e  on the B6 (a,c) and the B6:129 (b,d) backgrounds. Data are plotted 
as mean ±  SEM (e). N=3-4.
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5.4 Discussion
5.4.1 Summary
The experiments in this chapter were performed to see if knockout of the NK1 receptor 
altered HPA axis activity and if this differed between the strains. Increased release of 
corticosterone in response to restraint stress was found in the B6:129 strain compared 
to B6 although no difference was found between genotypes. Neurogenesis, which is 
known to be affected by corticosterone levels, was increased in the N K l_/_ mouse on 
the B6:129 background compared to their wildtype counterparts. This corresponds 
with previously published work using the MF1 strain (Morcuende et al., 2003). In 
contrast, knockout of the NK1 receptor on the B6 strain had no effect on neurogenesis. 
Similarly, levels of hippocampal glucocorticoid receptors were found to be increased 
in the NK l_/_ mouse on the B6:129 background compared to wildtype but were 
unaltered between the genotypes in the B6 strain. Other features of the HPA axis — 
basal CRF mRNA expression and stress-induced cFos mRNA in the PVN — were not 
found to differ between the genotypes in either strain.
5.4.2 HPA axis activity
These results suggest that there are strain-dependent changes in HPA axis activity. 
Stress-induced corticosterone release was shown here to be higher in B6:129 mice 
than in B6 mice. Wildtype 129 mice have previously been shown to have higher 
corticosterone than wildtype B6 mice (Peinado et al., 2005). Although no differences 
in basal corticosterone levels between B6 and the mixed B6:129 mice were found in 
the experiments presented here — either due to methodological differences or a strain- 
dose effect in the hybrid mouse — it seems likely that there are differences in HPA 
axis regulation between the strains. 129 mice have been shown to have an enlarged 
intermediate lobe of the pituitary compared to B6 mice (Kelly et al., 1997). Other work 
has shown that glucose metabolism also differs between 129 and B6 mice (Browne et al.,
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1999). The higher corticosterone levels reported in the B6:129 mice here suggest that 
other aspects of the HPA axis may also differ between the B6:129 and the B6 strains. 
Unfortunately, the design of the experiments in this chapter to examine CRF and cFos 
mRNAs and GR expression, precluded comparison across strains. Future work to 
quantify levels of these molecules using immunoblot and real-time PCR will be of use 
in determining the basis of the increased corticosterone levels.
Despite these strain differences, there was no difference between the genotypes in 
corticosterone levels implying that the NK1 receptor is not an important factor in either 
inducing or terminating corticosterone release in response to stress, at least under the 
conditions tested here. Similarly, levels of basal CRF and stress-induced cFos mRNA 
did not appear to be genotype dependent. However, one component of the HPA axis, 
hippocampal GR, did show a genotype-dependent increase in expression levels in the 
B6:129 strain. GR is the low affinity receptor for corticosterone and is associated with 
termination of the stress response via a negative feedback mechanism (Korte, 2001). 
Increased GR expression should therefore lead to a reduced corticosterone response to 
a stressor and a quicker return to baseline levels. This was not found in the experiments 
here in which no genotype-dependent effects in corticosterone release were observed. 
An explanation for this may involve the severity of the stressor (30 minutes restraint) 
which may have masked any differences in the ability of the knockout on the B6:129 
background to regulate its corticosterone levels differently than the wildtype. Another 
possibility is that different time points, either earlier or later than the ones chosen, may 
have uncovered differences between the genotypes in this strain. As well as acting to 
reduce corticosterone release, GR can also directly affect nuclear transcription (Hayashi 
et al., 2004; Herbert et al., 2006). When activated by corticosterone, GR can translocate 
to the nucleus and bind to specific response elements in the promoter regions of many 
genes. Additionally, GR also interacts with a wide range of transcription factors 
often resulting in histone modifications and chromatin remodelling (Hayashi et al.,
2004). Furthermore, glucocorticoids may also act non-genomically through G-protein 
coupled membrane receptors or via the GR/hsp90 complex to have more rapid effects
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on intracellular signalling (Croxtall et al., 2002).
Mineralocorticoid receptors (MRs) can also have a variety of effects both genom- 
ically and non-genomically in the brain and are likely to be affected by changes in 
the HPA axis between strains and genotypes. MRs show a more restricted expression 
pattern but levels are still high in key parts of the limbic circuitry such as the amygdala 
and the hippocampus (Korte, 2001; Herbert et al., 2006). MRs are activated by low 
levels of glucocorticoids, due to their high affinity, and maintain excitability of the HPA 
system. This is in opposition to GRs which act to reduce HPA axis activity and restore 
homeostasis after a transient rise in corticosterone. Clearly, a reduction in GR, as may 
be seen in the N K l- / ~ mouse, is likely to disrupt the normal function and control 
of the HPA axis. Although an increase in GR expression has been shown here in the 
N K l_/_ mouse, expression levels of MR have not been studied and would provide 
useful information on their role in mediating the phenotype observed in these mice.
5.4.3 The HPA axis and affective disorders
As discussed in the Introduction in section 1.4.3, dysfunction of the HPA axis has been 
associated with the pathophysiology of depression and addictive disorders (Modell 
et al., 1997; Holsboer, 2000; Samyai et al., 2001; Goeders, 2002; Gillespie and Nemeroff,
2005). Mice generated with mutations in certain components of HPA axis have 
been postulated as animal models of affective disorders (Muller and Holsboer, 2006). 
Additionally, animal models have been developed in which early life stressors result in 
HPA axis dysfunction in adulthood and lead to depressive-like systems (Plotsky and 
Meaney, 1993). These will be described below.
5.4.4 Mice with mutations in HPA axis function
Mice overexpressing CRF show anxiogenic behaviour (Stenzel-Poore et al., 1994) and, 
concordantly, mice with either global or brain-specific knockout of the CRF1 receptor 
display reduced anxiety-related behaviour (Smith et al., 1998; Muller et al., 2003).
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Knockout of GR has generally been shown to correlate with increased depression- 
related behaviours (Ridder et al., 2005; Boyle et al., 2006) whilst overexpression reduces 
these behaviours, especially in tests involving a stressor (Ridder et al., 2005). However, 
in some studies reduced anxiety-related behaviour has been found as a consequence 
of GR knockout (Tronche et al., 1999) and overexpression of GR has been shown to 
produce anxiogenic behaviour (Wei et al., 2004). In many of these studies behavioural 
tests have been confounded by profound alterations in HPA axis regulation, which has 
been suggested as a reason for some of these discrepancies (Muller and Holsboer, 2006).
NK l^/~ mice on the B6:129 background have been shown here to overexpress 
hippocampal GR in comparison to wildtype counterparts. On different backgrounds, 
here and elsewhere (Rupniak et al., 2001; Santarelli et al., 2001; Fisher, 2005; Herpfer 
et al., 2005), N K l_/_ mice have also been shown to display an anxiolytic and 
antidepressant-like phenotype. The GR overexpressing mice used by Ridder et al. 
(2005), as well as showing a resistance to developing helplessness, also show a 
significant increase in hippocampal BDNF, a feature that has also been found in 
Nk i ~ /-  mice (Morcuende et al., 2003).
In contradiction to this work, Wei et al. (2004) found that GR overexpression 
increased anxiety-related behaviour. They have explained this unexpected finding 
by arguing that these mice represent a model for increased emotional lability. In 
support of this hypothesis they also present work showing increased sensitisation to 
a rewarding stimulus, cocaine, and increased sensitivity to antidepressants. These 
GR overexpressing mice were also found to have increased CRF expression in the 
central nucleus of the amygdala and increased noradrenaline, serotonin and dopamine 
transporter expression in the locus coeruleus, dorsal raphe and ventral tegmental 
area, respectively. Additionally, as with the NK1- / -  mouse here, they showed no 
differences in circulating corticosterone basally or after a stressor.
Differences between the work of Ridder et al. (2005), Wei et al. (2004) and that 
conducted with the NK1- / -  mouse, indicate that GR is capable of modulating 
behaviour in a number of ways. Reasons for the discrepancies between each study
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are numerous. Differences in distribution of GR and regulation of the HPA axis, the 
manner of testing and the tests used, and the genetic background of the mice studied, 
are all likely to have been of importance. Ridder et al. (2005) and Wei et al. (2004) each 
used different methods to overexpress GR. The former study generated mice carrying 
two additional copies of the GR using a yeast artificial chromosome. A twofold increase 
in GR protein was detected in the hippocampus although other work using this system 
has shown mRNA for GR to increase by between 20 -  60% in other brain and peripheral 
tissues, including the pituitary (Reichardt et al., 2000). In contrast, Wei et al. (2004) 
used a different transgenic construct driven by the calcium-calmodulin-dependent 
protein kinase II oc promoter. They found the distribution of the transgene-specific 
GR to be primarily forebrain-specific with no expression in peripheral tissues. The 
highest expression levels were found in the hippocampus. The work presented in this 
chapter is the first attempt to examine levels of GR in N K l_ /~ mice. Here, we find 
an overexpression of GR in the hippocampus, specifically the CA1 region. As of yet, 
GR has not been compared in other hippocampal subfields, other brain regions, or 
peripheral tissue. Determination of these patterns will be of help in understanding the 
link between disruption of the NK1 receptor and changes in GR expression.
GR acts to terminate the corticosterone response to a stressor in many of the brain 
regions in which it is expressed, especially the hippocampus, the hypothalamus and 
in the pituitary (Korte, 2001). However, as detailed above, it can also have a variety of 
other effects within the cell, particularly the modulation of gene transcription (Hayashi 
et al., 2004).
As discussed extensively in this thesis, genetic background can have profound 
effects on behaviour, especially in anxiety-related models, and is also a major factor 
in determining an animals' HPA axis regulation. As such genetic background and 
its interaction with the HPA axis may have had a confounding effect on many of the 
behaviours examined in these studies (Muller and Holsboer, 2006).
More experiments are required to explain both the reasons for increased GR ex­
pression observed in the NKl_ /~ mouse and its significance. In addition, experiments
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to determine differences in MR levels between strains and genotypes would also be 
instructive.
5.4.5 Early life stress and the HPA axis
Early-life experience is known to bring about enduring changes in the HPA axis. 
Adverse experiences during the perinatal period in particular are known to lead to 
later dysfunctions in HPA axis regulation and a depressive-like phenotype (Plotsky 
and Meaney, 1993). There is an extensive body of literature in this field detailing work 
using rodents and primates in different paradigms including maternal separation, 
handling and immune response. Procedures such as these lead to profound changes 
in neurobiology and behaviour that last into adulthood. For example, maternal 
separation in pups produces changes in stress-responsivity and feedback sensitivity 
of the HPA axis when tested as adults (Plotsky and Meaney, 1993; Heim et al., 
2004). Additionally, marked behavioural changes also develop including anxiety-like 
behaviour, anhedonia, sleep disruption, decreased appetite and cognitive impairment 
(Huot et al., 2001; Heim et al., 2004). Adult neurogenesis is also reduced following early 
life stress (Korte et al., 2005).
Recently, work by Michael Meaney and colleagues has examined natural variation 
in maternal behaviour in rats and showed that this has an effect on the phenotype 
of these animals in adulthood (Liu et al., 1997; Francis et al., 1999; Weaver et al., 
2004). Rats were divided into groups of high and low responders on the basis of 
a particular form of nursing provided by the dams. Offspring of low responders 
developed with hyperactive responses to stress and dysregulation of the HPA axis. 
This was found to correlate with low expression levels of GR and the expression of 
a behavioural phenotype including anxiety-like behaviour and anhedonia (Liu et al., 
1997). These pups were observed to grow up as low responding mothers and, vice 
versa, the offspring of high responders became high responding mothers. Interestingly, 
it was also found that by cross-fostering pups this trend could be reversed implying
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an epigenetic mechanism (Francis et al., 1999). Examination of chromatin structure in 
these animals revealed that differences in DNA methylation and histone acetylation 
existed between the groups, in particular, in the region of the GR promoter (Weaver 
et al., 2004). As such, in high responders transcription factors could more easily bind 
this promoter leading to increased expression of GR.
Further studies have shown a number of different signalling systems and be­
haviours are also affected by these differences in maternal care including GABAer- 
gic pathways (Caldji et al., 2003), long-term potentiation and spatial learning (Liu 
et al., 2000), and survival of new-born cells in the hippocampus (Bredy, Grant, 
Champagne and Meaney, 2003). Additionally, although these changes are relatively 
stable, interventions such as environmental enrichment (Francis et al., 2002; Bredy, 
Humpartzoomian, Cain and Meaney, 2003) or treatment with agents to affect the 
chromatin structure (Weaver et al., 2005,2006) are able reverse this programming.
In this thesis, differences between HPA axis activity, anxiety-related behaviour and 
morphine-induced locomotion have been seen between the strains. These observations 
may in part be explained by differences in maternal behaviour and/or DNA methy­
lation between the strains. B6 mice have been compared to BALB/c mice in many 
studies examining genotype-phenotype interactions due to their strikingly different 
behavioural profiles. B6 mice show low anxiety in novel environments whilst BALB/c 
mice are substantially more neophobic (Belzung and Griebel, 2001). In studies to 
examine maternal behaviours, B6 mice have been shown to have upregulated GABA^ 
receptor binding in the amygdala compared with BALB/c mice, an effect that was, 
however, abolished after crossfostering to BALB/c mothers (Caldji et al., 2004). The 
effect of mothering behaviour has not been examined in any of the 129 substrains but 
their anxiety-like profile and hypolocomotor response to novel environments suggests 
that they exhibit a behavioural profile that has more in common with the BALB/c than 
the B6 strain. This in turn would imply that similar differences may exist in mothering 
behaviour between the 129 and B6 mice as have been found between BALB/c and B6 
mice by Caldji et al. (2004).
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Furthermore, as the NK1~/ -  mice used in this study were bred on homozygous 
backgrounds, an intriguing possibility is that there may be variations in maternal care 
between the genotypes that lead to their differential expression of GR. Although much 
of the work with antagonists would suggest that disruption of the NK1 signalling 
pathway is able to have an acute effect on the behaviours we have examined, there 
is still a possibility that the effect of mothering behaviour may be important for the 
experiments presented here. Changes in GR expression in the work by Meaney have 
been associated with a number of other alterations in signalling that have also been 
found in N K l_/_ mice, including differences in the monoaminergic system (Santarelli 
et al., 2001; Guiard et al., 2004; Fisher, 2005; Herpfer et al., 2005) and hippocampal 
BDNF (Morcuende et al., 2003). One interpretation of these findings is that an NK1 
receptor-dependent pathway is recruited in BALB/c mice in the study by Caldji et al.
(2004) and in wildtype B6:129 in this study leading to a reduction of GR expression. 
Differences in the genotypes observed between the NKl~/_ and wildtype mice here 
are a result of removal of this pathway. In contrast, B6 mice do not recruit this pathway, 
possibly due to their lower levels of stress, and consequently have a high level of GR 
expression regardless of whether they have a functional NK1 receptor or not.
5.4.6 Neurogenesis
A related finding is that NKl~/_ mice on the B6:129 strain were shown here to exhibit 
increased hippocampal neurogenesis as previously published in the MF1 and 129:B6 
strains of N K l_/_ mice. This may be related to their increased expression of GR as 
these receptors are known to modulate neurogenesis, possibly via their regulation of 
HPA axis activity (Duman and Monteggia, 2006). Prolonged elevated corticosterone 
levels have been shown to decrease neurogenesis and the survival of newly bom 
progenitor cells (Cameron and Gould, 1994; Gould and Tanapat, 1999; Wong and 
Herbert, 2004; Lledo et al., 2006). The finding that neurogenesis is increased in NK l- / ~ 
mice on the B6:129 background is likely to have many implications for the behavioural
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phenotype of these mice as neurogenesis has been postulated to have a role in several 
behaviours involving the hippocampus.
5.4.6.1 Neurogenesis in learning and memory
Neurogenesis has been shown to be important for learning and memory processes. 
As such, hippocampal-dependent learning increases neurogenesis (Gould et al., 1999) 
and blocking neurogenesis results in impairments in hippocampal-based tasks (Shors 
et al., 2001; Snyder et al., 2005). The results in this chapter would therefore predict an 
enhancement of hippocampal-dependent learning in the N K l_ /~ mouse on the mixed 
B6:129 background. However, in a comprehensive study of learning and memory 
behaviours in the NKl- / ~ mouse on the mixed MF1 background few differences were 
found between the genotypes in any of the tests (Gadd, 2003). Both hippocampal tasks 
and non-hippocampal tasks were examined and included the Morris water maze, fear 
conditioning, working memory tasks and Rota-Rod performance. A subtle increase in 
selectivity during probe trial behaviour in the water maze was detected in NKl_ /~ 
mice, suggesting they may be slightly quicker at demonstrating spatial memory. 
However, this is a minor difference in comparison to the increases in neurogenesis 
observed. More recent work examining the role of neurogenesis in spatial memory 
has shown that preventing neurogenesis impairs long- but not short-term performance 
in the Morris water maze (Snyder et al., 2005). New hippocampal neurons in the 
dentate gyrus may then be required for the formation and/or consolidation of long­
term memories and the encoding of time (Aimone et al., 2006). Further investigation 
of the N K l- / ~ mouse using different paradigms and experimental conditions may 
uncover more interesting behavioural differences between the genotypes.
5.4.6.2 Neurogenesis and antidepressants
As well as learning and memory, neurogenesis is also believed to be somewhat 
involved in the pathophysiology of depression and the actions of antidepressants
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(Malberg et al., 2000; Duman et al., 2001; Santarelli et al., 2003). It has been more 
difficult to determine the precise role of neurogenesis in depression mainly due to the 
difficulties in reliably assaying traits related to depression in animal models (Cryan and 
Mombereau, 2004). This has led to inferences about the role of newly-born granule cells 
in the disease based on the effects of established antidepressants on neurogenesis and 
in behavioural models. Clinically, depression has been linked to reduced hippocampal 
volume (Sheline et al., 1996) and antidepressant treatment is believed to ameliorate 
this reduction (Czeh et al., 2001) adding support to the neurogenesis hypothesis of 
depression. However, questions still remain as to whether these findings are artifacts 
linked to treatment of the disease or other social conditions such as drug abuse or 
poverty, which are also associated with depression. Despite these caveats it seems 
likely that the increases in neurogenesis observed here in the N K l- / ~ mouse on the 
B6:129 background — and previously on the mixed MF1 background (Morcuende et al., 
2003) — are linked to the antidepressant phenotype observed in the knockout mouse 
and in wildtype mice after administration of NK1 receptor antagonists. Although 
the N K l- / ~ mouse has been studied using the forced swim and the tail suspension 
tests (Rupniak et al., 2001), further examination using paradigms involving a longer 
temporal component such as repeated psychosocial stress may help to elucidate the 
contribution of newly-born neurons and the role of the NK1 receptor in depression. 
An attempt to link the observed increase in GR expression in the NKl~/_ mouse on 
the B6:129 background with the increase in cell proliferation would be a promising 
direction for future study. If these two features were linked, chronic antagonism of the 
GR receptor would be expected to decrease neurogenesis and have consequent effects 
on behaviour.
5.4.7 Strain differences in neurogenesis and the HPA axis
NK1 receptor knockout did not affect either GR expression or neurogenesis in the 
B6 strain whereas there was a large effect in the B6:129 strain. As the B6:129 strain
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were also shown to have elevated levels of corticosterone after a stressor compared to 
B6 it could be hypothesised that a HPA axis-mediated pathway involving the NK1 
receptor was recruited in the B6:129 mice but not in the B6 mice. One site that 
may be important in mediating this response is the locus coeruleus (LC). The LC is 
activated by numerous stressful stimuli as shown by patterns of cFos expression after 
stress (Ceccatelli et al., 1989; Passerin et al., 2000), the electrophysiological response 
of its neurons (Abercrombie and Jacobs, 1987) and by release of noradrenaline into 
regions that it innervates (Gresch et al., 1994; Pacak et al., 1995; Quirarte et al., 1998). 
The NK1 receptor is expressed in very high levels in the LC (Maeno et al., 1993; 
Chen et al., 2000) and NK1 antagonists (Millan et al., 2001; Maubach et al., 2002) and 
substance P (Guyenet and Aghajanian, 1977; Cheeseman et al., 1983) both affect the 
firing properties of its neurons. NKl_/_ mice have been shown to have increased 
cortical noradrenaline under anaesthesia, an effect that is mimicked by NK1 receptor 
antagonists (Fisher, 2005). Increased serotonin efflux after SSRI administration has 
also been shown in the NKl_/_ mouse (Froger et al., 2001) and this is believed to be 
dependent on increases in the noradrenergic system (Gobbi et al., 2006). Importantly, 
the autoregulatory receptors for noradrenaline and serotonin, the 5-HTi^ receptor and 
the a2-adrenoceptor, respectively, are believed to be involved in these changes through 
a reduction in their functional activity (Froger et al., 2001; Santarelli et al., 2001, 2002; 
Fisher, 2005). Increased activation of the LC in response to a stressor then may be 
altered in animals lacking a functional NK1 receptor. The larger this activation the 
more important the presence of NK1 receptors would be supposed to be. The larger 
increase in HPA axis activity observed in B6:129 mice compared with B6 mice may 
mean that a pathway involving the LC is more strongly stimulated in this strain and 
hence the role of the NK1 receptor is also of more importance.
The behavioural experiments presented in this thesis also support a role for the 
LC in mediating some of the NK1 receptor-dependent behaviours. Alterations in the 
opiate system seen in some NKl- / ~ mice may be involve the LC as the LC has also 
been implicated in the development of opiate dependence (Nestler et al., 1994; Nestler
133
Chapter 5
and Aghajanian, 1997; Nestler et al., 1999) and both \i opioid and NK1 receptors are 
localised on these cells' somata (Chen et al., 2000; Moyse et al., 1997).
The expression of other tachykinin receptors could also be involved in the observed 
strain differences. Microdialysis studies have implicated NK3 receptor activation in the 
LC as being essential for the effects of NK1 receptor agonists in this region (Bert et al., 
2002). Developmental compensations after genetic disruption of the receptor could 
show interstrain variability and account in part for the observed differences.
5.4.8 Interactions between strain and genotype
There are several other studies in which similar strain-dependent effects on phenotype 
have been found in genetically-modified mice involving the HPA axis. Peinado et al.
(2005) used two null mouse models to study the role of prohormone convertase 
(PC2) and its helper protein 7B2. By breeding the mutations into both B6 and 129 
backgrounds they were able to study their affects on HPA axis activity. Wildtype 
B6 mice were found to have lower corticosterone levels than wildtype 129 mice, 
a result partially backed up by findings in this thesis. Additionally B6 mice also 
had higher blood glucose levels. The 7B2 mutation results in a lethal phenotype 
in the 129 background due to the development of a Cushing's-like disease. In the 
B6 mutant, however, mice with the null mutation survived and showed decreased 
corticosterone and increased blood glucose levels, most likely due to their increased 
adrenal resistance to ACTH stimulation. The authors also show that the B6 background 
strongly predominates over the 129 background as a single generational cross into the 
B6 background results in protection from the lethal effects of the 7B2 mutation (Peinado 
et al., 2005).
In a study examining the effect of 11 /5-hydroxysteroid dehydrogenase type 1 
(11/3-HSD1) knockout in the mouse, similar strain-genotype interactions have been 
found. 11/5-HSD1 is an enzyme responsible for regulating aspects of HPA axis 
activity via the conversion of inactive 11-dehydroxycorticosterone (11-DHC) into
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active glucocorticoids. It has been associated with many disease states including 
metabolic disturbances and psychiatric conditions including depression and PTSD 
(Carter, 2006). On the original mixed 129/MF1 background the 11/5-HSD1 knockout 
showed decreased glucocorticoid negative feedback as well as a shift in peak circadian 
levels and elevated a.m. levels of plasma corticosterone (Kotelevtsev et al., 1997; Harris 
et al., 2001). After backcrossing onto a congenic B6 background although some of 
the metabolic and cognitive effects seen in the MF1/129 remain, basal corticosterone 
and ACTH levels no longer differ between genotypes. Additionally, the impaired 
negative feedback, as assayed by the return to baseline levels of corticosterone and 
ACTH after restraint stress, is no longer present in the 11/5-HSD1 knockout on the B6 
background. Comparison of the mutation on a number of backgrounds led the authors 
to suggest that genetic modifiers within the 129 strain contribute to the attenuation of 
negative feedback seen in the 11/5-HSD1 knockout. Further work examining molecular 
components of the HPA axis in these mice, in particular the glucocorticoid receptor 
(GR), suggests that a key difference between the strains may involve regulation of GR 
(Carter, 2006).
Interestingly, the gene for GR uses several different promoters and can be regulated 
by many different transcription factors. Among the transcription factors known to 
regulate expression of GR is zif268 which binds to a promoter region in the non-coding 
exon 1 region of the GR gene (Weaver et al., 2004). Additionally, glucocorticoids are 
known to exert many of their effects via a pathway involving zif268 (Revest et al., 2005). 
zif268 has been implicated in many behaviours including drug addiction (Lee et al., 
2005; Valjent et al., 2006), learning and memory (Davis et al., 2003) and pain processing 
(Wong, 2006).
These studies show that genetic background interacts with the HPA axis in a 
number of ways. Altering a component of this finely-tuned system can result in 
changes in many of its other parts as it tries to return to homeostasis.
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5.4.9 Summary and conclusions
In this chapter a number of aspects of HPA axis regulation and a related phenomenon, 
neurogenesis, have been examined in two strains of NKl- / ~ mouse. Changes across 
strain and genotype indicate that there are important interactions between the NK1 
receptor and stress-responsive systems. The importance of genetic background has 
again been highlighted and show that care must be taken when interpreting the results 
of studies using mice, especially when genome engineering and behavioural tests are 
used. In the final chapter, findings from this thesis will be brought together to consider 
the implications of this work and possible areas of future study.
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General Discussion_________________
6.1 Introduction
Genetic background has a profound effect on mouse phenotype. The experiments 
presented in this thesis demonstrate how the effect of a genetic manipulation can be 
drastically altered by the strain of mouse it is examined in. Specifically, the aim was to 
study the physiological role of the NK1 receptor. Previous research indicated that this 
receptor may be a promising therapeutic target for the treatment of opiate addiction 
or affective disorders such as depression or anxiety. A mouse line lacking a functional 
NK1 receptor was created using homologous recombination. Pharmacological study 
using antagonists had been limited by species differences in the primary structure of 
the receptor protein. The NK1 knockout mouse presented an interesting phenotype 
including anxiolysis, antidepressant-like behaviour and a reduced potential for opiate 
addiction. For reasons of experimental rigour, and to enable the continued study 
of more complex cognitive behaviours, the receptor mutation was transferred onto a 
different genetic background. The experiments in this thesis have examined the effect 
of NK1 receptor disruption in three different background strains.
6.2 Summary of results
The experiments in the first chapter compare the effect of NK1 receptor knockout in the 
C57BL/6 strain (B6) with its effect in the existing MF1:129:B6 mixed background (MF1).
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The attenuation of morphine-induced hyperlocomotion observed in N K l_/_ mice on 
the MF1 background was lost in the B6 background. Additionally, the increased basal 
locomotion seen in NKl- / ~ mice on the MF1 background also disappeared in the B6 
strain.
In the light/dark exploration box (LDEB) several behaviours associated with 
anxiolysis that were increased in the NKl_/_ mouse on the MF1 strain showed no 
difference between genotypes in the B6 background. The one behaviour that did differ 
between genotypes in the B6 strain was number of transitions between compartments, 
a behaviour normally associated with exploratory activity. NKl~/_ mice performed 
less transitions than wildtype indicating perhaps a decrease in exploration and an 
anxiogenic effect of the mutation.
The next set of experiments involved transferring the mutation onto a mixed B6:129 
background. It was hoped that this would recapitulate, at least in part, the phenotype 
seen in the mixed MF1 background. The B6:129 mouse had a lower hyperlocomotor 
response to morphine than B6 mice even at the highest dose. Surprisingly, at one dose 
a strong stimulating effect on locomotion was observed in the NK l_/_ mouse that was 
not seen in their wildtype counterparts.
In the LDEB no significant differences were found between the genotypes although 
the general phenotype was one that was intermediate between the MF1:129 and B6 
strains. There were, however, trends towards an anxiolytic phenotype in the knockout.
Finally, a set of experiments was undertaken to examine aspects of the HPA axis 
in the B6 and B6:129 strains. Stress-induced corticosterone levels were shown to be 
higher in the B6:129 strain than the B6 strain. No differences in corticosterone levels 
were attributable to genotype. Hippocampal neurogenesis may be an important part 
of the pathophysiology of depression or of antidepressant treatment. It was previously 
shown to be increased in the NKl~/_ mouse on the MF1 background. Here, it was 
shown not to differ between genotypes on the B6 background. Creation of the NKl~/_ 
mutation on the mixed B6:129 background recapitulated the increase in neurogenesis 
previously observed in the knockout. Levels of glucocorticoid receptor (GR) were also
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increased in the N K l- / ~ mouse compared to wildtype in the B6:129 strain. In contrast, 
no difference between genotypes in neurogenesis or GR expression were seen in the B6 
strain. Basal corticotrophin releasing factor (CRF) and stress-induced cFos mRNAs in 
the PVN were found not to differ between genotypes on either strain.
The results presented have shown a key interaction between strain and genotype 
in the N K l_/_ mouse. Of central importance seems to be regulation of systems 
mediating anxiety-like behaviours in the mouse and their genetic component. The 
HPA axis contributes to the expression of these behaviours and shows a high degree of 
variability between animals, partly as a result of genetic background but additionally 
due to environmental conditions. Morphine acts in a number of ways on the nervous 
system and how these effects at a molecular, cellular and systems level are translated 
into behaviour is a complex issue demanding further study. This will enable more 
successful treatment of those unfortunate enough to suffer from opiate addictions and 
and will also aid in the medical use of opiates to treat conditions such as chronic pain.
Taken together, the results in this thesis demonstrate the profound differences 
that exist between different strains of mice. Furthermore, these experiments show 
that a specific mutation can have a variety of phenotypic effects which are strain- 
dependent. Clearly there is an important interaction between strain and genotype 
which can lead to surprising results. Given what we know about the underlying 
biological complexity this should not come as a surprise. One of the key criticisms, or at 
least caveats, of studies using knockout animals is that developmental compensations 
will occur. Physiological systems are comprised of many finely-tuned components 
and the removal of one protein or signalling molecule will often trigger a host of 
changes designed to return the network to homeostasis. Careful consideration should 
be applied when conducting or interpreting experiments of this nature.
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6.3 Future directions
Although the work presented in this thesis has shown that there are complicated 
interactions between strain and genotype, particularly with respect to the NKl_/_ 
mouse, there exist many opportunities for future study. The key finding is that 
genetic background has a major effect on morphine-induced locomotion, behaviour 
in the light/dark exploration box, components of the HPA axis, and neurogenesis. 
Importantly, these differences in genetic background drastically altered the effect of 
NK1 receptor disruption. Throughout this thesis I have tried to present possible 
explanations for these findings and suggest areas of future study. Here, I will review 
some of the common themes that are applicable to all of the findings.
6.3.1 Receptor distribution and activity
Firstly, it seems clear that to properly understand the function of substance P and 
the NK1 receptor in the different strains, a comprehensive study of their relative 
distribution and activity in the central nervous system is required. In behavioural 
studies heterozygotes seem to resemble NKl- / ~ mice indicating a haplosufficiency 
of the NK1 gene (Santarelli et al., 2001). However, differences other than absolute 
expression level could also contribute to altering the function of the NK1 receptor 
between different genetic backgrounds. Changes in the distribution of the receptor 
or its functional activity could have profound effects on its involvement in different 
phenotypes. These may be conferred by changes in both the exonic or intronic 
sequences as has been noted with other receptors, leading to differential trafficking 
and/or functional activity between the strains (Zhou et al., 2001). Furthermore, 
this information is also required for other receptors, proteins, transmitters or other 
components that may be involved in the behaviours or features of a phenotype that 
show strain-genotype interactions. Of particular interest to the work in this thesis 
would be a comparison of \i opioid receptors and of glucocorticoid receptors between 
the strains.
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6.3.2 Other tachykinins
The role of other tachykinins has been discussed in this thesis but almost completely 
ignored in studies using NKl_/_ mice. Although dogma suggests that the other 
neurokinin receptors are unlikely to be involved in regulation of the same systems 
as the NK1 receptor, there has been little work to specifically examine NK2 and NK3 
receptors in the NKl_ /~ mouse. Likewise, the other tachykinin agonists, especially 
NKA, may have a role to play in modulating NK1 receptor-mediated circuits along 
with substance P (Maggi and Schwartz, 1997). Evidence is accumulating that NK2 and 
NK3 receptors (or their ligands) may be involved in similar physiological actions as 
substance P and the NK1 receptor (Culman and Unger, 1995; Piot et al., 1995; Teixeira 
et al., 1996; Salome et al., 2006) and this is an area that therefore warrants further study.
6.3.3 Epigenetic effects
The important and highly complex manner in which genes and environment interact 
is now an avidly studied area of research. Despite this, these interactions are often 
not fully examined in work using genetically modified mice. This is of particular 
relevance due to the variety of breeding strategies which are implemented. Both the 
behaviour of parents and offspring can vary as the result of genetic manipulation. 
These changes although having a genetic origin may lead to epigenetic changes which 
may then be passed down non-genomically as shown by cross-fostering studies (Caldji 
et al., 2004). An interesting avenue of future study would be to examine the role of 
the NK1 receptor in these processes. NKl_ /~ mouse pups are known to emit fewer 
neonatal vocalisations suggesting the possibility that their adult phenotype may result 
from differential maternal responses (Rupniak et al., 2000). Similarly, changes in GR 
resulting from NK1 receptor disruption in dams may also give rise to differences in 
mothering behaviour with consequent effects on behaviour. Experiments using cross- 
fostering between litters and examining chromatin modifications in these mice may 
provide useful information about how the NK1 receptor is involved in regulation of
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these systems and why there are such pronounced differences between the strains 
(Mager and Bartolomei, 2005).
6.3.4 Regional-specific studies of the NK1 receptor
More experiments are required to determine the precise site of action of substance P 
or the NK1 receptor in each of the phenotypes revealed. The work by Gadd et al. 
(2003) was useful in determining the amygdala as an important mediator of effects on 
anxiety and morphine-related behaviours. However, although selective, the substance 
P-saporin conjugate still results in the destruction of many cells which may be crucial 
for normal function and so a method of deleting the receptor in a region-specific 
manner whilst leaving the cell population intact would be preferable (Ryding et al., 
2001). Several methods now exist such as the introduction of antisense oligonucleotides 
or the conditional knockout of a receptor using site-specific mutagenesis such as the 
Cre-LoxP system (Morozov et al., 2003; Glaser et al., 2005). Additionally, restoration 
of function by using viral reintroduction of the NK1 gene in NKl- / ~ mice would 
also give useful information about the specific brain areas which are important in 
producing the phenotype seen in NKl~/_ mice. Furthermore, using a temporally 
restricted knockout strategy to ameliorate any developmental compensations that may 
occur with the NKl_ /~ mouse used in this study, is also an option (Morozov et al., 
2003).
6.4 Final conclusions
The work presented in this thesis raises important issues that are relevant to all studies 
using genetically modified mice. That background strain can have such a profound 
influence on the effect of a genetic manipulation is a finding that warrants much future 
study and consideration. Many genetically modified animals have been proposed 
as models for various affective disorders. Targeted mutations allowing the study of 
changes in a single gene provide an attractive way of examining many biological
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processes. However, epistatic interactions with the background that the mutation 
is expressed on, the influence of linked genes, and developmental compensations 
can often confound these findings. Different mouse strains provide a rich source 
of behavioural phenotypes and may, even without genetic manipulation, serve as 
animal models of disease. As such, comparison of strains which differ markedly 
might provide useful information on the underlying physiology that contributes to 
behavioural differences. Using animals exhibiting a trait, such as increased anxiety­
like behaviour, as an enduring feature of the particular strain, rather than because 
of the disruption of a single gene, can overcome some of these problems. Complex 
traits are likely to involve multiple genetic and environmental factors and may be more 
rigourously studied in this manner.
Vulnerability to external events, such as stress, as a factor involved in the develop­
ment of affective disorders or drug addiction is well documented in human patients 
and is likely to be in part conferred by genetic background. It is likely that a similar 
spectrum of vulnerability also exists between different strains of mice. Healthy humans 
are unaffected by antidepressant treatment. Additionally, many human patients do not 
respond to treatments that are effective in other patients. These phenomena may be 
investigated by exploring the various vulnerabilities or protective factors implicated 
by the different responses observed among mouse strains.
Vast amounts of time and money are currently spent developing new treatments for 
disease. Drug addiction and depression/anxiety disorders are two of the most costly 
burdens on world health. This is at a personal, financial and societal level. Many 
drugs show efficacy in only a small percentage of the patient population and this often 
leads to lengthy and complex changes to their treatment regimen before finding an 
appropriate program. This is especially the case with depression as our diagnostic tools 
and disease classifications are still relatively crude. The full sequencing of the human 
genome is a huge leap forward in science and should in time provide an aid to our 
understanding of the genetic component underlying disease. Similarly, it may become 
possible to begin tailoring treatments to specific patients on the basis of their individual
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genetic profile. The variety of mouse strains available for laboratory research is a 
valuable resource that needs to be fully utilised by the scientific community, especially 
those using mutant models. Careful experimentation and analysis using these mice 
will provide important information on the genetic bases of complex diseases.
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Detailed protocols
A. 1 Labora tory solu tions
Phosphate buffer (PB; 0.1 M; pH 7.4):
190 mM NaH2P 0 4 (BDH, Poole, UK)
810 mM Na2H P04 (BDH)
Tris buffer (0.15 M; pH 7.6):
127 mM Tris HC1 (Sigma, Poole, UK)
23 mM Tris base (Sigma)
Heparanised phosphate-buffered saline (PBS):
0.9 % NaCl (Baxter, Lessines, Belgium)
5A U /m l heparin (CP Pharmaceuticals, Wrexham, UK)
5 mM PB
Normal Goat Serum (NGS) solution:
0.1 M PB
3 % NGS (Vector Laboratories, Burlingame, USA)
0.3% Triton X-100 (BDH)
0.02 % NaN3 (Sigma)
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A.2 Genotyping
All mice used in this thesis were checked for genotype using polymerase chain reaction 
(PCR) of tail tip DNA. The protocols for DNA extraction and the NK1 PCR reaction are 
given over the next few pages. Figure 2.3 in the Materials and Methods shows an 
example gel.
A.2.1 DNA extraction from tail tip
• Remove 5 mm of tail tip using a razor blade and place in a 1.5 ml microfuge tube.
• Add 750 fil tail lysis buffer1 and 22.5 /d Proteinase K (20 mg/ml; Sigma) to tube 
and leave overnight at 55 °C.
• Vortex and spin for 3 min at 13,000 g.
• Transfer supernatant to fresh tubes leaving hair etc.
• Add 200 fd Protein Precipitation Solution (Puregene, Minneapolis, USA) and 
vortex for 2 0  s.
• Centrifuge for 3 min, 13,000 g. A tight light coloured pellet should form.
• Pour supernatant into new tubes containing 600 /d 100 % isopropanol and mix 
thoroughly by gentle inversion. A stringy white precipitate should form.
• Centrifuge for 3 min at 13,000 g.
• Discard supernatant and add 300 fil70 % ethanol.
• Centrifuge for 3 min at 13,000 g.
•  Remove supernatant and leave open to air dry for 1-2 h.
• Add 250 fd TE. Tap and quick spin again.
• Leave at 4 °C overnight to dissolve precipitate.
^ail lysis buffer: 50 mM Tris pH 8,100 mM EDTA pH 8,10 mM NaCl, 1 % SDS; Sigma
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A.2.2 NK1 PCR protocol
•  Make up PCR reaction mix:
-  dH20  32.50 }i\
-  Taq DNA polymerase 10 x buffer (Promega) 5.00 f/1
-  25 mM MgCl2 (Promega) 3.00 \i\
-  10 fiM dNTP mix (Promega) 1.00 }i\
-  NeoF1 (0.5 ^g/^1; Sigma Genosys, Cambridge, UK) 1.00 jtl
-  NK1-F2 (0.5 ^g/^1; Sigma Genosys) 1.00
-  NK1-R3 (0.5 ^g/^1; Sigma Genosys) 1.00 }i\
-  Taq DNA polymerase (5 u//d; Promega) 0.50 }i\
-  DNA sample 5.00 jil
-  Total 50.00 jil
• Place tubes in PCR temperature cycler (PTC-100 Programmable Thermal Con­
troller, MJ Research, Boston, USA) and run the following programme repeating 
steps 2 to 4,34 times:
1NeoF: 5'-GCAGCGATCGCCTTCTATC-3'
2NK1-F: 5'-CTGTGGACTCTAATCTCTTCC-3'
3NK1-R: 5'-acagctgtcatggagtagatac-3'
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• Add 5 }i\ loading buffer4 and mix well.
• Rim 11 fil of each sample on a 2 % agarose gel in TBE buffer (National 
Diagnostics) containing 10 ^g/m l ethidium bromide (Sigma) at 120 mV for 
approximately 1 h.
• Visualise and photograph under ultraviolet transillumination.
4Loading buffer: 0.25 % bromophenol blue (Sigma), 0.25 % xylene cyanol FF (Sigma), 30 % glycerol 
(BDH)
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A.3 Immunocytochemistry
Immunocytochemistry was used in this thesis to identify and quantify tissue con­
stituents. The theory behind the technique is described in section 2.2 in the Materials 
& Methods chapter. Here, a detailed description of the protocols used for chromogenic 
and fluorescent detection methods is given.
For the BrdU staining it was necessary to pre-treat sections by incubating in 2 N 
HC1 for 30 min followed by 0.1 M boric acid for 10 min.
A.3.1 Immunocytochemistry with chromogenic detection using DAB 
Gentle agitation of sections on a tissue rocker at RT is used for all steps, except where indicated.
• Rinse sections in 0.1 M PB.
• Quench endogenous peroxidase activity by incubating sections in 0.6 % H2O2 in 
0.1 M PB for 30 min.
• Block non-specific binding by incubating in Normal Goat Serum (NGS) solution 
for 1 h1.
• Incubate sections in primary antibody in NGS solution overnight at RT or for 2-3 
d at 4 °C.
• Wash sections 3 x 10 min in 0.1 M PB.
• Incubate sections in biotinylated anti-rabbit IgG raised in goat2 (1:500 in NGS; 
Vector Laboratories) for 90 min.
• Prepare avidin-peroxidase solution using Vectastain Elite ABC Kit (Vector Labo­
ratories) and leave on rocker for 30 min before using.
1The serum used m ust be that of the animal in which the secondary antibody was raised.
2 The secondary antibody must be raised that against the animal in which the primary antibody was
raised.
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• Wash sections 3 x 10 min in 0.1 M PB.
• Incubate sections in avidin-peroxidase solution for 30 min.
• Wash sections 3 x 10 min in 0.1 M PB.
• Make up DAB solution3 from kit.
• Incubate in DAB solution for 3-10 min.
• Quench in dH2 0  and then transfer to 0.1 M PB.
• Mount sections onto gelatine-coated slides from 0.01 M PB and leave to air dry.
• Dehydrate sections through ethanol series (dP^O, 70 % ethanol x 2 ,95 % ethanol 
x 2 , 1 0 0  % ethanol x 2 ; 2  min each).
•  Clear in Histoclear (2 min x 2; National Diagnostics).
• Coverslip using DPX mounting medium (BDH).
3DAB solution: 2 drops buffer, 4 drops DAB, 2 drops peroxidase, 2 drops nickel in 5 ml db^O ; Vector 
Laboratories
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A.3.2 Inununocytochemistry with fluorescent detection
Gentle agitation of sections on a tissue rocker at RT is used for all steps, except where indicated.
• Rinse sections in 0.1 M PB.
• Block non-specific binding by incubating in Normal Goat Serum (NGS) solution 
for 1 h1.
• Incubate sections in primary antibody in NGS solution overnight at RT or for 2-3 
d at 4 °C.
• Wash sections 3 x 10 min in 0.1 M PB.
For directly-conjugated Alexa 488:
• Incubate sections in the dark in AlexaFluor488 (Molecular Probes, Oregon, USA) 
for 2  h.
• Wash sections 3 x 10 min in 0.1 M PB in the dark.
• Rinse sections in the dark in 0.01 M PB
• Mount sections onto gelatine-coated slides and leave to air dry in the dark.
• Coverslip with Citifluor (Citifluor, London, UK).
Or, for FITC fluorescence (avidin-biotin method):
• Incubate sections in biotinylated anti-rabbit IgG raised in goat2 (1:200 in NGS 
solution; Vector Laboratories) for 90 min.
• Wash sections 3 x 10 min in 0.1 M PB.
1The serum used m ust be that of the animal in which the secondary antibody was raised.
2 The secondary antibody must be raised that against the animal in which the primary antibody was 
raised.
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• Incubate sections in the dark in Fluorescin Avidin D (1:200 in 0.1 M PB; Vector 
Laboratories) for 1 h.
• Wash sections 3 x 10 min in 0.1 M PB in the dark.
• Rinse sections in the dark in 0.01 M PB
• Mount sections onto gelatine-coated slides and leave to air dry in the dark.
• Coverslip with Citifluor (Citifluor).
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A.4 Immunoblotting
As the antibody for the glucocorticoid receptor had not been used in our laboratory 
before, an immunoblot was conducted to ensure binding to an antigen of appropriate 
size and distribution was observed.
A.4.1 Sample preparation
•  Remove brains and dissect on ice before freezing on dry-ice.
• Homogenize samples in 0.5-1 ml RIPA buffer containing a cocktail of proteinase 
and phospatase inhibitors1.
• Incubate samples on ice for 2 h.
• Centrifuge samples for 15 min (12,000 g, 4 °C) and collect supernatant.
• Normalise samples for protein content using BCA kit (Pierce, Rockford, IL).
A.4.2 R unning  the gel
• Mix samples with 1 X loading buffer2 and boil for 5-10 min to denature proteins.
• Load 10 ji\ (10 jig total protein) of each sample in 10 % SDS polyacrylamide gel 
(Bio-Rad).
• Run gel for 90 min at 100 V.
• Transfer proteins to Polyvinylidine difluoride (PVDF) membrane (Bio-Rad) at 
4°C for 45 min at 100 V.
1RIPA buffer: 1 % NP40, 20 mM HEPES pH  7.4,100 mM sodium chloride, 100 mM sodium fluoride,
1 mM sodium orthovanadate (Na3Vo4), 10 f/g/m l leupeptin and 1 ^g /m l; Sigma, Poole, UK
2Loading buffer: 10 % w /v  sodium dodecyl sulphate; 50 % v /v  glycerol and 0.5 % w /v  bromphenol 
blue; Sigma
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A.4.3 Detection o f  bands
• Block non-specific antibody binding with 5 % Bovine serum albumin (BSA) and 
PBS /  1 % Tween for 1 h at RT.
• Incubate with GR antibody at 1:1000 in 5 % Bovine serum albumin (BSA) and 
PBS /  1 % Tween overnight at 4°C
• Wash 6 x 5  min in PBS /  1 % Tween.
• Incubate with horseradish peroxidase-conjugated mouse anti-rabbit IgG (Amer- 
sham Biosciences, Buckinghamshire, UK) at 1:2000 for 90 min at RT.
• Wash 6 x 5  min in PBS /  1 % Tween.
• Identify bands using the enhanced chemiluminescence (ECL) detection system 
and X-ray film for 1-20 min (Amersham Biosciences).
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A.5 In situ hybridisation
In situ hybridisation has been used in this thesis to identify and quantify levels of RNA. 
Radioisotope-labelled antisense oligonucleotides corresponding to a section of the gene 
sequence of interest are hybridised to tissue sections. Exposure to photographic film 
results in an image being produced on the film. Additionally, sections can be dipped 
in photographic emulsion for more detailed examination of cellular localisation and 
distribution.
A.5.1 7issue prepara tion
• Remove brains and freeze in isopentane (Sigma) at -45 ±  5 °C.
• Cut sections on cryostat at 15 //m and thaw-mount onto poly-L-lysine-coated 
slides (BDH).
• Airdry for 1-2 h.
• Fix in freshly made, sterile, ice cold 4 % PFA in 0.1 M PBS for 5 min.
• Rinse in sterile PBS for 1 min.
• Dehydrate in sterile 70 % ethanol for 5 min.
• Store under sterile 95 % ethanol in cold room until hybridisation.
A.5.2 Probe labelling
• Dilute oligonucelotides to 5 ng/ftl.
• Set up labelling reaction:
-  Oligonucleotide (5 ng//ri)
-  rTdT 5 x buffer (Promega)
-  rTdT (5 u /fi 1; Promega)
185
2.0 fi 1
2.5 fi 1
1.5 fil
Appendix A
-  35 S dATP (Perkin-Elmer)
-  dH20
1.5 yl 
5.0 yl
-  Total 12.5 yl
• Incubate 1 h at 37 °C.
• Quench reaction with 40 yl TE1.
• Purify using column (Bio-Rad).
• Add 2 yl to 4 ml scintillation fluid and check on scintillation counter. Count 
required > 2 0 0 0 0 0 0  cpm /  2  yl.
• Add 1 yl DTT to labelled probe.
• Store at -20 °C.
A.5.3 Hybridisation to sections
• Remove slides from alcohol and allow to air dry.
• Prewarm hybridisation buffer2 to 42 °C.
• Prepare hybridisation chamber with filter paper soaked in 50 % formamide and 
5 x SSC buffer.
• Add 1 yl of probe to 100 yl hybridisation buffer per slide.
• Add 2 yl of DTT per 100 yl hybridisation mix and vortex.
• Prepare non-specific binding (NSB) control mix by adding 2 yl of unlabelled 
probe per 1 0 0  yl hybridisation mix.
1TE: 10 mM Tris pH  8,1 mM EDTA, pH  8; Sigma
2Hybridisation buffer: 50 % formamide (Sigma), 4 x SSC (National Diagnostics), 10 $ dextran sulphate, 
5 x Denhardt's, 200 f/g/m l acid-alkali cleaved salmon sperm DNA, 100 ^ g /m l long chain polyadenylic 
acid, 120 ^ g /m l heparin, 25 mM sodium phosphate ph 7.0,1 mM sodium pyrophosphate
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• Apply 100 p 1 of hybridisation mix to each slide and place a coverslip on top 
making sure the liquid covers all sections.
• Seal lid of the chamber with parafilm and leave overnight at 42 °C.
• Remove coverslips and wash slides twice in 1 x SSC at 55 °C for 30 min.
• Wash slides in 0.1 x SSC for 1 min at room temperature.
• Dehydrate sections in 70 % ethanol for 1 min RT follwed by 95 % ethanol for
1 min at RT.
• Airdry for 1-2 h.
• Expose to autoradiographic film for 1 week.
A.5.4 Emulsion dipping  in situ hybridised sections 
All procedures must be carried out in dark room under safe lights.
• Warm 15 ml of 0.5 % glycerol to 42 °C in a Falcon tube.
• Add emulsion gel (K5; Ilford, Mobberley, UK) up to a volume of 30 ml, making a 
1:1 ratio with glycerol.
• Melt emulsion at 42 °C for 30 min.
• Gently invert tube to ensure thorough mixing of emulsion.
• Individually dip slides into emulsion using dipping chamber and drain excess 
off. Allow slides to dry in a humid atmosphere for 3-4 h.
• Transfer slides to light-tight boxes containing some silica gel wrapped in tissue 
paper. Seal the box and store at 4 °C until ready for developing.
• When developing the slides transfer to glass racks under safe light conditions.
• Immerse in 250 ml developer (Kodak D19; Sigma) at 22°C for 2 min.
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• Rinse briefly in (IH2O for 30 s.
• Transfer to fix for 4 min.
• Rinse twice in dH^O for 15 min.
Lights can be turned on at this point
•  Counterstain for 2 min in thionin stain3.
• Dehydrate through ethanol series and Histoclear, mount and coverslip.
3Thionin stain: 2.5 ml 1 % thionin, 2.5 ml 1 M sodium acetate and 2.5 ml 1.2 M acetic acid, 242.5 ml 
dH2Q
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A.6 Corticosterone assay
• Add 10 jil of plasma to 500 }il of acidic citrate buffer1.
• Load in triplicate (100 y\ per tube) with 50 jd radioactive tracer (125I-corticosterone, 
0.0036 MBq/ml, Oxford Bioinnovation, UK) and 50 jil specific antibody (courtesy 
of Dr Gabor Makara, Institute of Experimental Medicine, Budapest Hungary) and 
vortex.
• Prepare sample standard curve with serially diluted corticosterone standards 
(Sigma). Also include tubes with pure tracer (50 ;d), tracer (50 /d) plus buffer 
(100 }i\), and quality control samples (from CORT stock, Sigma).
• Cover and incubate overnight at 4 °C.
• Add 500 }i\ activated charcoal solution2 and centrifuge at 4,000 rpm for 15 min at 
4 °C.
• Measure radioactivity in each sample using gamma counter.
1 Citrate buffer: 14.6 g tri-sodium citrate (Na3C6Hs0 7  • 2H20), BDH, UK; 13.8 g sodium dihydrogen
orthophosphate 1-hydrate (NaH2P0 4  • H20), BDH, UK; bovine serum albumin, 2 g, Sigma, UK, pH  to 3.0
with HC1, made to 21 volume w ith deionised water
2Activated charcoal solution: dextran T70 (0.05 m g /100 ml buffer; Amersham Parmacia Biotech AB,
Sweden), activated charcoal (5 g/100 ml buffer; Sigma, UK)
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